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Abstract 
 
Rituximab, a monoclonal antibody directed against the human CD20 antigen, causes 
profound depletion of all B cells. When used in patients with autoimmune disease, IgG 
autoantibody titres often fall whilst serum IgG anti-tetanus toxoid antibody titres are 
unaffected. Antibodies of both these antibody specificities have features associated with 
production by long-lived CD20
-
 plasma cells that should be resistant to Rituximab. 
Reasons for the differential loss of these apparently similar types of antibody were 
investigated.  
Initial experiments established multiplexed bead assays to measure, in parallel, serum 
titres of multiple antibody specificities. Paired acute and convalescent sera, from 11 
patients treated with Rituximab for Wegener‟s granulomatosis, were then studied. During 
5 months after treatment, and following clinical remission, IgG anti-Proteinase 3 
autoantibody titres fell gradually. All other measured antibody titres remained little 
changed. These findings favour the hypothesis that autoantibody producing plasma cells 
are sustained by disease related inflammation.  
Subsequent experimental studies support a wider hypothesis - that inflamed sites can 
support increased plasma cell numbers. In the prolific humoral response of QM mice to 
immunisation with NP-Ficoll, concurrent infection with attenuated Salmonella enterica  
serovar Typhimurium increases splenic capacity to support plasma cells. The enhanced 
support may reflect locally increased IL-6 production. 
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1 CLINICAL OBSERVATIONS LEADING TO THIS WORK, 
AND OUTLINE OF THE THESIS 
Rituximab is a monoclonal antibody directed against the human CD20 antigen, which is 
expressed on the surface of B cells but not expressed on terminally differentiated plasma 
cells [1]. This antibody, which was developed for the treatment of B cell neoplasms, 
causes profound depletion of CD20
+
 cell populations [2]. 
A formal randomised trial has also confirmed its therapeutic efficacy in rheumatoid 
arthritis [3]. To date evidence of efficacy in other autoimmune diseases is from case 
reports and case series [4-8], but further randomized controlled trials are currently 
underway [9;10].  
Some of these publications report the preservation, during Rituximab therapy, of levels of 
serum immunoglobulin and of serum titres of some antibody specificities including IgG 
against the protein antigen tetanus toxoid [3;11-13]. This is not surprising as the plasma 
cells that produce antibody in the blood and tissue fluids are not CD20
+
 [1], and so should 
not be affected directly by Rituximab. These same publications [3;11-13], and others 
[4;5] report that in contrast to the stability of total serum IgG levels following Rituximab 
treatment there is a selective decline in titres of IgG autoantibodies. The relevant 
autoantigens in these publications – immunoglobulins and proteinase-3 (PR3) – are also 
proteins. Thus, prior to these observations, it was tempting to assume that the production 
of corresponding autoantibodies was by a pathway analogous to that producing antibody 
against tetanus toxoid. The effect of Rituximab on autoantibody production was therefore 
unexpected. This thesis seeks to address this paradox. 
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Our first aim was to assess whether Rituximab therapy affected serum levels of a large 
number of antibodies specific for extrinsic antigens. The range of antibodies studied was 
chosen to reflect responses that are a) generated via the known different antibody 
production pathways, and b) generated from the whole spectrum of B cell subtypes. Tests 
were performed on paired sera from patients before and after treatment with Rituximab.  
All patients had Wegener‟s granulomatosis, and detectable levels of the associated 
autoantibody IgG anti-PR3. This autoantibody is one of those previously noted to decline 
after Rituximab therapy [4;5;12].  
The background to this work is discussed in detail in Chapter 2. Previously established 
methods that were used in studies reported in this thesis are reported in Chapter 3. Before 
the serological studies themselves could be performed it was necessary to develop the 
technology to assay some of the antibodies of interest – particularly those specific for 
pneumococcal capsular polysaccharides (PnCP). The development of these assays is 
described in Chapter 4. Findings from serological studies of human sera are reported in 
Chapter 5. 
The results of our human studies do not support the concept that the vulnerability of 
autoantibody production to Rituximab therapy was a feature of either i) a particular B cell 
subset or ii) a particular antibody production pathway. Furthermore the findings do not 
suggest that autoantibody forming cells (autoAFC) are predominantly short lived. We 
therefore sought other hypotheses to explain the paradoxical clinical observations.  
The most plausible alternative hypothesis appears to be that autoAFC are sustained in 
niches that are closely associated with disease-related inflammation. Treating the disease 
– and reducing the associated inflammation – would then be expected to reduce the 
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numbers of supported autoAFC, and so reduce circulating titres of autoantibody. In 
support of this hypothesis Muehlinghaus et al [14] have shown that in certain conditions 
antibody forming cells express the chemokine receptor CXCR3 and that this enables 
them to migrate to CXCL9, a chemokine found at sites of inflammation. A mouse model 
was used to test the hypothesis that „inflammatory niches‟ can support the extended 
survival of plasma cells. The results of this experiment are reported in chapter 6. 
Lastly the overall conclusions of this thesis, and the implications for further research into 
human health and disease, are discussed in chapter 7. 
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2 INTRODUCTION 
2.1 Wegener’s granulomatosis, and anti-Proteinase 3 
antibodies. 
Wegener‟s granulomatosis (WG) is one of the anti-neutrophil cytoplasm antibody 
(ANCA) associated vasculitides. These are rare systemic diseases typically associated 
with autoantibodies to antigens within cytoplasmic granules of neutrophils and 
monocytes. Disease manifestations can include necrotising inflammation in small vessels 
(arterioles, capillaries, and venules) of various tissues, granulomatous inflammation, and 
constitutional symptoms (including fever, malaise, weight loss, and arthralgias) [15]. 
Vasculitis within the kidney typically results in a glomerulonephritis that can result in 
acute renal failure. Capillaritis in the lung can cause life threatening pulmonary 
haemorrhage. The combined incidence of these vasculitides is 18.9 per million per year in 
the UK [16]. Disease activity is reported using the Birmingham Vasculitis Activity 
Scores (BVAS) (see Appendix 1) [17]. The aetiology of Wegner‟s granulomatosis 
remains obscure although its inflammatory nature and the presence of autoantibodies 
have led to it being classified among the autoimmune diseases. 
The ANCA in WG are usually specific for the neutrophil lysosomal enzyme - proteinase 
3 (PR3). Other ANCA that are specific for myeloperoxidase (MPO), which is also a 
lysosomal enzyme, are more closely linked with two other ANCA-associated vasculitides 
(microscopic polyangiitis, and Churg Strauss Syndrome). Combined serological testing 
by immunofluorescence (detecting any ANCA) and ELISA (detecting ANCA specific for 
PR3 or MPO) has a specificity for ANCA-associated disease of nearly 100% [18]. Bosch 
et al have recently written a comprehensive review of ANCA antibodies [19]. The 
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implications of the immunoglobulin V-region (Variable-region) somatic mutations 
identified in ANCA-producing antibody forming cells (AFC) are discussed below 
(section 2.2). 
In many patients with ANCA associated vasculitides, ANCA levels correlate with disease 
activity and severity, and changes in titres can reflect disease activity (see review by 
Harper and Savage [20]). ANCA antibodies are likely to contribute to disease 
pathogenesis [21]. Conventional therapy for induction of remission in ANCA-associated 
vasculitis involves substantial doses of the cytotoxic drug cyclophosphamide. 
Cyclophosphamide is toxic to plasma cells but also affects a wide range of other cell 
types, and the mechanism of its therapeutic action has not been confirmed.  
Toxicity can limit the therapeutic use of cyclophosphamide. Furthermore, relapses are 
common in WG - so further courses of cyclophosphamide are often needed and the risk 
of subsequent malignancy is related to cumulative exposure to the drug. As a result there 
has been much clinical interest in the potential for Rituximab to be used as an alternative 
therapeutic in ANCA-associated vasculitis. 
Professor Savage, one of my supervisors for the research undertaken here, has developed 
substantial clinical experience in the use of Rituximab in this setting. She runs a research-
orientated vasculitis clinic at the Wellcome Clinical Research Facility within the 
University Hospital Birmingham (UHB). The existence of this clinic not only provides a 
centre of excellence for the diagnosis and management of patients with WG but also 
facilitates both the recruitment of patients for research into therapies in vasculitis, and the 
collection of research samples from such patients. 
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2.2 The production of IgG Rheumatoid factor, and IgG PR3-
ANCA autoantibody, is vulnerable to Rituximab. 
Serum levels of IgG anti-PR3 ANCA (PR3-ANCA) – and IgG rheumatoid factor – 
typically fall after Rituximab therapy [3-5;11;12] although not all autoantibody 
production appears similarly vulnerable [22;23].  
Isotype switched PR3-ANCA and rheumatoid factor can exhibit variable (V)-region 
somatic mutations [24-26]. Others have identified V-region somatic mutations in IgM 
anti-PR3 from a patient with Wegener‟s Granulomatosis [27]. This later report includes a 
conformational model of the antibody-antigen interaction, and concluded that the 
acquired mutations were predominantly within the PR3 binding region [27]. This is 
consistent with a process of affinity maturation, as discussed in section 2.4.1 below, and 
is analogous to that seen in the response to tetanus toxoid [28].  
2.3 Rituximab and CD20. 
Rituximab is an IgG1 chimeric, human-mouse, monoclonal antibody specific for an extra-
cellular epitope on human CD20 [29]. CD20 is a 33-35 kDa surface antigen that is first 
expressed in large pre-B cells during primary B lymphopoiesis. It remains expressed 
throughout the B cell differentiation pathway, until B cells differentiate into plasma cells 
[1]. Surface CD20 is also detectable, at lower levels, in a small proportion of peripheral T 
cells from healthy controls and patients [30-32]. CD3
+
CD20
dim
 cells are reported to be 
predominantly CD8
+
CD45RO
+
CD28
+
HLA-DR
-
 [33], but their functional role – if any – 
is unclear.  
7The B cell surface protein, CD20, sits in the plasma membrane of B cells and crosses the
plasma membrane 4 times. Both the amino and carboxylic ends of the molecule are in the 
cytosol. This molecular structure and other largely indirect evidence has led to the 
suggestion that it acts as a calcium ion channel [34;35]. Although its function has been 
difficult to pin down, evidence supports a role for CD20 in B cell activation [34;35].
CD20 knockout mice have been developed, but have only mild phenotypic changes [36].
The role of CD20, if any, in other cell populations is unclear. 
High affinity binding of the drug results in the rapid and profound loss of virtually all B
cells from peripheral blood [2]. This depletion lasts for several months. As the B cell 
progenitors – haemopoietic stem cells and pro-B cells – do not express CD20, peripheral 
B cell repopulation occurs once therapeutic drug levels fall sufficiently. This usually 
takes place between 6 and 12 months after administration. Where studied, CD20dim non-
B cell populations were not detected in peripheral blood after Rituximab [31]. 
Rituximab-induced B cell depletion appears primarily to be due to antibody–dependent 
cell-mediated cytotoxicity (ADCC) [37]. Consistent with this, its efficacy may be 
influenced by polymorphisms in Fc RIIIa [38;39], a receptor involved in ADCC. In mice 
transgenic for human CD20, complement-mediated lysis appears to be the dominant 
mechanism in some anatomical locations [40]. This may be because ADCC is less 
effective in mice than humans or rats [41]. There is also evidence of a role for 
complement-mediated lysis in the action of Rituximab in certain human diseases [42]. 
Other reports indicate that Rituximab can also act, at least in vitro, by inducting apoptotic 
cell death [43]. 
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2.4 Follicular and extra-follicular pathways of AFC production. 
The B cell response to antigen can result in AFC production via one or both of two 
pathways: i) follicular responses associated with germinal centre formation or ii) extra-
follicular responses. Productive germinal centre (GC) responses only appear to be evoked 
by antigens that can elicit cognate interaction between T cells and B cells [44]. In most 
instances this means the antigen must have a peptide component. Extra-follicular 
antibody responses can be evoked both by T-dependent and T-independent antigens [45]. 
There is evidence that these are heterogeneous. Thus extrafollicular responses resulting 
from B2 cell activation are generally short-lived [45] while B1 cells can give rise to 
protracted extrafollicular responses with T independent memory B cell formation [46;47]. 
The systemic B cell response to antigen mainly occurs in the secondary lymphoid tissues 
– the spleen and the lymph nodes. Mucosal responses are not considered here. At sites of 
chronic inflammation, tertiary lymphoid structures can be formed [48-50]. These share 
features with but may not always be directly analogous to the secondary lymphoid tissues 
(which include the lymph nodes, splenic white pulp and Peyer‟s patches) [51;52]. Recent 
evidence indicates that, at least in Rheumatoid Arthritis, these structures do not have a 
direct role in autoantibody production [53].  
Antibody production can occur in the absence of antigenic stimulation. Thus germ-free 
mice fed on a chemically defined diet in stainless steel cages have normal IgM levels and 
secrete some IgA from the gut. These so-called natural antibodies are produced by B1 
cells [54;55]. These B1 cells can also participate in antigen-driven responses [46;56]. 
This is discussed further in section 2.5.2. 
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2.4.1 Follicular responses generate affinity matured antibody and 
CD20 - plasma cells that can be long lived. 
In responses to T-dependent antigens follicular and extrafollicular responses usually 
develop in parallel, although these can occur independently of each other (see, for 
example, work by Cunningham et al [57]). Cells producing high affinity, isotype 
switched, antibody are produced in germinal centres through cycles of proliferation and 
somatic hypermutation, followed by selection involving antigen uptake and cognate 
interaction with CD4 T cells [44]. Germinal centre responses give rise to plasma cells that 
have the capacity to be long lived [58;59] and this longevity does not require continued 
antigenic stimulation [59]. However, it should be intuitively obvious that not all AFC 
survive indefinitely as new antibody responses are generated throughout adult life while 
levels of serum immunoglobulin remain relatively stable in healthy adults. Thus the 
concept of plasma cell longevity evolved to include an understanding that plasma cells 
require extrinsic support in „niches‟ and that the number of these niches together with the 
number of plasma cells they can support is limited. Experimental evidence supports this 
at the level of whole organs. This was shown by studying responses where the number of 
antigen-specific B cells was varied. This resulted in peak plasma cell numbers which 
were roughly proportional to the number of specific B cells. Nevertheless, the number of 
splenic plasma cells present after 10 days had fallen so that these were more or less 
comparable in all groups [60]. Subsequently, studies have identified some of the local 
factors likely to contribute to plasma cell survival in niches. These are considered further 
in the introduction to Chapter 6. 
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As plasma cells do not express CD20 [1] one would not expect B cell depletion by anti-
CD20 antibodies to shorten their natural lifespan. This has recently been confirmed in 
experimental mice [61]. On the contrary if Rituximab prevents the new formation of 
plasma cells, B cell depletion might actually prolong natural plasma cell lifespan by 
removing competition for niches that secure plasma cell survival. The functional correlate 
of AFC sparing during B cell depletion therapy – preservation of serum immunoglobulin 
levels, and specific antibody titres including as anti-tetanus toxoid antibodies – has been 
reported in humans [3;11-13], and more recently in mice [62].  
2.4.1.1 Germinal centres generate CD20+ memory B cells as well as plasma 
cells.  
Germinal centre responses generate memory B cells as well as plasma cells [44;63]. 
Memory B cells, which have also acquired somatic mutations, and which are isotype 
switched, are found in the blood [64], and in the marginal zone (MZ) of the spleen [65]. 
Such cells can be recruited into subsequent extrafollicular responses which can generate 
further antibody. Memory B cells are CD20
+
 [66]. In animal models anti-CD20 
monoclonal antibodies deplete memory B cells [61], and abolish the recall response to T-
dependent antigens [62]. Evidence in humans is more difficult to obtain for ethical 
reasons, but recall responses to antigens are reduced (though not absent) after Rituximab 
[67;68]. Thus Rituximab should greatly reduce, if not absolutely prevent, further 
production of new plasma cells from memory B cells. 
In the response to a widespread, and persistent, antigen – such as a blood-borne 
autoantigen – ongoing activation of memory B cells could result in production of massive 
numbers of plasmablasts and unsupported plasma cells. Importantly, both these cell types 
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can secrete antibody. As the memory B cells entering the extra-follicular response, and 
plasmablasts produced by it, are all CD20
+
, the production of new plasma cells from 
memory B cells should wane rapidly after Rituximab therapy. Unsupported AFC would 
die by apoptosis within days [60], and so this process would be swiftly followed by a 
decline in any antibody production. The indirect evidence that immunoglobulin levels are 
stable after B cell depletion by Rituximab indicates that the contribution of short-lived 
plasma cells to total serum antibody levels is probably small, although their contribution 
may be critical to countering specific infections. This thesis considers if autoantibody-
producing cells are shorter lived than those generated in response to extrinsic antigens. It 
will also consider whether Rituximab treatment can alter the number of niches that 
sustain autoantibody-producing cells.  
While memory B cells are likely to be Rituximab sensitive, germinal centre responses 
which generate memory B cells are also likely to form substantial numbers of plasma 
cells that have the capacity to find and compete for niches that can secure their own long-
term survival. It has previously been proposed that a chronic process of memory B cell 
activation is required to renew and maintain the „stable‟ plasma cell pool [69]. Such 
renewal of the pool from CD20
+
 cells would be expected to be Rituximab sensitive. If 
this was a process necessary for sustaining autoantibody levels, it too could explain the 
decline in autoantibody levels following Rituximab. The relative preservation of anti-
tetanus toxoid titres suggests that these are not being sustained by chronic memory B cell 
activation, a conclusion supported by long-term analysis of specific serum antibody titres 
in man [70]. The numbers of plasma cells in the spleen and bone marrow of mice are 
unaffected by B cell depletion therapy that results in prolonged depletion of memory B 
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cells [71]. This has been taken as evidence against the argument that ongoing renewal of 
the plasma cell pool is biologically significant. A more likely interpretation of the 
available data is that AFC will continue to occupy niches unless there is competition from 
newly-formed AFC. If this is the case it follows that plasma cells present in niches before 
Rituximab administration are likely to have an extended lifespan, when the treatment 
stops the formation of new AFC. 
2.4.2 Extra-follicular antibody responses. 
Extrafollicular antibody response can be induced by all classes of antigen – T-
independent type I (TI-1) [72], TI-2 antigens [56;73] or T-dependent (TD) antigens [60]. 
Antigens based on pure polysaccharide cores evoke a pure extrafollicular antibody 
response and do not form productive GC. Most commonly these responses have been 
studied using synthetic antigens such as haptenated polysaccharides such as Ficoll and 
hydroxyl ethyl starch [45]. Although less well studied, it is likely that responses against 
bacterial capsular polysaccharides, such those of pneumococci, behave in the same way. 
Many of the antibody forming cells produced in extrafollicular responses are short-lived 
[74;75]. This is likely to be because not all AFC produced in such an extra-follicular 
response find supportive niches required for long time survival [60].  
In the same way that ongoing stimulation of the memory B cells population could result 
in substantial Rituximab-sensitive antibody production by unsupported plasmablasts and 
plasma cells (see section 2.4.1.1), ongoing stimulation of naïve B cells could also 
generate substantial antibody production. However, evidence discussed in section 2.2 
indicates that the autoantibodies of interest are likely to be the product of a process of 
affinity maturation. Therefore this pathway is only a plausible candidate for Rituximab 
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sensitive autoantibody production if extra-follicular responses can generate somatically 
mutations.  
2.4.2.1 Extra-follicular responses can generate somatic mutations in V-
region genes. 
Extrafollicular responses, both to TI and TD antigens, are associated with isotype 
switching, but have not conventionally been associated with the somatic hypermutation 
and affinity maturation seen in the TD follicular response. Nevertheless, published 
evidence shows that low level mutation can occur in TI responses [76], including 
autoantibody responses [77], and also in patients unable to develop GCs due to defective 
CD40-CD40L signalling [78]. Indeed, extra-follicular responses against a protein 
autoantigen have been demonstrated, which include accumulation of somatic mutations in 
immunoglobulin genes, and lead to affinity maturation of the corresponding autoantibody 
response [79;80] (Figure 2-1). 
 
Figure 2-1 shows that autoantibody producing cells can accumulate at the border of the T zone and 
red pulp. Image taken from William et al.  [79].   
Panel A.  Antibodies against Thy1.1 (brown) and CD22 (blue) identify the splenic T zone and B cell 
follicle respectively. In Panels B, C, and D, anti-idiotype antibody (4.44) (brown) identifies rheumatoid 
factor producing AFC, and CD22 (blue) identifies B cells. Boxes in panel B indicate areas enlarged in 
panel C (extra-follicular focus) and panel D (B cell follicle). Panel C shows Id4.44+CD22variable cells of 
plasma cell morphology in extra-follicular foci. Panel D shows smaller Id4.44+CD22+ B cells in the B cell 
follicle. 
The affinity maturation occurring within an extrafollicular response justifies 
reconsideration of the possibility that human autoantibody production can occur by an 
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extrafollicular pathway. Furthermore this pathway appears able to recruit a range of B 
cell subtypes (see below). If this pathway produced plasma cells that were only (or 
predominantly) short lived, this could offer one explanation for the observations relating 
to Rituximab therapy. 
2.5 Subsets of B cells. 
In addition to the existence of more than one pathway to antibody production, the 
presence of several B cell subsets adds further complexity to the field. B cells have been
categorised into B1 and B2 subtypes on the basis of differences in the process of primary 
B lymphopoiesis, their capacity to self renew as mature cells and their phenotype. These 
subtypes of B cell also show distinct functional differences and to some extent, 
anatomical segregation. Although the concept of B1 and B2 cells is well established and 
the cells of these lineages have characteristic phenotypes in mice it is often not possible 
to be confident on the basis of phenotype alone that a B cell belongs to the B1 or B2 
lineages. Importantly, this ambiguity is greater in humans than in mice [81;82]. 
2.5.1 B2 cells.
Naïve B2 cells are divided into a majority population of naïve recirculating cells 
(sIgM+sIgD+B220hiCD21+CD23+), and cells typified by the fraction of splenic MZ B 
cells that are naïve (sIgMhisIgDloB220hiCD21+/hiCD23-). The recirculating B cells in adult 
rats were found to have an average lifespan of about 6 weeks and MZ B cells probably 
somewhat less [83-85]. Their survival is governed by the rate at which immature B cells 
are induced to mature into recirculating or MZ cells, and by signals such as those 
delivered by BAFF (the tumour necrosis factor alpha (TNF- ) family member B cell 
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Activating Factor) [86], and APRIL (A proliferation inducing ligand) [87]. In the absence 
of competition from immature B cells recently produced in the marrow (e.g. when 
transferred into severe combined immunodeficiency, SCID, mice), mature B cells can 
survive indefinitely and many maintain a virgin phenotype [88]. Immature B cells, by 
contrast, only live around 3 days and will die by apoptosis within days, unless they 
manage to secure a signal that induces them to differentiate either into a recirculating B 
cell or a MZ B cell [83], or they are recruited to enter an immune response by antigen 
[89].  
If B2 cells encounter antigen, and receive antigen-specific T-cell help, recirculating B2 
cells can be recruited into both follicular and extrafollicular responses [90;91]. Unlike 
naïve recirculating B cells, MZ B cells (both naïve and memory) can respond to TI-2 
antigens as well as TD antigens [92;93]. The fate of self-reactive B cells depends 
primarily on the degree of antigen receptor engagement [94] and availability of T cell 
help [89].  
2.5.2 B1 cells. 
In mice, B1 cells are sIgM
hi
sIgD
lo
CD11b
+
B220
intermediate
CD21
lo
CD23
lo
, and are further 
subdivided into B1a cells that express CD5, and B1b cells that do not [95]. B1 cell 
production is dominant over B2 production during fetal life and first occurs in the fetal 
liver [96] before moving to the splenic red pulp and bone marrow. Recently, a distinct 
phenotype for B1 cell progenitor has been characterised [97]. Postnatal B cell production 
is dominated by B2 lymphopoiesis. The B1 cell repertoire is limited as fetal pre-B cells 
do not express terminal deoxynucleotide transferase (TdT), preventing N nucleotide 
insertions during VDJ rearrangements. However, evidence has been presented suggesting 
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that 60% of adult mouse peritoneal B1 cells contain N insertions [98], which supports the 
concept that B1 lymphopoiesis also occurs in adult mice. V-region somatic mutations are 
not found in peritoneal B1 cells [99]. This is taken as evidence that B1 cells do not form 
GC. 
B1 cells can produce „natural‟ IgM and some IgA antibody in the absence of antigenic 
stimulation [54;55]. Its limited repertoire intrinsically provides protection against a 
number of pathogens, and includes specificities for phosphorylcholine (PC) (a constituent 
of cell wall carbohydrate of bacteria including pneumococci) [100]. Serotype-specific 
responses to type 3 pneumococci may also be included in the B1 repertoire in mice [101]. 
Evidence for this applying in humans is limited but it is consistent with the findings that 
vaccine responses to this serotype can be seen at an age when conventional extra-
follicular responses are not established [102].  
Isohaemagglutinins, human natural antibodies against A and B blood group antigens 
[103], are taken to be produced by B1 cells. Direct evidence for this has been limited, but 
relatively recently Zhou et al have reported that human IgM
+ 
B cells which bind the blood 
group A antigen are CD11b
+
CD5
+
, consistent with a B1a phenotype [104].  
Many studies have shown that immature high affinity autoreactive B cells are deleted or 
rendered anergic [105-108]. Clearly this is not absolute and low affinity autoreactive B 
cells can be positively recruited into the MZ and B1 pools [109-111]. For example, NZB 
mice develop spontaneous auto-immune haemolytic anaemia. This can be prevented by 
intra-peritoneal injection of water - a treatment that results in apoptosis of local B1 cells 
but not circulating B2 cells [112]. Early evidence indicated that some human 
autoantibody producing cells are derived from putative B1 cells (CD5
+
 B cells) [113] 
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though another, more recent, report indicates that anti-DNA antibodies [114] arise from 
CD5
-
 B cells. 
In addition to natural antibody production, B1 cells (including B cells which can generate 
isohaemagglutinin responses) have capacity for antigen dependent responses 
[46;101;115]. These are probably B1b responses [46;101;105;116], and may be very 
persistent [46]. Isotype switching of B1 responses has been described in mice [46], and 
natural human IgG against blood group antigens are also described [117;118]. 
It is not clear if B1 cells can undergo conventional TD responses to protein antigens 
[119]. However, Ferry et al have reported intriguing findings from a model in which mice 
have widespread intracellular expression of a protein antigen (mHEL-KK), and in which 
their B cells express a transgenic anti-HEL B cell receptor (BCR) [120]. The mice have 
greatly increased numbers of antigen-specific B1b cells in the peritoneum. They also 
describe greatly increased numbers of HEL–specific AFCs in the spleen, and T-
independent production of anti-HEL antibody. The wider implications of this complex 
transgenic system are not clear, but it is interesting to note that many autoantigens are 
intracellular. The autoantigen of greatest interest here – PR3 – is a protein of cytoplasmic 
granules of macrophages and neutrophils, but it is externalized upon phagocyte 
activation.  
2.6 Extra-follicular immune responses in the spleen. 
Much of our understanding of immune responses has emerged from the study of splenic 
responses to antigen in experimental mice. Two examples, which are pertinent to the 
animal studies reported in chapter 6, are described below after an outline of the structure 
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of the mouse spleen. These are followed by a more detailed discussion of the splenic 
extra-follicular responses to antigen. Splenic follicular responses, which are not a feature 
of the antibody responses studied in chapter 6, are not discussed further here. 
2.6.1 The structure of the spleen. 
The spleen is the largest secondary lymphoid organ in mammals. It is the predominant 
site of immune responses to blood borne antigens (and peritoneal antigens). The spleen 
consists of distinct areas of white and red pulp. The red pulp consists largely of vascular 
sinusoids containing erythrocytes and macrophages. Scattered through the red pulp are 
fibrous collagen bundles, or trabeculae, which run between the major red pulp blood 
vessels and the splenic capsule [45]. 
Lymphoid white pulp areas are scattered throughout the red pulp, and are divided into T 
zones and B cell areas (follicles) according to the dominant lymphocyte subtype present 
in the non-immunised state. In the resting state, B cell areas can be further subdivided 
into primary follicles, through which naïve recirculating IgM+IgD+ B2 cells pass, and the 
outer MZ which contains naïve IgM+IgDlow/ B cells and can also contain memory B cells 
[45;121]. 
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Figure 2-2 is a schematic diagram of areas within the splenic white pulp.  T: T zone. F: B cell follicle. 
MZ: marginal zone. Taken from MacLennan et al.  2003 [45]. 
In the resting state, the MZ can thus be identified by the presence of IgM+IgDlow/ cells.
The marginal sinus that separates the more peripheral MZ from the B cell follicle can be 
identified by the presence of “marginal zone metalophillic macrophages”. These cells 
express the MOMA-1 antibody, also known as CD169 [122]. 
2.6.2 Two informative animal models of the immune response. 
2.6.2.1 The Quasi-monoclonal (QM) mouse. 
Cascalho et al reported the development of the QM mouse in 1996 [123], and it has 
subsequently been widely used in the study of the response to the hapten NP (4-hydroxy-
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3-nitrophenyl acetyl). Conjugation of NP to the neutral polysaccharide Ficoll results in 
the formation of the TI-2 antigen NP-Ficoll. 
The QM mouse has one transgenic immunoglobulin heavy chain gene – μH 17.2.25 – and 
can neither express genes that encode for germline heavy chains nor those that encode for 
κ light chains. Thus the transgenic heavy chain can only combine with a λ light chain. 
Any such combination results in a primary antibody specificity for NP. In practice 
subsequent somatic mutation and secondary rearrangements result in a naïve B cell 
repertoire that is 80% specific for NP [123]. 
When such mice are immunised with NP-Ficoll a massive extra-follicular response is 
generated, filling the splenic red pulp with NP-specific AFC [60] by day 3. AFC numbers 
then decline precipitately, with steady state numbers reached by day 8 to 10 which are the 
comparable to the number present pre-immunisation.  This is consistent with an extrinsic 
(tissue related) limit to the number of AFC that can be supported by the tissues [60]. 
“QMxB6 mice” are generated locally by crossing QM mice with C57/BL6 mice for 10 
generations, selecting for the NP heavy chain each time. In these mice approximately 5% 
of naïve B cells are specific for NP. Intraperitoneal immunisation of such mice with NP-
Ficoll still results in a very substantial, and reproducible, T-independent extra-follicular 
response; and generates numbers of NP-specific AFC far in excess of those that can be 
supported by the spleen in the longer term. 
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2.6.2.2 The splenic immune response to attenuated Salmonella enterica 
serovar Typhimurium. 
After intraperitoneal injection of 10
5
 viable S. Typhimurium (strain SL3261), susceptible 
C57/BL6 develop clinical infection which lasts more than 1 month [57]. This infection is 
characterised by progressive splenomegally which typically reaches 10 times its original 
size by 3 weeks, before gradually resolving. This is accompanied by a massive TD extra-
follicular immune response which results in relative increases in numbers of splenic IgM- 
and IgG2c- (equivalent to IgG2a- in other strains of mice) AFC that are even greater than 
the concurrent increases in splenic size. TD follicular responses only emerge as the 
bacteria are largely cleared during the second month of infection. 
By day 7 post infection, few of the AFC generated from extra-follicular responses are 
dividing (as assessed by Ki67
+ 
staining) yet their numbers decline only slowly and remain 
well above baseline values through to 1 month. This is consistent with an increased 
capacity for the infected spleen to support non-dividing plasma cells. 
2.6.3 The splenic extrafollicular response to antigen. 
If naïve recirculating B cells or MZ B cells encounter protein antigen within the 
circulation they exit the splenic vasculature and migrate to the outer splenic T zone [72]. 
These antigen-activated B cells acquire the ability to find and make cognate interaction 
with primed T cells, which also accumulate in the outer T zone.  After interaction with 
appropriate, primed, T cells the B cells begin to proliferate and after 2 to 3 days either 
enter follicles and form GC or become migrate to extrafollicular foci and become 
plasmablasts as part of an extra-follicular response [45]. Available evidence indicates that 
recirculating B2 cells do not generally respond to TI-2 antigens [92;93]. 
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MZ B cells, which do not recirculate through the blood [124], but migrate back and forth 
between local follicles [125], are capable of responding to TI-2 antigens as well as TD 
and TI-1 antigens [93]. TI-2 antigens include haptenated Ficoll [92]. The extra-follicular 
response to NP-Ficoll has been extensively studied, including in our laboratory. Upon 
activation via their B cell receptor, NP-specific B cells migrate into the outer T zone 
within 8 hours [126]. Towards the end of the second day after immunization, these cells 
start to upregulate CD138 - a surface and cytoplasmic marker associated with plasma 
cells [1]. These cells then upregulate Blimp-1 (B-lymphocyte induced maturation protein-
1) – a transcription regulator required for further differentiation into plasma cells [127]. 
By 48 hours after B cell activation by NP-Ficoll, the B cells have undergone three 
divisions. 
As the proliferating B cells (B-blasts) differentiate into plasmablasts, they migrate to 
extra-follicular foci at the margin between the T zone and the red pulp [45;128], and on 
into the red pulp itself [128]. Not all of these plasmablasts survive, and most are short 
lived [60;74;75].  
In mice with a high proportion of B cells that are specific for NP, the plasmablasts 
generated following immunisation fill the red pulp by day 3 [60;128]. In the response to 
NP-Ficoll in QM mice [60], mass apoptosis of plasmablasts is seen between 4 & 6 days, 
such that only about 5% of AFC remain by day 8. Our group has reported that AFC 
contact with, or at least proximity to, CD11c
hi
 dendritic cells contributes to subsequent 
AFC survival [128]. These CD11c
hi
 cells are usually confined to the interface between 
the red pulp and T zone [128]. However, others have presented evidence that AFC 
numbers at day 6 post immunization are unaffected by the absence of CD11c
hi
 cells 
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[129]. Recently Mohr et al [130] have shown that CD11c
+
 dendritic cells, associated with 
plasmablasts in lymph nodes (LN), are the main source of IL-6 in LN during T-dependent 
antibody responses. 
Those plasmablasts that do survive differentiate into plasma cells. Whilst both 
plasmablasts and plasma cells secrete antibody, plasma cells are probably more 
productive of antibody on a per cell basis [131;132]. As already mentioned plasma cells 
are terminally differentiated antibody secreting cells, that have the potential to be very 
long lived [58;59;70]. Longevity appears to depend upon the plasma cells finding 
extrinsic support (see section 2.8). Importantly, it appears that tissues have only limited 
capacity to provide such support [60]. In the steady state, splenic plasma cells are 
predominantly found clustered around large collagen fibres in the red pulp [45;133].  
2.7 Chemokines mediate co-ordinated migration of AFCs. 
Migration of AFCs from extra-follicular foci of the spleen, to their final site of retention 
is co-ordinated by chemokines, and occurs at the plasmablast stage [133;134]. 
Chemokines are chemotactic cytokines; small (8-15 kDa) structurally related molecules 
with diverse roles in cell trafficking. The CXC subfamily of chemokines, so called 
because they all have one intervening amino acid between their two N-terminal cysteine 
residues, includes CXCL9, CXCL10, CXCL11, and CXCL12 [135]. 
2.7.1 Four CXC chemokines: CXCL9, CXCL10, CXCL11 and CXCL12. 
The chemokines CXCL9, CXCL10, and CXCL11 are also known as Monokine induced 
by gamma interferon (MIG), Interferon gamma inducing protein-10 (IP-10) and 
Interferon–inducible T Cell Alpha Chemoattractant (ITAC), respectively. All are ligands 
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for the receptor CXCR3 which is expressed on T cells, NK cells, and some AFC, but not 
monocytes or neutrophils [136]. CXCL11 has the highest affinity interaction with 
CXCR3, and CXCL9 has the least [137]. As implied by their names, γ-Interferon (γ-IFN) 
induces expression of all three chemokines in macrophages [138;139]. However γ-IFN, 
often alternatively IFN-α, and sometimes also TNF- , can induce expression from a 
range of other cell types including endothelial cells [140;141], fibroblasts [141-143], and 
eosinophils [144]. Constitutive CXCL9 mRNA expression has been found in splenic 
CD11c+ dendritic cells and splenic B220+ cells in mice, though in both these cell types 
levels of CXCL9 mRNA are also enhanced by γ-IFN stimulation [145]. CXCL10 is 
reported to be constitutively expressed in spleen stromal cells [146]. Lipopolysaccharide 
can induce expression of CXCL10 and CXCL11 in macrophages by an γ-IFN 
independent pathway [147;148]. 
CXCL12 (Stromal derived factor-1; SDF-1) is constitutively expressed at high levels on 
bone marrow stromal cells (at the level of mRNA), and at lower levels in stromal cells 
from the LN or spleen [149]. It is also found in high concentrations in the inflamed 
rheumatoid joint, where it produced by synoviocytes [150]. In vitro, CXCL12 is 
chemotactic for B cells, T cells and macrophages [151] and plasmablasts [133]. All these 
cell types express CXCR4, the main receptor for CXCL12 [133;135;152]. The in vivo
role of CXCL12 in guiding plasmablast chemotaxis is further discussed in section 2.8.
CXCR4 is also widely expressed on many other cell types including neutrophils [153] 
and plasma cells [134]. Its possible role as a receptor that enhances plasma cell survival 
factor is discussed in section 2.8.1.3.
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2.7.2 CXCR4 mediated AFC migration. 
At least in secondary responses to protein antigens, most AFC express CXCR4, the 
receptor for CXCL12 [14;134]. The absence of CXCR4 greatly reduces, but does not 
abolish, the accumulation of AFC in the bone marrow after a secondary immune 
response, thus other mechanisms for guiding migration to bone marrow are likely to co-
exist [133]. 
In the primary response to intra-peritoneal NP-Chicken Gamma Globulin (NP-CGG), 
splenic AFC are more frequent than bone marrow AFC [133]. Six days after 
immunization with NP-CGG, most of these AFC appear to cluster near fibres or vessels 
in the splenic red pulp [133]. In contrast, six days after similar immunization of CXCR4-/-
mice the AFC are aberrantly located within the spleen – residing largely in the MZ 
though some are scattered through the red pulp. However in elegant studies of the 
response to NP-CGG in chimeric mice, at day 14 after immunization, splenic numbers of 
IgG1 CXCR4 NP-specific AFC and IgM CXCR4 NP-specific AFC are little affected by 
the co-existence of CXCR4+ NP-specific AFC [133]. From these studies one can 
conclude that i) CXCR4 is normally expressed by most AFC emerging from a primary 
splenic TD response, that ii) CXCR4 expression on AFC influences their migration 
within the spleen, but that iii) the absence of CXCR4 does not impair splenic AFC 
survival, at least in that model, and that iv) some AFC migrate into the splenic red pulp 
without CXCR4 [133]. Equivalent, detailed studies of the splenic T-independent extra-
follicular response to antigen have not been reported.  
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2.7.3 CXCR3 mediated AFC migration. 
A proportion of plasmablasts migrate towards CXCL9 and CXCL10 and CXCL11 in 
secondary responses in vitro [134]. The proportion of memory B cell derived AFC that 
express CXCR3, and the proportion that migrate to CXCL9 and CXCL10 and CXCL11 is 
increased by in vitro incubation of the precursor memory B cells with γ-IFN [14]. Most T 
cells present at sites of inflammation express CXCR3 [136]. It is tempting to assume that 
CXCR3 expression on AFC accounts for the observed accumulation of some AFC at sites 
of inflammation, but it has yet to be formally demonstrated, in mice or humans, that a 
high proportion of AFC at these sites express CXCR3. CXCR3 expression on AFC from 
primary responses is yet to be reported. Conversely CXCL12 expression is present at 
some inflamed sites [154], and so CXCR4 mediated AFC migration to sites of 
inflammation is also possible.  
2.8 Niches that allow plasma cell survival.  
It is inherently probable that there is likely to be finite capacity to the number of AFC an 
organism can support. As individual plasma cells can be very long lived [58;59], and 
antigenic stimulation continues throughout life, a virtually limitless capacity for support 
of AFC would result in a steady rise in immunoglobulin titres throughout life. This is not 
the case [155].  
By extension, the capacity of an individual organ to accommodate plasma cells is likely 
to be limited. Evidence to support of this concept, with respect to the spleen, has 
previously been published by our group [60]. They found that the number of AFC 
persisting in the spleen 10 days or more after an immunization is constant, even where a 
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huge excess of plasma cells is generated early in the response. AFC numbers were 
comparable in both T-dependent, and T-independent responses. This is consistent with a 
fixed number of niches available to accommodate AFC generated from any type of 
response.  
It follows that if an organism‟s capacity is constant, new AFC can only acquire niches by 
displacing in-situ AFC. Odendahl et al have offered evidence to support this [156]; six 
days after immunization of humans with tetanus toxoid, relatively immature blood-borne 
AFC were largely specific for tetanus toxoid, while co-existent mature AFC in the blood 
were not.  
2.8.1 Extrinsic factors that may contribute to plasma cell survival. 
As discussed above, only a small proportion of plasma cells generated in a splenic 
immune response achieve longevity [60;74;75] but, at least in the bone marrow, plasma 
cells can be very long lived [58;157]. In vitro and in vivo studies have identified multiple 
extrinsic factors that may contribute to this survival.  
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Figure 2-3 shows some putative factors associated with plasma cell survival in niches. Taken from 
Tarlinton et al. 2008 [158]. 
2.8.1.1 Interleukin-6. 
Interleukin-6 (IL-6) can be produced by a wide range of cell types including fibroblasts, 
macrophages, B cells, T cells, and synovial „nurse-like cells‟ [159-161] and CD11c+ 
dendritic cells [130]. Whilst plasma cell numbers decline precipitately if cultured in vitro 
with medium alone [160;162], the addition of IL-6 to such cultures greatly increases the 
proportion of cells surviving, at least to 3 days [162]. Others have offered evidence that, 
in co-culture, bone marrow stromal cells can similarly prolong plasma cell survival; an 
effect dependent in part on stromal cell production of IL-6 [160]. However the same 
group have subsequently demonstrated that even though splenic stromal cells generate 
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more IL-6 than bone marrow stromal cells, it is the latter cell type that has greater 
efficacy at ensuring plasma cell survival [149]. 
Results from in vivo studies are also superficially conflicting. Twenty-one weeks after 
immunization of IL-6 deficient mice with alum-precipitated ovalbumin (OVA), serum 
levels of IgG anti-OVA, and numbers of OVA-specific AFC in the bone marrow are no 
different to wild type animals [162]. In contrast an earlier report demonstrated that excess 
IL-6 results in greatly increased numbers of plasma cells in multiple lymphoid tissues, 
and greatly increased serum levels of IgG1, but only modest increases in serum levels 
other IgG subclasses or IgM [163]. The plasma cells in this latter study did not have 
neoplastic features, but the findings could be due to increased proliferation of AFC 
precursors, rather than increased plasma cell survival. Recently published evidence 
indicates that IL-6 dependent effects on serum levels of IgG1 after immunization are 
mediated by IL-21 [164] (see section 2.8.1.5 below). Nevertheless, collectively, these 
results are compatible with two conclusions: i) that increased levels of IL-6 may enhance 
plasma cell survival and ii) that there is functional redundancy between IL-6 and other 
factors that support in vivo plasma cell survival. 
At least in vitro, IL-6 demonstrates marked synergy with other factors that can enhance 
plasma cell survival. These include BAFF [165], and ligands for CD44 [162] (see 
sections 2.8.1.2.2 and 2.8.1.7).  
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2.8.1.2 Members of the Tumour Necrosis Factor  superfamily. 
2.8.1.2.1 Tumour Necrosis Factor- . 
TNF-  is predominantly produced by macrophages and T cells [166], though secretion 
from activated B cells also occurs [167;168]. TNF-  significantly enhances plasma cell 
survival in vitro [162]. In a direct comparison with IL-6, the supportive effect of TNF-
is less marked, at least at the concentrations used [162]. Limited data in humans come 
from reports regarding therapeutic administration of anti-TNF therapy (Etanercept). This 
therapy does not appear to result in a fall in total serum immunoglobulin levels [169].
The possibility that TNF-  may have synergistic effects with other plasma cell survival 
factors has not been reported. 
2.8.1.2.2 B cell activating factor (BAFF) and A proliferation inducing ligand 
(APRIL).
BAFF and APRIL are also members of the TNF-  superfamily [170]. Both exist in a 
secreted form, though BAFF can also be expressed in a transmembrane form [170].
BAFF and APRIL are both expressed by monocytes, macrophages, cells of dendritic 
morphology, and T cells [170;171]. Expression of BAFF has also been reported in a 
range of other cell types, including synoviocytes [172], Vascular cell adhesion molecule-
1+ (VCAM-1+) bone marrow stromal cells [173], and neutrophils [174;175]. More 
recently expression of BAFF and APRIL (at the level of both mRNA and protein) has 
been reported in the B-lymphocyte lineage [176]. Interestingly, the same report presented 
data to indicate that splenic plasma cells in autoimmune-prone NZB/NZW F1 mice 
express both BAFF and APRIL. 
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Three recognised receptors can interact with either BAFF or APRIL, or both. These are 
the BAFF receptor (BAFF-R), transmembrane activator and calcium modulator and 
cyclophilin ligand interactor (TACI), and B cell maturation antigen (BCMA). Only BAFF 
can interact with the BAFF-R. TACI and BCMA can be activated by either APRIL or 
BAFF [170]. Syndecan-1 (CD138) has also been reported to bind APRIL though 
downstream effects mediated through this interaction have not been confirmed [177].  
BAFF-R and TACI are expressed on B cells [170]. TACI is also expressed on 
macrophages [170], whilst BAFF-R is expressed on some T cells [170;178]. As B cells 
differentiate into plasma cells BAFF-R is down-regulated TACI is little changed and 
BCMA is massively up-regulated [130]. This implies a stronger role for APRIL in 
securing plasma cell survival. Recently GR1
+
 macrophages in the medullary cords of LN 
that are surrounded by clusters of plasma cells have been found to be potent producers of 
APRIL [130]. Downstream effects mediated by ligation of BAFF-R or TACI are not 
further discussed here.  
BCMA is also expressed on bone marrow plasma cells [165]. Ligation of this receptor 
greatly enhances in vitro survival of bone marrow derived plasma cells and, as mentioned 
above, their survival is further augmented by the additional presence of IL-6 [165]. In 
vivo studies support this; in BCMA
-/-
 mice numbers of bone marrow PCs are greatly 
reduced (but remain detectable) several weeks after immunisation [165]. In keeping with 
previous studies [177], recent evidence from transfer experiments [179] appears to 
indicate that the presence of APRIL, but not BAFF, in the recipient bone marrow 
enhances survival of engrafted AFC up to 48 hours after transfer. 
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2.8.1.3 CXCL12. 
During early in vitro studies CXCL12 – the ligand for CXCR4 – was reported to enhance 
plasma cell survival [162]. VCAM-1
+
 bone marrow stromal cells express CXCL12 [173], 
and it appears that in vivo most bone marrow plasma cells are in proximity to these cells 
[180]. However, as discussed above (section 2.7.2), experimental data indicates that 
CXCR4
-
 AFC are at little or no survival disadvantage, within the spleen, compared to 
CXCR4
+
 AFC [133]. Furthermore, although at 14 days after an immunization numbers of 
CXCR4
-
 AFC in the bone marrow are reduced when in competition with CXCR4
+
 AFC 
[134], separate studies indicate that at 90 days after immunisation the numbers of bone 
marrow AFC are comparable in mice with CXCR4
- 
AFC and those with CXCR4
+
 AFC 
[181]. More recently, and in contrast to earlier work [162], Minges-Wols et al have found 
that plasma cell survival during in vitro co-culture with stromal cells is not affected by 
the addition of neutralising anti-CXCL12 antibody [149].  
Thus whilst there is strong evidence that CXCR4 is a significant chemotactic factor for 
plasma cell precursors is strong (see section 2.7.2), the evidence that CXCR4 is also an in 
vivo survival factor for plasma cells themselves is less convincing. 
2.8.1.4 Interleukin-5. 
Interleukin-5 was amongst the extensive range of cytokines investigated by Cassese et al 
for capacity to support plasma cell in vitro [162]. At the concentrations used, it 
substantially enhanced plasma cell survival to 3 days, though to a lesser extent than IL-6 
or CXCL12. 
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However, the same report noted that bone marrow supernatants from IL-5-/- mice were no 
less effective than supernatants from wild type mice in supporting plasma cell survival in 
vitro - consistent with significant functional redundancy, and a therefore lesser role for 
IL-5 in vivo. 
2.8.1.5 Interleukin-21.
Interleukin-21 has been described only relatively recently [182]. It is secreted by CD4+ T
cells, and has homology to several other cytokines including IL-2, IL-4 and IL-7 [183].
The receptors for these various cytokines all share a common c chain [183].
IL-21 has many known functions, affecting a range of immunological cell types [183]. 
Excess production of IL-21 by transgenic mice results in increased plasma cell numbers 
[184] in part, at least, through upregulating Blimp-1 [184]. Other actions of IL-21 on cells 
of the B-cell lineage are complex and are discussed below: 
IL-21 receptor knockout mice have impaired antigen specific IgG1 responses, whilst 
corresponding antigen specific IgM responses are relatively spared [185]. Furthermore,
recently published data indicates that IL-21 mediates the increased in vivo production of 
antigen specific IgG1 that occurs when antigen is co-administered with IL-6 (but without 
any other adjuvant) [164]. The IgM response to antigen is not enhanced in the same way 
[164]. 
It appears that when B cell IL-21 receptor ligation occurs concurrently with BCR 
activation, then B cell proliferation is induced [186]. In contrast in the absence of BCR 
activation, IL-21 receptor ligation results in induction of apoptosis – even if Toll Like 
Receptor (TLR)-mediated B cell signalling is available [186].  
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IL-21 has also been proposed as a putative plasma cell survival factor [158].  
2.8.1.6 Cells that may support plasma cell survival.  
Although many molecules that are putatively supportive of plasma cells have been 
identified, the cells that comprise plasma cell niches have been relatively less well 
characterised.  
Some cells types that may support plasma cell development or survival have already been 
discussed above. These include CD11c
hi
 dendritic cells in the spleen (section 2.6.3), and 
VCAM-1
+
 bone marrow stromal cells that express CXCL12 (section 2.8.1.3), and/or 
BAFF (section 2.8.1.2.2). Markers that identify putative niche-forming cells in the spleen 
are less well investigated. As VCAM-1 is very widely expressed in the splenic red pulp 
[187] it is unlikely, on its own, to define a cell type that supports plasma cells. 
BP3 (CD157) was identified as a surface antigen on bone marrow stromal cells [188], 
whilst the same antigen had already been identified on cells in the spleen [189]. BP3
-/-
 
mice exhibit defects in the immune response to TI-2 antigens [190]. The mechanism 
underlying this is not clear, and it was considered plausible that BP3 cells contribute to 
splenic plasma cell niches. 
Mice deficient in CD169 (sialoadhesin) are reported to have lower levels of IgM [191]. 
More recently Mohr et al [130] have reported that CD169
+
 cells are present at several 
sites within the LN, and that some subsets of these CD169
+
 cells, identified according to 
expression of CD11b and F4/80, are associated with AFC in the LN outer T zone and 
medullary cords. Some of these cells expressed CXCL12 and adhesion molecules that 
35 
may assist interaction with AFC. It therefore appeared plausible that CD169
+
 cells could 
contribute to the formation of splenic plasma cell niches. 
2.8.1.7 Other factors that may contribute to plasma cell survival. 
Plasma cells express CD44. Cassese et al have also demonstrated that CD44 mediated 
signalling, whether induced by activating antibodies or by hyaluroniuc acid, can 
significantly enhance plasma cell survival in vitro [162]. Interestingly this effect appears 
to be synergistic with the effects of IL-6.  
Others have demonstrated that VLA-4 (Very late antigen-4) mediated signals may 
promote plasma cell survival at least in vitro, though this does not appear to be via 
interaction with VCAM-1 [160]. More recently DiLillo et al have reported in vivo 
findings that may support this, or at least support a permissive role for VLA-4 in ensuring 
plasma cell survival in supportive niches [62]. In experimentally immunised mice that are 
unable to regenerate their plasma cell pool (due to depletion of plasma cell precursors), 
co-blockade of LFA-1 (Lymphocyte function-associated antigen-1) and VLA-4 results in 
a significant fall in both a) numbers of antigen specific AFC in the bone marrow and b) 
levels of antigen-specific serum IgG. 
2.9 Outline of human serological work. 
It should be clear from the evidence discussed above, that the conventional pathway for 
production of most affinity-matured, isotype-switched, antibody specific for protein 
antigens – namely the GC pathway – should not be sensitive to Rituximab. Available 
evidence regarding most antibody production still supports this concept. B cell depletion 
by Rituximab does not significantly affect titres of neutralising antibodies against tetanus 
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toxoid [3;11;12]. Falls in serum immunoglobulins are also generally modest, although 
falls in serum IgM have been seen after repeated cycles of treatment [192]. This makes 
the Rituximab-related falls in titres of certain autoantibodies, which otherwise exhibit 
features similar to anti-tetanus antibody, all the more striking. The wider literature 
introduced above raises the possibility that other pathways – and other B cell subtypes – 
could generate IgG anti-PR3 autoantibodies and IgG rheumatoid factor.  
We initially considered three possible explanations for the observations that production of 
some autoantibody species appears sensitive to Rituximab therapy. Based on the results 
set out in Chapter 5, a fourth possibility has emerged that seems consistent with available 
data. These explanations are not mutually exclusive:  
1. Autoreactive B cells which differentiate into autoAFC could be contained in a 
different B cell subset to those containing specificities for other protein antigens.  
2. autoAFC could be generated via a different antibody production pathway to that 
used for conventional protein antigens. 
3. autoAFC could be intrinsically short lived, with ongoing production of 
autoantibody dependent on constant renewal of the autoAFC population by 
differentiation of new B cells. 
4. autoAFC may selectively occupy sites in inflammatory tissues that maintain their 
survival, but these sites are vulnerable to Rituximab treatment. 
The primary aim of the first phase of my research fellowship was to determine whether 
established antibody production derived from these other pathways and from other B cell 
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subtypes is also sensitive to disruption by Rituximab. To achieve this, it was initially 
necessary to develop the technology to assay antibodies to multiple PnCP in parallel.  
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3 METHODS 
3.1 Commonly used reagents. 
Protocols for the preparation of some standard laboratory reagents, used widely in this 
research, are reported below: 
 Carbonate Coating Buffer: Dissolve 0.8g Na2CO3, and 1.47g NaHCO3 in 500ml distilled 
water, then add Sodium Azide to a final concentration of 0.02%. 
Trisma Base solution: Dissolve 121.14g tris(hydroxymethyl)aminomethane in 5L 
distilled water. 
Tris pH 7.4: Made by mixing 2 parts Trisma base solution in distilled water (0.2M), 3 
parts stock NaCl solution in water (42.5g per 5L), and 3 parts dilute hydrochloric acid 
(0.1N). 
Tris pH 9.2:  Trisma base solution was pH adjusted to 9.2 using concentrated NaOH, and 
before distilled water was added to make up to twice the original volume. 
Phosphate buffered saline (PBS): Consists of distilled water containing 150mM Sodium 
Chloride and 150mM Sodium Phosphate, adjusted to pH 7.2. 
3.2 Methods used in human studies. 
3.2.1 Ethical approval for human studies, recruitment of subjects, 
and details of process for obtaining consent. 
The research protocol, and the relevant patient information sheets and consent forms, for 
the human research undertaken for this thesis were approved by the Oxfordshire South 
Research Ethics Committee (B) (REC application number 06/Q1605/49). 
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Patients with ANCA-associated vasculitis attending UHB, and considered as potentially 
suitable for participation in this research, were first identified by their clinicians. Such 
patients were provided with written information about the proposed research and their 
potential role in it, and were given an opportunity to ask questions before written consent 
was obtained. 
3.2.2 Patients and samples. 
Samples were collected from 11 patients with disease that fulfilled the ACR classification 
criteria for Wegener‟s Granulomatosis [15] and had detectable serum anti-PR3 antibody 
before treatment. All were under follow up at Queen Elizabeth Hospital, UHB NHS 
Foundation Trust. Nine patients received Rituximab for induction of remission after a 
disease relapse. Two received Rituximab for newly diagnosed disease. Patients received 
2g to 3.2g intravenous (i.v.) Rituximab in divided doses. Eight patients received 
concurrent i.v. cyclophosphamide in two divided doses (median total dose 1.25g, range 
0.9 – 2.4g). Two patients also received i.v. methylprednisolone (1g and 1.5g). All i.v. 
therapy was completed within four weeks, and thereafter patients continued a reducing 
course of oral prednisolone. Six patients continued previous immnunosuppresive 
medications (Mycophenolate mofetil, Azathioprine, or Methotrexate) at doses unchanged 
throughout the study period. No patients had previously received Rituximab. All patients 
gave written informed consent for research participation. 
3.2.3 Collation of clinical data on consenting patients. 
Demographic data, disease activity scores (BVAS) (see Appendix 1, page 183) [17], 
serum autoantibody titres, levels of serum immunoglobulins, and serum levels of C-
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reactive protein were obtained from clinical laboratory results, patient notes, and hospital 
databases.  
3.2.3.1 Estimation of absolute B cell counts in patients’ peripheral blood. 
An estimate of the absolute number of CD19
+
 B cells per μl of patient‟s whole blood was 
derived the combination of from two sources: 
1. The proportion of blood lymphocytes that were CD19+ was estimated by flow 
cytometric analysis of fresh whole blood samples, after lysis of red cells by the 
addition of FACS lysis solution (Becton Dickenson). At least 10,000 flow 
cytometric events were counted per sample. This is routinely performed by the 
University of Birmingham Clinical Immunology service on 
Ethylenediaminetetraacetic acid (EDTA)-anticoagulated samples of peripheral 
blood taken from those patients attending the UHB Vasculitis clinic that were 
likely to receive Rituximab, or had previously received Rituximab. 
2. Contemporary samples were also sent for semi-automated estimation of various 
haematological indices including absolute lymphocyte counts per μl of whole 
blood, by the UHB Hematology Laboratory service.  
Measurements were performed before Rituximab treatment (except in one patient), and at 
intervals during the subsequent 4-5 months (in all patients).  
3.2.3.2 Measurement of anti-PR3 antibody titres in patients’ serum. 
Levels of anti-PR3 antibodies in fresh serum samples were routinely analysed, by the 
University of Birmingham Clinical Immunology service, for all patients attending the 
UHB Vasculitis clinic. Assays were performed using a commercially available Enzyme 
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linked immunospecific assay (ELISA) detection kit (The Binding Site, Birmingham, 
UK), according to the manufacturers instructions. 
3.2.3.3 Measurement of levels of serum immunoglobulins and C-reactive 
protein in patients’ serum. 
Total serum IgG and IgM were measured by the University of Birmingham Clinical 
Immunology service using a routine turbidometric assay (Modular P800, Roche 
Diagnostics). 
Highly sensitive assays for C-reactive protein were performed by the University of 
Birmingham Clinical Immunology service using a routine turbidometric assay (Hitachi P-
module, Dako). 
3.2.4 Collection of research blood samples from consenting patients. 
Serum samples, and whole blood samples, for research were obtained from consenting 
patients at the same time as clinical blood samples – usually during routine inpatient 
phlebotomy rounds or at the time of outpatient appointments. 
Serum samples were obtained from clotted blood samples as follows: half an hour after 
venesection, filled vacutainer tubes were centrifuged at 2000g for 10 minutes. Serum was 
then removed by pipetting and aliquotted into approximately 500μl quantities for freezing 
at -20˚C or below. Serum samples were moved to -70˚C within 1 month of collection. 
Whole blood samples for flow cytometric analysis were collected into EDTA-containing 
vacutainer tubes and kept at room temperature until use within 18 hours.  
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3.2.5 Customized microsphere-based assays of serum antibody 
concentration.  
IgM, IgG1 or IgG2 antibody each specific for tetanus toxoid, PnCP 1, 3, 6b, 9v, 14, 19, 
and 23f, PC, and purified pneumococcal cell wall polysaccharide (CWPS) (Serum Statens 
Institute, Denmark) were measured by customized multiplexed assays using antigen-
coated fluorescent microspheres after Lal et al [193]. The local development, and 
validation, of these assays is described in chapter 4. 
3.2.5.1 Conjugation of antigens to microspheres. 
3.2.5.1.1 Carbohydrate conjugation to linker protein (poly-L-Lysine). 
 Each of the seven pneumococcal capsular polysaccharides (PnCP) (LGC Prochem / 
ATCC, UK) (5mg/ml in sterile water), and CWPS (1mg/ml in sterile water) were 
separately added to equal volumes of dilute NaOH (0.01%). The alkalinized solutions 
were separately added to cyanuric chloride (5mg/ml) (Sigma), vortexed briefly, and 
100 L poly-L-lysine (Sigma) (0.1%) was added to each. After further vortexing, the 
mixtures were incubated overnight in the dark at 4°C, with agitation. Coupled 
polysaccharides were purified with separate PD-10 desalting columns (Amersham 
Biosciences) by elution with 3.5ml PBS, and aliquots of each frozen at -80°C. 
3.2.5.1.2 Protein conjugation to microspheres. 
Subsequently, each of the poly-L-lysine-coupled polysaccharides, tetanus toxoid 
(48 g/ml) (List Biological Labs) and Bovine Serum Albumin- (BSA)-conjugated 
Phosphorylcholine (PC) (200 g/ml) (BioSearch, CA, USA) were separately conjugated 
to carboxylated microspheres (BioRad Labs, UK). Microspheres were first washed (PBS-
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Tween 0.05%), and activated with N-(3-Dimethylaminopropyl)-N′-ethylcarbodiimide 
hydrochloride (Sigma, UK) (5mg/ml) and N-hydroxysulfosuccinimide sodium salt 
(Sigma, UK) (5mg/ml) in distilled water containing 1.06g NaH2PO4 and 0.32g 
Na2HPO4 per 100ml (pH 7.3). After 2 further washes (PBS), activated microspheres 
were separately incubated with solutions of each required antigen (300 l) for 2 hours or 
overnight, at room temperature in the dark, with agitation. Antigen-conjugated beads 
were then washed twice in PBS containing 0.1% bovine serum albumin, and 0.05% 
NaN3, and stored in the dark until use. 
3.2.5.2 Performing microsphere based assays of serum antibodies. 
Serum antibody levels against PnCP 1, 3, 6b, 9v, 14, 19, & 23f were measured in patient 
samples and the standard reference serum (Serum 89SF, Food and Drug Administration, 
Maryland, USA). Seven 4-fold dilutions (1/20-1/81920) of each sample and standard 
were prepared in diluent buffer consisting of PBS containing 1% BSA (Sigma), 0.05% 
Tween, and CWPS (2 g/ml). PnCP 22f (5 g/ml) was also added to diluent buffer for 
samples, in accordance with the WHO (World Health Organization) protocol for ELISA 
detection of PnCP antibodies [194]. 
Diluted samples and standards were incubated in 96 well MultiScreenHTS microfilter 
plates (Milipore, UK) with a mixture of the relevant antigen-coated beads (2500 per bead 
type) for 1 hour at room temperature, in the dark with shaking, and then washed twice in 
wash buffer (PBS-Tween 0.05%). Beads were then incubated with phycoerythrin (PE)-
conjugated mouse anti-human immunoglobulins (Ig) (specific for IgM, IgG1 or IgG2) 
(1/200 dilution in wash buffer) (Southern biotech, AL, USA) for 30 minutes at room 
temperature, in the dark with shaking. After a further wash, beads were re-suspended in 
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wash buffer (130 l), and median fluorescence intensities (MFI) for each bead/sample 
combination were obtained by Luminex 100 machine (Luminex Corp, TX, USA). IgM, 
IgG1 and IgG2 antibodies against tetanus toxoid, CWPS, and PC were separately tested 
in an analogous fashion, except that samples and standard were diluted in buffer without 
CWPS or PnCP 22f. 
3.2.5.3 Data analysis of microsphere-based assays of serum samples 
Standard curves of MFI obtained with Luminex were computed by BioPlex Manager 
software (version 4, BioRad Labs, CA, USA). Standard curves were generated for each 
antibody specificity and for each immunoglobulin subclass, for each sample and for the 
standard serum 89SF. Hypothetical dilutions of samples and standard predicted to result 
in an equal MFI of 4 x background were obtained from standard curves, and thus relative 
concentrations of each antibody (compared to the standard) were obtained for each 
immunoglobulin subclass within each sample.  
The limit of detection for each antibody was inferred by the ratio between the dilution of 
standard serum that generated a MFI equal to 4x background, and the least diluted 
standard (1 in 20). 
3.2.6 Microsphere-based assays of serum cytokine levels 
Serum samples from patients of interest were collected and stored as described in section 
3.2.4. The cytokine assay kit (BioRad Labs) was used according to the manufacturer‟s
instructions. In summary: 
When needed, sample aliquots were thawed on ice, and diluted 1:3 with the sample 
diluent. The cytokine standard was reconstituted with 500 μL serum standard diluent and 
45 
left on ice for 30 minutes.  Serial dilutions of the standard were then prepared – the top 
dilution consisted of 128 μL of reconstituted standard diluted with 72 μL serum standard 
diluent. Thereafter 7 further dilutions were created using 1:3 fold dilutions. Fifty μl of 
diluent was kept aside for use as a „blank‟ (0 U/ml). All diluted standards were then kept 
on ice.  
96 well filter plates (Millipore) were pre-wet with assay buffer, 50 μL of the multiplex 
bead working suspension was added to each well, and the beads were washed with 100 μl 
wash buffer; with each vacuum filtration of excess fluid between each step. Fifty μl of 
relevant standards or sample were then added to the appropriate wells, and the plate was 
incubated at room temperature in the dark with shaking. Three further washes were 
performed before 25μl of biotinylated detection antibody was added to each well. The 
plate was then reincubated in similar conditions to previously for 30 minutes. After three 
further washes, 50μl strepavidin-PE was added to each well and the plate re-incubated 
under similar conditions for 10 minutes. After 3 further washes, the beads were 
resuspended in 125 μl assay buffer, and MFI associated with each bead region, in each 
well, were read on the previously calibrated Bioplex 100 platform (BioRad).  
Relative concentrations of cytokines in the samples were calculated by BioPlex Manager 
software (version 4, BioRad Labs, CA, USA) using 5 parameter logistic regression 
algorithms, with reference to the MFI values obtained for the serial dilutions for the 
standards.  
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3.2.7 Enzyme Linked ImmunoSpecfic Assay (ELISA) of IgG anti-
Epstein-Barr Virus Capsid Antigen in human serum samples. 
Human serum samples had previously been collected and stored as described in section 
3.2.4. ELISA assays for levels of serum IgG against Epstein-Barr Virus Capsid Antigen 
(EBV-CA) were performed according to the manufacturer‟s instructions (DiaPro). 
Briefly, 100μl of each diluted sample (101-fold dilution in sample buffer), and control 
serum, and pre-diluted calibration samples were placed in separate wells pre-coated with 
EBV-CA, and incubated at 37˚C for 60 minutes. Wells were then washed with 300μl 
wash buffer and shaken dry, with this cycle being repeated 4 times. One hundred 
microlitres of pre-prepared enzyme conjugate was then added to each well, and the plate 
incubated for another 1 hours at 37˚C. After further washes (as before) 100μl chromogen 
substrate was added to each well, and the plate incubated at room temperature for 20 
minutes. The reaction was stopped by the addition of 100μl sulphuric acid (provided by 
manufacturer) and the wells read on an „Emax‟ plate reader (Molecular Devices) using a 
450nM filter. After confirming test validity according to the manufacturer‟s 
predetermined criteria, serum anti-EBV-CA IgG levels were inferred from the standard 
curve derived from calibration samples. One patient‟s samples were found to have levels 
above the limit of accurate detection (100 Arbitrary units/ml) whereupon both assays of 
both pre-and post-Rituximab samples were repeated using 1 in 300 and 1 in 1000 
dilutions, in parallel with a new standard curve. The lower limit of detection for the assay 
was reported by the manufacturers. 
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3.2.8 Measurement of levels of isohaemagglutinins in patients’ serum 
samples. 
IgM isohemagglutinins were measured by hemagglutination. Twofold serial dilutions of 
serum were incubated separately with standard red blood cells (RBC) (blood groups A 
and B) in Allsevers (National Blood Service, Liverpool, UK), at room temperature. The 
greatest dilution causing agglutination after 45 min was recorded. Where both anti-A and 
anti-B antibodies were present in the pretreatment sample, the antigen giving the higher 
antibody titer in the pretreatment sample was used throughout the study. 
3.3 Methods used for mouse studies. 
3.3.1 Animal Licence. 
All procedures were performed under a Home Office licence to Dr Adam Cunningham, 
licence number 40/2904, and were approved by the University of Birmingham Ethics 
Committee. 
3.3.2 Animals and animal husbandry. 
“QMxB6 mice” were raised by crossing Quasi-monoclonal (QM) mice [123] with 
C57/BL6 mice for  6 generations, selecting for the presence of the QM-related transgene 
each time. Mice were bred and maintained in specific pathogen free conditions in the 
University of Birmingham BioMedical Services Unit (BMSU). They were provided with 
unlimited amounts of standard feed, and water.  
Where used, 5-Bromo 2΄-deoxyuridine (BrdU) was provided ab libitum at 1mg/ml in 
animal‟s drinking water between 24 hours and 120 hours after inoculations.
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3.3.3 S. Typhimurium – culture and preparation for inoculation. 
The bacteria used for the experiments were kindly cultured and prepared by Ms Saeda 
Bobat. An attenuated strain of Salmonella – Salmonella enterica serovar Typhimurium 
(S. Typhimurium) (SL3261 strain) [195] – was cultured overnight in LB media at 37˚C, 
with aeration. Prior experiments had established the relationship between the cell density 
of S. Typhimurium in exponential phase culture, and the optical density (OD) of the 
bacterial suspension, measured at 600nm. Once an OD between 0.8 and 1.2 was reached, 
bacteria were harvested by centrifugation (6000g for 5 minutes). Pelleted cells were then 
washed twice in PBS (with further centrifugation at 6000g for 5 minutes after each), 
before being resuspended in 1ml PBS. This was then diluted, as necessary, to give a 
predicted final concentration of 10
5
 cells per 200μl for use in immunisations.  
3.3.4 Animal inoculations. 
Mice aged between 6 and 8 weeks each received one intra-peritoneal injection of 200μL 
phosphate buffered saline, to which had previously been added either a) 30μg NP-Ficoll 
(Biosearch Technologies, Novato, CA), or b) 10
5
 live S. Typhimurium or c) both. Control 
(non-immunised) mice did not receive sham injections. Injections were kindly performed 
by Ms Jennifer Marshall, Dr Elodie Mohr, and the staff of BMSU. 
3.3.5 Animal sacrifice and the obtaining of samples. 
Animals were sacrificed at differing timepoints from 4 to 35 days after inoculation, by 
cardiac puncture under terminal anaesthesia. Control mice were sacrificed at the end of 
the experiment (day 35). Procedures were kindly performed by Ms Jennifer Marshall, Dr 
Elodie Mohr, and the staff of BMSU. 
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3.3.5.1 Preparation and storage of serum from mouse blood samples. 
Blood samples obtained by cardiac puncture under terminal anaesthesia were allowed to 
clot at room temperature, and then centrifuged at 16,060g for 10 minutes before 
extraction of serum by pipetting. Serum samples were then aliquotted and frozen at -20˚C 
or below before use. 
3.3.5.2 Preparation and storage of spleens from sacrificed mice. 
Spleens obtained after mouse sacrifice were divided, and both segments weighed. In each 
case, the larger part was stored for subsequent use in histology (section 3.3.8). The 
smaller part was used immediately in flow cytometric studies (section 3.3.7). 
3.3.6 ELISA-based assay for measurement of isotype specific anti-NP 
antibody levels in mouse serum samples. 
Samples were prepared as described in section 3.3.5.1. Nunc Maxisorb 96 well plates 
were coated with antigen by overnight incubation, in a dampened box at 4˚C, with 100μl 
per well of coating buffer (see section 3.1) containing 5mg/ml NP2-BSA. Sufficient plates 
were coated for the contemporary measurement of all samples to be compared. 
Plates were prepared for use by first being washed three times in PBS (by immersion), 
and being dried between each by shaking and by banging on dry paper. Plates were then 
blocked by incubation at 37˚C for 1 hour with 100μl per well of PBS containing 1% 
BSA, and then washed once again in PBS with shaking and banging to dry. 
Meanwhile, samples were prepared for analysis by preparing serial dilutions in PBS 
containing 1% BSA and 0.05% Tween-20, in a separate non-absorbent 96 well plate. For 
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assays of IgM anti-NP samples were diluted 1 in 10, and 4-fold thereafter. For assays of 
other isotypes, starting dilutions of 1 in 100 were used.  
One hundred microlitres of all samples‟ dilutions to be tested were then transferred to the 
pre-coated, blocked and washed ELISA-plates, and incubated at 37˚C for 1 hour, after 
which plates were washed and dried three times, as described previously. Plates were left 
with wells filled with additional PBS, until washing of all concurrently incubated plates 
was completed. Control (blank) wells, were loaded with diluent alone. 
Secondary antibodies used were alkaline-phosphatase conjugated polyclonal goat 
antibodies against specific mouse immunoglobulin isotypes (all from Southern BioTech). 
Anti-IgM was used at 1 in 2000 dilution, whilst others were used at 1 in 1000 dilution, in 
PBS containing 1% BSA, and 0.05% Tween-20. One hundred μl of the relevant antibody 
was added to each sample well, and to blank wells, and the plates re-incubated for 1 hour 
at 37˚C, before being washed as described previously. 
Meanwhile the buffer for use with enzyme substrate was prepared by dissolving 1 Tris 
tablet (Sigma) into 20ml distilled water. One p-Nitrophenyl Phosphate (pNPP) Fast
TM
 tab 
(Sigma) was then added, per 20ml Tris buffer, to be fully dissolved just before use.  
One hundred microlitres of pNPP Fast
TM
 solution was then added to each sample and 
control well and the plate then incubated at 37˚C until sufficient colour had developed for 
reading at 405nM by plate reader. 
Within sets of samples assayed for the same isotype of anti-NP antibody, changes in 
405nM absorbance were plotted against each sample‟s dilution (log scale), and a cut-off 
absorbance threshold was determined. Relative titres of measured antibody in each 
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sample were considered to be the inverse of the hypothetical concentration which 
generated the threshold optical density.  
3.3.7 Flow cytometric studies of mouse spleen cell suspensions. 
3.3.7.1 Estimation of splenic CD138+ cell counts by flow cytometry. 
This work was kindly performed by Ms Jennifer Marshall.  
Segments of freshly obtained mouse spleen were pulped, suspended in  5ml RPMI 
supplemented with 10% fetal calf serum (FCS) and  sieved  through a 70mm nylon mesh, 
before being incubated with appropriate antibodies (Table 3-1) suspended in PBS with 
1% FCS  at predetermined optimal concentrations for 20 minutes at 4˚C. 
  FL-1 FL-2 FL-3 FL-4 
Reagent anti-B220-FITC NP-PE - anti CD138-
Biotin and 
steptavidin 
APC 
Source  eBiosciences Dr P. Lane   Beckton 
Dickinson 
Table 3-1 shows reagents used for the estimation of CD138
+
 cell numbers by flow cytometry. 
FITC: Fluorescein-isothiocyanate. PE: Phycoerythrin. APC: Allophycocyanin. 
 
Samples were then immediately analysed on a Facscalibur (Becton Dickenson) flow 
cytometer using CellQuest Software.  Off-line analysis was achieved with FlowJo 
software for Mac (Version 6.3.2). Apoptotic cells were excluded by their forward / side 
scatter characteristics. Amongst the remaining cells, the proportion that were CD138
+
, 
and the proportion of these that were also NP-specific, was calculated.   
An estimate of the total cell count per spleen was obtained by counting with an improved 
Neubauer haemocytometer using Trypan blue exclusion.  
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3.3.7.2 Other flow cytometric studies of mouse spleen cell suspensions. 
This work was kindly performed by Dr Elodie Mohr. 
One third of the spleen was mashed between two glass slides in RPMI containing 5% 
FCS, 1 mg/ml of collagenase type II (Lorne Laboratories Ltd) and 0.15mg/ml DNase I 
(Sigma-Aldrich). The cell suspension was prepared by repeated pipetting for 20 
min through a fine tip pastette (alphaLaboratories). It was then treated for 5min with 
10mM EDTA (Sigma-Aldrich), before being filtered through a nylon mesh, and 
centrifuged for 5 min at 1500 rpm. Cells were resuspended in Flow-assisted cytometric 
sorting (FACS) buffer containing 5% normal mouse serum and 20% v/v of supernatant 
from 2.4G2 hybridoma culture and incubated for 10 minutes on ice. Cells were then re-
centrifuged for 5 min at 1500 rpm and resuspended in FACS buffer. A proportion of the 
prepared cells were recentrifuged and stored as a dry pellet at -20˚C until needed for 
RNA extraction (see section 3.3.14.1).  
Samples were then incubated with the appropriate antibodies (which were either directly 
conjugated to fluorochromes or to biotin) for 30 minutes on ice (see Table 3-2, Table 3-3, 
Table 3-4, and Table 3-5). Where biotinylated secondary antibodies were used, an 
additional wash step was first performed (using 150 μl PBS containing 2mM EDTA, and 
0.1% FCS). Samples were then incubated with the appropriate streptavidin conjugated 
fluorochrome for 30 minutes on ice, before the final 2 washes. 
 FL-1 FL-2 FL-3 FL-4 
Reagent anti-CD169 FITC anti F4/80 PE anti-CD11b 
PerCP-Cy5.5 
anti Gr1 biotin 
+ Strept APC 
Source 
(company) 
Serotec e-Bioscience BD 
Pharmingen  
e-Bioscience, 
BD 
Pharmingen 
Table 3-2 shows reagents used for the estimation of splenic granulocyte numbers by flow cytometry. 
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FL-1 FL-2 FL-3 FL-4
Reagent anti F4/80 FITC anti-CD11c 
PE
anti-CD8 
PerCP
anti-CD4 APC
Source 
(company)
Sertotec BD 
Pharmingen
BD 
Pharmingen
e-Bioscience
Table 3-3 shows reagents used for the characterization of splenic granulocytes with antibodies to 
CD11c, CD8 , CD4 and F4/80, by flow cytometry.  
FL-1 FL-2 FL-3 FL-4
Reagent anti  IgM FITC NP-PE anti-B220 
PerCP-Cy5.5
anti-CXCR3 
APC
Source 
(company)
Southern Biotech Dr Elodie 
Mohr
BD 
Pharmingen
Both BD 
Pharmingen 
Table 3-4 shows reagents used to assess expression of the chemokine receptor CXCR3 on putative 
NP-specific AFC, by flow cytometry.  
FL-1 FL-2 FL-3 FL-4
Reagent anti  IgM FITC NP-PE anti-B220 
PerCP-Cy5.5
anti-CXCR4 
biotin, and 
steptavidin 
APC
Source 
(company)
Southern Biotech Dr Elodie 
Mohr
BD 
Pharmingen
R&D Systems
Table 3-5 shows reagents used to assess expression of the chemokine receptor CXCR4 on putative 
NP-specific AFC, by flow cytometry. 
Where needed, intracellular staining for flow-cytometry was performed using 
Cytoifx/Cytoperm kit (BD Biosciences), and the BrdU APC flow kit (BD Biosciences), 
according to the manufacturers instructions (see also Table 3-6).
FL-1 FL-2 FL-3 FL-4
Reagent anti-BrdU FITC NP-PE anti-B220 
PerCP-Cy5.5
anti-CD138 
APC
Source BD Pharmingen Dr Elodie 
Mohr
BD 
Pharmingen
BD 
Pharmingen
Table 3-6 shows reagents used for the estimation of splenic numbers of NP-specific AFC, including 
those that have incorporated BrdU, by flow cytometry. 
Samples were then analysed on a Facscalibur (Becton Dickenson) flow cytometer using 
CellQuest Software. Off-line analysis of flow cytometric data was performed with 
FlowJo software for Mac (Version 6.3.2). 
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3.3.8 Preparation of tissues for histology. 
Part of each spleen obtained after mouse sacrifice was dip frozen in liquid nitrogen and 
stored at -70 until use.  
6µm spleen sections were cut by cryostat (Bright) and placed on multispot glass slides 
(Hendley), air dried for at least 40 minutes, and fixed in acetone (Baker) (for 20 minutes 
at 4˚C). Sections were then briefly air dried, and stored at -20˚C or below until required. 
 
3.3.9 Immunohistochemistry. 
3.3.9.1 Incubation of tissues with antibodies. 
Tissue sections were prepared in advance as described in section 3.3.8. Slides were 
brought to room temperature and placed under a fan, for at least 15 minutes, before being 
rehydrated in Tris pH 7.4 (see section 3.1) for at least 10 minutes at room temperature.  
Primary antibodies were mixed as necessary, and diluted to the pre-determined optimal 
concentrations in Tris pH 7.4. Antibody combinations used are listed in Table 3-7, Table 
3-8, Table 3-9, Table 3-10, Table 3-11, and Table 3-12. Seventy five microlitres of the 
antibody mix was added to each tissue section, which was then incubated for 45 minutes. 
During this, and subsequent, incubations slides were kept at room temperature in a moist 
cabinet. Slides were washed for at least 5 minutes in Tris pH 7.4, with stirring, between 
incubation steps. 
Secondary antibodies were mixed as necessary and then pre-absorbed with normal mouse 
serum (NMS) for 30 minutes before use - 1µl NMS being added per 10ul of mixed 
undiluted antibody. Secondary antibodies were then diluted to pre-determined 
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concentrations in Tris pH 7.4 for use. Again, 75µl of diluted antibody was added to each 
section, and the slides incubated for 45 minutes.  
 Alkaline Phosphatase Peroxidase 
Incubation 
phase 1 
Rt @ CD3 BD Pharmingen  IgD – Sh Ig Dr Khan  
Incubation 
phase 2 
(With NMS) 
Rb @ Rt bt Dako Dk @ Sh 
Peroxidase 
The Binding 
Site 
Incubation 
phase 3 
Strept AP Vector   
Table 3-7 shows the protocol for immunohistochemical staining of mouse tissue sections for CD3
+
 
cells and IgD
+
 cells.  
Rt: Rat. Sh: Sheep. Rb: Rabbit. Dk : Donkey.  
 
 Alkaline Phosphatase Peroxidase 
Incubation 
phase 1 
NP – Sh Ig Dr Khan Rat @ IgD BD 
Pharmingen 
Incubation 
phase 2 
(With NMS) 
Dk @ Sh bt The Binding Site Rb @ Rt 
Peroxidase 
The Binding 
Site 
Incubation 
phase 3 
Strept AP Vector   
Table 3-8 shows the protocol for immunohistochemical staining of mouse tissue sections for cells with 
anti-NP Ig, and for IgD
+
 cells. 
Where used, Steptavidin-Biotin Alkaline Phosphatase complex (Strept AP) was prepared 
from component solutions „A‟ and „B‟ (Vector). Specifically, 10µl of each solution was 
added to 1ml Tris pH 7.4 and incubated for 30 minutes at room temperature prior to use. 
When Rabbit Peroxidase / Antiperoxidase complex (Rabbit PAP) was also used for two 
colour staining, this was added to the Strept AP just before use at a final concentration of 
1/100. Seventy five microlitres of the required, diluted, solution was added to each 
section, and the slides incubated for 30 minutes. 
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 Alkaline Phosphatase Peroxidase 
Incubation 
phase 1 
NP – Sh Ig Dr Khan Rb @ Ki67 Dako 
Incubation 
phase 2 
(With NMS) 
Dk @ Sh bt The Binding Site Sw @ Rb Ig Dako 
Incubation 
phase 3 
Strept AP Vector Rb PAP Dako 
Table 3-9 shows the protocol for immunohistochemical staining of mouse tissue sections for cells with 
anti-NP IgG. and for cells expressing the nuclear marker for proliferation – Ki67. 
 
 Alkaline Phosphatase Peroxidase 
Incubation 
phase 1 
Gt @ 
human 
Collagen III 
Southern BioTech NP – Rb Ig Dr Khan  
Incubation 
phase 2 
(With NMS) 
Dk @ Sheep 
Bt 
The Binding Site Sw @ Rb Ig Dako 
Incubation 
phase 3 
Strept AP Vector Rb PAP Dako 
Table 3-10 shows the protocol for immunohistochemical staining of mouse tissue sections for 
structures that bind antibodies against human Collagen III, and for cells with anti-NP Ig. 
 
Table 3-11 shows the protocol for immunohistochemical staining of mouse tissue sections with anti-
BP3 antibody and for cells with anti-NP Abs. 
 
Table 3-12 shows the protocol for immunohistochemical staining of mouse tissue sections with anti-
ER-TR7 antibody, and for cells with anti-NP Abs. 
 Alkaline Phosphatase Peroxidase 
Incubation 
phase 1 
Rt @ BP3 
(CD157) 
Accurate Chemical and 
Scientific  
NP – Sh Ig Dr Khan 
Incubation 
phase 2 
(With NMS) 
Rb @ Rt Bt Dako Dk @ Sh 
Peroxidase 
The Binding 
Site 
Incubation 
phase 3 
Strept AP Vector   
 Alkaline Phosphatase Peroxidase 
Incubation 
phase 1 
Rat @ 
ER-TR7 
BMA Biomedicals NP – Sh Ig Dr Khan  
Incubation 
phase 2 
(With NMS) 
Rt @ Rat 
Bt 
Dako Dk @  Sh - 
Peroxiadse 
The Binding 
Site 
Incubation 
phase 3 
Strept AP Vector   
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3.3.9.2 Enzymatic development of coloured substrates. 
3.3.9.2.1 Visualisation of peroxidase associated antibodies with 
3,3’Diaminobenzidine tetrahydrochloride. 
One tablet (10mg) 3,3‟Diaminobenzidine tetrahydrochloride (DAB) (Sigma) was brought 
to room temperature before being dissolved in 15ml Tris pH 7.4, and then filtered. 
Approximately 100µl Hydrogen peroxide (30% w/v) (Sigma) was then added to 10ml 
DAB solution immediately prior to use.  
Approximately 100 µl of the resulting mixture was added to each slide, and the sample 
observed by light microscopy to asses the progression of colour development. Once 
optimal development was achieved, the reaction was stopped by washing in Tris pH 7.4. 
3.3.9.2.2 Visualisation of Alkaline phosphatase associated antibodies with 
Fast BlueTM. 
Fast Blue
TM
 and Napthol AS-MX phospate reagents (both Sigma) were stored at minus 
20˚C and brought to room temperature before use. Four milligrams of Napthol AS-MX 
phosphate (Sigma) was placed in a glass bijou, to which 370 µl N-N-Dimethyl 
Formamide (Sigma) was added in a fume cupboard. The resulting solution was then 
added to 8mg Levamisole (Sigma) previously dissolved in Tris pH 9.2 (see section 3.1).  
Into the resulting mixture was added 10-12 mg Fast Blue
TM
, which was then mixed 
gently, and filtered before use. The final solution was protected from light if not used 
immediately. Approximately 100 µl was added to each slide, and the section observed by 
light microscopy to asses the progression of colour development. Once optimal 
development was achieved, the reaction was stopped by washing in Tris pH 7.4. 
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3.3.9.3 Final preparation of developed slides for permanent storage and 
use. 
After development of the relevant substrates and washing in Tris pH 7.4, slides were 
briefly washed in distilled water before being allowed to dry. Sections were covered with 
glass cover-slips (Surgipath) using Immu-mount fluid (Thermo Electron Corporation). 
3.3.10 Estimating splenic NP-specific AFC numbers by counting 
cells in histological sections. 
Estimates of the relative number of NP-specific AFC present in mouse spleens were 
made using the Weible point counting method [196]. Six micrometre thick splenic 
sections, that had previously been immunohistochemically stained for anti-NP antibodies 
and for CD138
+
 cells, were viewed at 100x magnification through an eyepiece with a 
10x10 graticule. NP-stained cells that were overlain by intersections on the grid were 
counted (excluding those on the right and lower margins of the grid). An estimate for the 
relative number of cells per section, for each spleen of interest, by starting in one corner 
and sequentially moving the section back and forth, one „row‟ at a time. An estimate of 
the relative number of cells per spleen was then obtained by multiplying the section‟s 
AFC count by the total splenic weight. 
3.3.11 Photography of immunohistochemically stained tissue 
sections. 
Photomicrographs of stained sections were obtained using a Hitachi HV-D30 digital 
camera attached to the P.A.L.M. microdissection platform (Microlaser Technologies 
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GmbH, Zeiss). Photomicrographs were saved as TIFF images. These were cropped or 
contrast-adjusted using Paint-Shop Pro Version 7 for windows. 
3.3.12 Laser scanning confocal microscopy. 
3.3.12.1 Incubation of tissues with antibodies. 
Tissue sections were prepared in advance as described in section 3.3.8. Slides were 
brought to room temperature under a fan, for at least 15 minutes, before being rehydrated 
in PBS at room temperature for at least 10 minutes.  
Primary antibodies were mixed and diluted as necessary. Five percent (by volume) NMS 
was then added to the antibody mixture, which was incubated at room temperature for 30 
minutes before 75µl was added to each tissue section. Sections were incubated for 1 hour 
with primary antibody, at room temperature. During this, and subsequent, incubations 
slides were kept at room temperature in a moist cabinet. Slides were washed for at least 5 
minutes in PBS with stirring, between each incubation step. 
Second and subsequent layers of staining (up to 6 more per section), were performed in a 
similar manner. Antibodies were pre-mixed with 5% NMS, or another species‟ normal 
serum able to bind any residual antibody from the previous layer of staining. Seventy five 
microlitres of antibody mixture was added to the section each time. Second and 
subsequent incubations were all 30 minutes at room temperature. Once fluorochrome-
conjugated antibodies had been applied, all incubations and wash steps were performed in 
the dark. Antibody combinations used are listed in Table 3-13 and Table 3-14. 
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After all staining was completed, sections were washed in fresh PBS. Excess liquid 
around the margin of the slide was removed, and sections were mounted in 2.5% [1,4-
Diazabicyclo(2,2,2) octane] pH 8.6 in 90% glycerol in PBS.  
 
Table 3-13 shows protocol for staining adjacent sections of mouse tissue for visualization of selected 
combinations of CD169
+
 cells, F4/80
+
 cells, Gr1
+
 cells, CD11b
+
 cells, cells specific for NP, and IgM
+ 
cells by confocal microscopy. 
AMCA: 7-amino-4-methylcoumarin-3- acetic acid. NGS: Normal goat serum. 
Reagents were obtained from the following sources: NP-Sheep Ig (Dr Khan), Dk@Gt Cy-5 (Jackson 
Immunoresearch), Sh@ Rt bt (Binding Site), Strepta Cy3 (Jackson Immunoresearch), Rt @ F4/80 FITC 
(Serotec), Rt @ CD11b FITC (e-Bioscience), Rb @ FITC (Dako), Gt @ Rb FITC (BD Pharmingen), Gt @ 
IgM AMCA (Jackson Immunoresearch), Rt@ CD169 FITC (Serotec). Normal animal sera were obtained 
from The Binding Site. 
 
Staining 
combinations 
displayed in 
thesis 
CD169 
F4/80  
anti-NP Ab 
IgM 
 
F4/80 
Gr1 
anti-NP Ab 
IgM 
CD11b 
Gr1 
anti-NP Ab 
IgM 
Corresponding 
Negative controls 
Incubation 
phase 
Staining combinations used 
Phase 1 NP-Sheep Ig  
Rt @ F4/80 
NMS 
NP-Sheep Ig  
NMS 
NP-Sheep Ig 
NMS 
 
NMS 
Phase 2 Dk@Gt Cy-5 
NMS 
Dk@Gt Cy-5 
NMS 
Dk@Gt Cy-5  
NMS 
Dk@Gt Cy-5  
NMS 
Phase 3 NGS NGS NGS NGS 
Phase 4 Sh@ Rt bt   
NMS 
Rt @ Gr1 bt 
NMS 
Rt @ Gr1 bt 
NMS 
 
NMS 
Phase 5 Strepta Cy3  
NRS 
Strepta Cy3  
NRS 
Strepta Cy3 
NRS 
Strepta Cy3 
NRS 
Phase 6 Rt @ CD169 
FITC  
NMS 
Rt @ F4/80 
FITC 
NMS 
Rt @ CD11b 
FITC 
NMS 
 
NMS 
Phase 7 Rb @ FITC 
NMS 
Rb @ FITC 
NMS 
Rb @ FITC 
NMS 
Rb @ FITC 
NMS 
Phase 8 Gt @ Rb FITC 
Gt @ IgM 
AMCA  
Gt @ Rb FITC 
Gt @ IgM 
AMCA 
Gt @ Rb FITC 
Gt @ IgM AMCA  
Gt @ Rb FITC 
Gt @ IgM 
AMCA  
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Table 3-14 shows protocol for staining sections of mouse tissue for visualization of F4/80
+
 cells, 
CD11c
+
 cells, CD4
+
 cells and IgM
+ 
cells by confocal microscopy. 
Hs: Hamster. Reagents were obtained from the following sources: Hs@ CD11c (Serotec), Gt @ Hs Cy3 
(Jackson Immunoresearch), Rb @ FITC, Gt @ Rb-FITC (Dako), Rt @ CD4-APC (e-Bioscience), Gt @ 
IgM AMCA (Jackson Immunoresearch). Normal mouse serum was obtained from The Binding Site. 
3.3.12.2 Confocal microscopy – image acquisition and analysis. 
Sections were examined with a Zeiss LSM510 laser scanning confocal microscope using 
a x10 objective. A 488nm argon laser was used to excite FITC-conjugated antibodies; a 
543nm HeNe laser was used for Cy3–conjugated antibodies; a 633nm helium laser for 
Cy5 conjugates, and 351 / 364nm lasers were used for AMCA conjugated antibodies. The 
four lasers scanned separately, to obtain discrete images of 2048x2048 resolution. These 
were analysed off line using Zeiss LSM image browser version 3,5,0,376 to generate 
combined images in false-colour.  
Staining 
combinations 
displayed in thesis 
F4/80 
CD11c  
CD4 
IgM 
Corresponding 
Negative controls 
Incubation phase  
Phase 1 Hs@ CD11c 
NMS 
NMS 
Phase 2 Gt @ Hs Cy3 
NMS 
Gt @ Hs Cy3 
NMS 
Phase 3 Rt @ F4/80 FITC 
NMS 
NMS 
Phase 4 Rb @ FITC 
NMS 
Rb @ FITC 
NMS 
Phase 5 Gt @ Rb-FITC 
Rt @ CD4-APC 
NMS 
Gt @ Rb FITC 
NMS 
Phase 6 Gt @ IgM AMCA Gt@ IgM 
AMCA 
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3.3.13 Laser microdissection and capture of tissue sections for 
use in Real Time Reverse Transcriptase Polymerase Chain 
Reaction assays (RT2-PCR). 
3.3.13.1 Cresyl violet staining of sections for dissection. 
Sections for subsequent microdissection were prepared and stored as for histology 
(section 3.3.8), except that PALM® MembraneSlides NF were used.  For use, slides were 
removed from the freezer, and brought to room temperature under a fan, for at least 20 
minutes. Sections were then rehydrated by passage through RNAse free 100% ethanol, 
70% ethanol, and 50% ethanol (all from Sigma), and stained for 3 minutes with cresyl 
violet (sigma) 1% W/V in RNAse free 100% ethanol. Slides were then dipped 
sequentially in 50%, 70%, 100% to dehydrate, and air-dried.  
3.3.13.2 Use of immunohistochemically stained slides to determine 
areas of splenic tissue for microdissection.  
Two pairs of serial sections, cut before and after the sections intended for 
microdissection, were prepared for conventional histology (section 3.3.8). Within in each 
pair, one section was stained with NP and anti-IgD, the other with NP and anti-Ki67 
(according to methods described in section 3.3.9). 
Each section was photographed in entirety, and a composite image constructed in 
PowerPoint version 2002 (Microsoft). Tissue areas of interest were identified within this 
composite image – red pulp containing NP-specific antibody forming cells (AFC), red 
pulp not containing NP-specific AFC, IgD
+
 areas, T zone, and extra-follicular foci (in 
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infected mice) – and cross-referenced with corresponding areas on the cresyl violet 
stained tissue for microdissection (Figure 3-1).   
 
 
 
 
 
 
 
Figure 3-1 shows photomicrographs of two proximate splenic sections from a mouse sacrificed 8 days 
after NP-Ficoll immunization, demonstrating relationship between appearances after cresyl violet 
staining, and after immunohistochemical staining for IgD and anti-NP antibodies.  
Left image shows section immunohistochemically stained for IgD (brown) and with NP (blue). Right image 
shows section stained with cresyl violet, revealing intense staining of the B cell follicle, slightly weaker 
staining of the T zone, and light staining of the red pulp.  
In mice sacrificed at day 4 post NP-Ficoll immunization, no red pulp areas devoid of 
plasma cells could satisfactorily be identified for dissection (see section 6.4.2). Extra-
follicular foci of antibody secreting cells, of adequate size for microdissection, were only 
satisfactorily identified in the S. Typhimurium infected mice. 
3.3.13.3 Laser microdissection and tissue capture. 
Laser microcapture was performed using a Microbeam HT microscope (PALM 
Microlaser Technologies). Twenty to forty similar areas were microdissected, and 
catapulted into twenty microlitres of RNeasy RLT buffer (Qiagen), and snap frozen on 
dry ice (-78˚C). Samples were stored at minus 20˚ C until use. 
Day 8, NP-Ficoll. Cresyl Violet. x50 Day 8, NP-Ficoll. NP. IgD. x50 
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3.3.14 cDNA preparation for semi-quantitative RT2-PCR. 
3.3.14.1 RNA isolation from spleen cell suspensions. 
This work was kindly performed by Dr Elodie Mohr. 
Cell suspensions were previously prepared as described in section 3.3.7.2. The frozen 
pellets were resuspended in 1ml of RNABee (Tel-test Inc), and homogenised by pipetting 
up and down and then vortexing. The extraction was then performed by adding 200 μl of 
chloroform and vortexing for 30 sec. After centrifugation for 15 min at 16,060g at 4C, the 
aqueous phase was removed, and the RNA precipitated by incubation with 500 μl 
isopropanol for 10 min at room temperature. The RNA was pelletted by centrifugation for 
5 min at 16,060g at 4C, and the pellet then washed twice in 1 ml of 75% ethanol, with 
similar centrifugations between washes. 
After leaving the pellets to dry slightly, they were resuspended in 30 μl of diethyl 
pyrocarbonate (DEPC, Sigma-Aldrich)-treated water containing 20U of RNAseOUT
TM
  
RNAse-inhibitor (Invitrogen). 
The concentration of RNA obtained was estimated by optical density (at 260 nm), based 
on the assumption that 40 μg/μl of RNA gives an OD of 1. Two micrograms of RNA was 
used for cDNA preparation. This amount of RNA is incubated with 1ug random 
hexanucleotides (Promega) in 13 μl total.  
3.3.14.2 RNA isolation from microdissected tissue. 
RNA isolation and cDNA preparation were performed using RNAeasy Micro Kits 
(Qiagen), according to the manufacturer‟s instructions. Microdissected samples, 
contained with twenty microlitres of RLT buffer, were lysed by micropipetting in 350μl 
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of RLT buffer, to which β-mercaptoethanol (1%) and carrier RNA (to a final 
concentration of 57ng/ml) had been previously added. The lysed solution was then placed 
in a QIAShredder spin column, itself placed within a 2ml collection tube, and centrifuged 
for 2 minutes at 16,060g. The collected volume was mixed by pipetting with 350μl of 
RNAse free 70% Ethanol (sigma), placed in an RNeasy MinElute spin column, and 
centrifuged for 15 seconds at 8,000g. After discarding the flow through, the column 
contents were was washed by adding 350μl RW1 buffer and re-centrifuging at 8,000g for 
15 seconds.  
Eighty microlitres of diluted DNAse 1 solution (10μl of DNAse1 stock with 70 μl RDD 
buffer) was then added directly to the top of the column which was then incubated for 15 
minutes at room temperature, before being washed by adding a further 350 μl RW1 
buffer and then centrifuged at 15 seconds at 8,000g.  
After placing the column into a new collection tube, 500μl RPE buffer was added to the 
column before centrifuging at 8,000g for 15 seconds, and discarding the flow through. 
Next 500μl 80% Ethanol (RNAse free) was added to the column which was centrifuged 
for 2 minutes at 8,000g, after which the flow through and collection tube were discarded. 
After placing the column into a clean collection tube, it was centrifuged again, this time 
with the cap kept open, at 16,060g for 5 minutes to dry the column contents.  
To elute the RNA, 22μl RNAse free water was added directly to the top of the column, 
which was centrifuged at 16,060g for 1 minute, with the flow through collected in a fresh 
1.5ml eppendorf tube. 
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3.3.14.3 Preparation of cDNA from isolated RNA. 
In preparing cDNA from bulk spleen cell suspensions, 2 μg extracted RNA was mixed 
with 1μl random primer hexa-nucleotides (3mg/ml, Promega) in 13μl RNAse free water. 
By contrast for microdissected samples, 2μl random primer hexa-nucleotides (3mg/ml, 
Promega), were mixed with 20μl of RNA containing eluate (see section 3.3.14.2). 
Thereafter similar methods were used for preparation of cDNA from both sources. 
Mixtures were denatured at 70˚C for 10 minutes, and shock cooled on ice to prevent re-
annealing. Meanwhile the reverse transcriptase solution was prepared. This contained 6.4 
μl RNAse free water, 8μl 5x first strand buffer (Promega), 1.5μl nucleotide mix (dATP, 
dCTP, dGTP, d, TTP at 10mM each), 0.625μl RNAseOUTTM RNAse-inhibitor (40U/μl, 
Invitrogen), 1.5μl Moloney Murine Leukemia Virus reverse transcriptase (200U/ml, 
Promega). To this solution was added the 22μl water containing the RNA and primers, 
and the PCR tube contents were mixed well by pipetting.  
The mixture was incubated at 42˚C for 1 hour, before being heated to 90˚C for 10 
minutes to denature the reverse transcriptase, and then allowed to cool. The resulting 
cDNA was stored, without further dilution, at -20˚C. 
3.3.15 Quantitative Reverse Transcriptase Polymerase Chain 
Reaction Assays (RT2-PCR). 
Assays for the relative quantification of target cDNA in samples were performed, where 
possible, in duplex with assays for β2-Microglobulin or β-actin cDNA. Otherwise, 
relative amounts of target and reference gene cDNA were quantified in simultaneously 
performed, simplex, assays. Primers used had either been designed by others within the 
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research group using Primer Express computer software (Applied Biosystems) and then 
synthesized by Eurogenetec, or were purchased directly from Applied Biosystems. All 
primers were used at previously determined optimal concentrations and with standard 
reaction conditions for TaqMan PCR. Probes were detected by 5‟ conjugation to FAM 
(target species), or 5‟ conjugation to VIC or Yakima Yellow. Details of primer and probe 
sequences used, and their corresponding concentrations, are contained in Table 3-15. 
mRNA species Origin Fluoro- Assay Reference Final reagent concentration (nM)
phore configuration gene used
Forward
primer
Reverse
primer Probe
IL6 MacLennan group FAM Simplex β2-microglobulin 150 80 60
BAFF MacLennan group FAM Simplex β2-microglobulin 150 120 120
APRIL MacLennan group FAM Simplex β2-microglobulin 175 60 60
Blimp-1 MacLennan group FAM Duplex β2-microglobulin 175 80 100
-IFN MacLennan group VIC Simplex β2-microglobulin 150 120 120
IL-21 MacLennan group FAM Simplex β2-microglobulin 125 80 80
CXCL12 MacLennan group FAM Simplex β2-microglobulin 175 80 80
BCMA MacLennan group FAM Simplex β2-microglobulin 80 80 175
CXCL9 Applied Biosystems FAM Duplex β2-microglobulin 0.4μl per well
CXCL10 Applied Biosystems FAM Duplex β2-microglobulin 0.4μl per well
CXCL11 Applied Biosystems FAM Duplex β2-microglobulin 0.4μl per well
TNF-α Applied Biosystems FAM Duplex β2-microglobulin 0.4μl per well
CXCR3 Applied Biosystems FAM Duplex β2-microglobulin 0.4μl per well
CXCR4 Applied Biosystems FAM Duplex β2-microglobulin 0.4μl per well
β2-
microglobulin MacLennan group
Yakima 
Yellow Both 175 60 80
Table 3-15 shows mRNA species analysed by RT2-PCR, the fluorophore associated with each probe, 
their assay’s configuration (duplex or simplex) and working concentrations of primers and probes 
used.  
Primer and probe sequences are listed in Appendix 2, page 184. FAM: 6-carboxyfluoroscein.  VICis a 
proprietary dye from Applied Biosystems.   
RT2-PCR assays were performed in 8μl final reaction volume. Quantities of target 
species‟ forward primers, reverse primers, and probes, sufficient to achieve the desired 
final concentrations, were mixed in advance with PCR master mix (Promega), and diluted 
to 7 μl with RNAse free water.
One microlitre of sample cDNA was added to the appropriate well of a 384 well 
MicroAmp plate (Applied Biosystems) which was then centrifuged for 2 minutes (200g).  
Seven microlitres of the previously prepared mix of primers, probes, enzymes and buffer 
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was then added to the sample cDNA, and the mixture re-centrifuged before being covered 
with an optically clear adhesive film (Absolute Q-PCR Seal, Thermo Scientific).  
Assays were performed using an ABI 7900 machine (Applied Biosystems), in which 
samples were heated to 50˚C for 2 minutes, then to 95˚C for 10 minutes, followed by 40 
cycles of high temperature (95˚C for 15 seconds) and lower temperature (60˚C for 60 
seconds). Results were analyzed using SDS version 2.2.2 software (Applied Biosystems).  
3.4 Statistical analysis and presentation of data. 
Statistical analysis was performed using Prism software version 5.01 (GraphPad). 
Statistical comparisons were made with the two-tailed unpaired non-parametric Mann 
Whitney test. Figures presented either were created using Excel 2002 and PowerPoint 
2002 (both Microsoft), or Prism software version 5.01 (GraphPad). 
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4 DEVELOPMENT OF MICROSPHERE BASED ASSAYS 
4.1 Introduction. 
There are considerable advantages to technologies that allow the accurate and 
reproducible performance of multiple assays, in parallel, using small amounts of a 
biological sample. In addition to their potential to save time, and minimise consumption 
of stored sera, such techniques (known as “multiplexing”) eliminate intra-assay 
variability due to pipetting, and minor changes in experimental condition. These causes 
of variability are inherent in the execution of serial assays. This is of greatest relevance 
when performing within-subject comparisons amongst the relevant assays – an 
experimental design anticipated, and subsequently used, elsewhere in this thesis. 
Prior studies have used “Luminex” microsphere based assays to measure, across a wide 
dynamic range, levels of antibodies specific to different pneumococcal capsular 
polysaccharides (PnCP) [193;197]. Although the appropriate machine was available, only 
preliminary steps towards establishing such assays had previously been made at the 
University of Birmingham. My project required accurate assays to determine within 
single samples specific class and subclass levels of antibody against all of the different 
recognized classes of antigen. Consequently I sought to establish, validate and 
standardise a local microsphere-based assay for this purpose. The aim was to use this 
approach to assess levels of antibodies against different serotype specific PnCP, as well 
as antibody specific for tetanus toxoid, phosphorylcholine (PC), or CWPS. 
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4.2 Principles of microsphere-based assays. 
Microsphere assays are analogous to enzyme-lined immunospecific assays (ELISAs). 
The binding of a soluble factor (e.g. antibody) to an immobilised substrate (e.g. antigen) 
is not linearly related to the concentration of either, or the affinity of the interaction. 
For microsphere-based assays the substrate is covalently bound to microscopic beads. 
These can be commercially obtained with substrate already attached (e.g. in cytokine 
assays) or purchased bearing carboxyl groups, for use in customised bead assays (see 
section 3.2.5.1 for conjugation method used in this work). Beads are available in a range 
of „regions‟, which are distinguished by the relative amount of two fluorochromes they 
contain. Thus when run through an appropriate machine, analogous to a flow cytometer, 
distinct bead „regions‟ can be identified by their fluorochrome signature (Figure 4-1). 
 
Figure 4-1 is a map of 100 distinct beads regions available for Luminex microsphere-based assays. 
Figure downloaded from BioRad corporation website (http://www.bio-rad.com) 
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To quantify the amount of soluble factor binding to the bead-bound substrate, an excess 
of secondary antibody, which is usually directly conjugated to phycoerythrin (PE), is 
added to the sample well. Where additional amplification is needed (e.g. cytokine 
assays), biotinylated secondary antibodies can be used and binding of this is detected 
using an avidin-PE complex. 
When running the assay, the machine reads a variable (pre-defined) number of beads 
(usually 100) of each region being studied. It measures the associated intensity of PE 
fluorescence for each bead and calculates a „median fluorescence intensity‟ (MFI) for the 
region. This is assumed to be proportional to the amount of soluble factor associated with 
the bead.  
Median fluorescence intensities assigned to a bead region are then compared to a standard 
curve (generated using dilutions of a standard preparation of the soluble factor in parallel 
wells) to obtain a measure of the relative or absolute quantity of the soluble factor in the 
sample fluid.  
As various substrates can be bound to beads of different regions, which can then be 
distinguished when run on the machine, it is tempting to perform assays for multiple 
factors within the same well with consequent saving of time, and sample. This can be 
done so long as it is shown that there is minimal interference between the parallel assays. 
A priori where the soluble factor has a measurable affinity for another available substrate, 
the effective quantity of substrate is increased, and so binding to the „true‟ substrate 
(bound to the relevant reporter bead) may be reduced. Conversely, where another soluble 
factor with measurable affinity for the „true‟ substrate is present, the apparent binding of 
the factor being measured (via the reporter bead) may be increased. Confirming the non-
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interference of assays performed in parallel was a crucial part of establishing confidence 
with this technique, especially as significant cross reactivity between antibodies against 
various PnCP has been reported [198]. It should be noted that experimental confirmation 
of non-interaction between different multiplexed assays does not exclude expected 
interference between antibodies of appropriate specificities, but differing isotypes (e.g. an 
IgM anti-PnCP-1 antibody, causing interference with an assay for IgG anti-PnCP-1). 
4.3 Early assay development. 
Preliminary experiments used beads that Dr Mark Cobbold had conjugated to 
pneumococcal antigens using periodate conjugation (after Biagini et al) [197]. Antibody 
binding to the coated beads was detected using PE conjugated anti-human IgG obtained 
from BD. Standard curves were produced, but with very poor signal/background ratios, 
and poor absolute signal strength compared to that achieved using published techniques. 
A poly-L-Lysine conjugation method derived from other published work [193] was then 
used, with limited improvements in signal/background ratio (Figure 4-2). Advice was 
then sought from Dr Lindsey Ashton (Institute of Child Health, London), in developing 
the protocol subsequently used and described in the methods chapter of this thesis 
(section 3.2.5.1). PE conjugated anti-human IgG supplied by BectonDickenson was 
replaced by antibody obtained from Southern BioTech, resulting in a marked 
improvement in the assay performance (Figure 4-2). Consequently, this reagent was used 
exclusively in subsequent studies. 
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Figure 4-2 shows preliminary results in establishing microsphere assays. 
Comparison of three different experimental techniques to assay IgG antibodies against pneumococcal 
capsular polysaccharide (Pn-CP) 19F, using antigen-conjugated microspheres. The blue line was obtained 
using beads conjugated using the periodate method, with anti-IgG antibody from BD (diluted 1 in 20). The 
red line was obtained using beads conjugated with the poly-L-lysine method, and IgG antibody from BD 
(diluted 1in 20). The black line was obtained in a separate experiment using beads conjugated with the 
poly-L-lysine method, and IgG antibody from Southern BioTech (diluted 1 in 200). 
4.4 Suboptimal conjugation of substrate to bead affects assay 
performance. 
As discussed above (section 4.1), first principles indicate that substrate density may affect 
assay performance. This was tested when developing the bead-based assay for antibodies 
to tetanus toxoid (Figure 4-3). When limiting amounts of tetanus toxoid were available 
during bead conjugation, subsequent assay performance was adversely affected in that the 
mean fluorescent intensity (MFI) was reduced, and prozone phenomena were noted.  
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Figure 4-3 shows that limiting amounts of available antigen during conjugation to beads affects 
subsequent assay performance.  
Comparison of three different experimental techniques to assay IgG antibodies against tetanus toxoid (in 
standard pneumococcal reference serum). Techniques varied only in the concentration of tetanus toxoid 
used during the bead-conjugation reaction - the red line represents a coating concentration of 5μg/ml, the 
blue line 7.5μg/ml and the back line 12μg/ml. 
4.5 No evidence of inter-assay interactions within multiplexed 
system. 
As discussed above, variations in bead‟s substrate density can affect assay performance, 
and certain anti-PnCP antibodies have been reported to be cross reactive with other 
PnCPs [198]. Thus it was important to confirm that anti-PnCP antibody assays were 
minimally affected by PnCPs bound to other beads present during multiplexed assays. 
Seven PnCP were selected for use to assay levels of specific anti-PnCP. Assays for 
antibodies against each PnCP were therefore performed separately (monoplex) and 
together (multiplex) (see Figure 4-4 for an example). Standard curves for each assay were 
comparable under the two conditions, and it was concluded that subsequently these 
assays could be performed as multiplex.  
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Figure 4-4 shows an assay of IgG antibodies against PnCP-9 – demonstrating consistency between 
monoplex and multiplex methods. 
Detectable levels of anti-PnCP-9 antibody in serial dilutions of standard serum were comparable whether 
measured alone (monoplex) or in the presence of six other sets of beads; each set being coated with one of 
the six other PnCP serotypes. 
4.6 Confirming optimal pre-absorbtion conditions for assay of 
serotype specific anti-pneumococcal antibodies. 
Commercial preparations of PnCP contain contaminating CWPS [199]. Furthermore, as 
discussed in section 4.2, the WHO advises that sera are preabsorbed with CWPS and 
PnCP-22f, which has epitopes that cross react with other PnCP, prior to performing 
assays for serotype specific anti-PnCP antibodies, to reduce the levels of cross reactive 
antibodies present [194].  
Optimal preabsorption conditions in the context of a microsphere-based assay were 
tested. A range of different concentrations for the two preabsorbing agents were used 
(Table 4-1), and their effect on subsequent assay performance was tested.  
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 Concentration of CWPS 
0 μg/ml 0.5 μg/ml 1 μg/ml 2 μg/ml 
 
Concentration 
of PnCP-22f 
0 μg/ml     
1.25 μg/ml  
   
2.5 μg/ml  
   
5 μg/ml  
   
Table 4-1 shows the range of concentrations of preabsorbing agents tested during development of 
pneumococcal antibody assay. 
 
Representative examples of these experiments are shown in Figure 4-5. Measured levels 
of some, but not all, antibodies tested were reduced by pre-absorption with CWPS alone. 
Minimal incremental difference was noted with the higher concentration, but 2 μg/ml was 
chosen for subsequent experiments to ensure maximal efficacy. Similarly, pre-absorption 
with PnCP-22f, in addition to CWPS, attenuated the measured levels of some, but not all 
antibody specificities. Little difference was seen between the high concentrations used, 
and 5 μg/ml was chosen for subsequent experiments.  
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Figure 4-5 shows the effect of varying pre-absorption conditions on subsequent performance of IgG 
anti-PnCP antibody assays. 
Panels A, and B: show the consequences of varying preabsorbing CWPS concentration. (No polysaccharide 
22F was used). Red line – no CPS, Blue line – 0.5 μg/ml CWPS, black line – 2 μg/ml CWPS. Panel A – 
measuring antibody to PnCP-19f; panel B – measuring antibody to PnCP-23. 
Panels C, and D: consequences of varying preabsorbing concentration of PnCP- 22f. (CWPS concentration 
kept constant at 2μg/ml). Red line – no PnCP22f, blue line – 2 μg/ml PnCP22f , black line – 5 μg/ml PnCP-
22f. Panel C – measuring antibody to PnCP-1; panel D – measuring antibody to PnCP-14. 
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4.7 Specificity of anti-PnCP antibodies measured by multiplex 
assay. 
The specificity of IgG and IgM antibodies measured in each multiplexed assay was then 
tested by separately pre-incubating eighty-fold dilutions of standard serum 89SF with 
excess amounts (2.5 μg/ml) of each test antigen in addition to standard pre-absorbents 
CPS (2 μg/ml) and PnCP-22f (5 μg/ml). Assay results for these antibody-depleted 
samples were compared with a standard curve from the same serum. This process was 
also subsequently used to confirm successful bead-antigen conjugations when preparing 
more assay reagents. 
Pre-assay depletions resulted in mean reductions in the measured level of all 
corresponding IgG antibody specificities - ranging from 15 fold (PnCP-19f), to over 300 
fold (for PnCP-14) (Figure 4-6, Figure 4-7, and Figure 4-8). Across all tested 
combinations of depleting-antigen and subsequently measured PnCP-specific IgG, the 
average inter-PnCP effect was an 18% reduction in measured specific IgG titre. The 
greatest inter-specificity effect was seen with pre-incubation with 2.5 μg/ml PnCP-1, 
which caused an average 41% reduction in IgG against PnCP-9v, but greater than 95% 
reduction in measured IgG anti-PnCP-1. 
The effect of preabsorption on levels of IgM, specific for the same or other PnCPs, was 
tested once, in a similar manner, for each depleting PnCP (Figure 4-6, Figure 4-7, and 
Figure 4-8). Although depletion of the corresponding antibody was generally less, 
qualitatively analogous findings regarding test specificity were seen. It was concluded 
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that the assays were sufficiently independent during multiplexing that test sera could be 
measured in this manner. 
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Figure 4-6 shows selective depletion of IgM and IgG serotype specific anti-pneumococcal capsular polysaccharide antibodies by excess antigen 
(serotypes 1, 3, and 6b).  
Preabsorption of an 80 fold dilution of standard serum 89-SF with single PnCP specificities (at 2.5μg/ml) in addition to CWPS (2μg/ml) and PnCP-22f (5μg/ml) 
resulted in substantial depletion of serotype specific antibodies and modest or minimal depletion of other antibody specificities.  Upper panels – one experiment 
measuring specific IgM titres after depletions. Lower panels – mean ± SD of 6 separate experiments to measure specific IgG titres; each experiment used 
separately prepared bead sets.   
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Figure 4-7 shows selective depletion of IgM and IgG serotype specific anti-PnCP antibodies by excess antigen (serotypes 9v, 14, and 19f). 
Preabsorption of an 80 fold dilution of the standard serum 89-SF with single PnCP specificities (at 2.5 μg/ml) in addition to CWPS (2 μg/ml) and PnCP-22f (5 
μg/ml) resulted in substantial depletion of serotype specific antibodies and modest or minimal depletion of other antibody specificities.  Upper panels – one 
experiment measuring specific IgM titres after depletions. Lower panels – mean ± SD of 6 separate experiments to measure specific IgG titres; each experiment 
used separately prepared bead sets.   
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IgG anti-PnCP-14 antibodies
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Figure 4-8 shows selective depletion of IgM and IgG serotype specific anti-PnCP antibodies by excess 
antigen (PnCP-23). 
Preabsorption of an 80 fold dilution of the standard serum 89-SF with single PnCP specificities (at 
2.5μg/ml) in addition to CWPS (2μg/ml) and PnCP-22f (5μg/ml) resulted in substantial depletion of 
serotype specific antibodies and modest or minimal depletion of other antibody specificities.  Left panel –
one experiment measuring specific IgM titres after depletions. Right panel – mean ± SD of 6 separate 
experiments to measure specific IgG titres; each experiment used separately prepared bead sets.   
4.8 The human antibody response to phosphorylcholine does 
not fully reflect the response to Pneumococcal Cell Wall 
Polysaccharide. 
It was also intended to establish assays for natural antibodies taken to be representative of 
the B1 cell repertoire (see section 2.5.2). So, based on published research in the mouse 
immune response [100], I sought to establish microsphere based assays for 
phosphorylcholine (PC), the proposed antigenic determinant of CWPS [200-202].
Antigens (either CWPS, or BSA-conjugated Phosphorylcholine) were conjugated to 
microspheres as described previously (see section 3.2.5.1). Assay specificities were tested 
by pre-absorption of 100-fold dilutions of standard serum with either reagent at 
concentrations of 2.5μg/ml, and 10μg/ml, without the addition of PnCP 22f (see Figure 
4-9).
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Depletion testing of the conjugated beads, with the identical antigen was consistent with 
successful conjugation of antigen to the relevant beads, though prozone phenomena were 
also seen on serial dilutions. Pre-absorption with 2.5 and 10 μg/ml PC-BSA reduced 
measured IgM anti-CWPS by 5-10 fold (median of 3 experiments), approximately 
comparable to its effect on IgM anti-PC Abs (10 fold reduction for each concentration, in 
the same experiment). In contrast pre-absorption with 2.5 and 10μg/ml CWPS resulted in 
greater depletion of measured IgM anti-CWPS titres, but less fall in measured IgM anti-
PC levels. 
Figure 4-9 shows cross depletion testing of assays for IgM, IgG1, and IgG2 against phosphorylcholine 
(PC) and Cell wall polysaccharide (CWPS). 
Pre-absorption of a one-hundred fold dilution of standard serum 89-SF with either PC, or CWPS resulted in 
depletion of the relevant IgM antibody specificity, but incomplete cross depletion (upper panel). Lower 
panel demonstrates comparable experiments for IgG1 (blue) and IgG2 (red); partial cross-specificity 
depletion was seen when measuring IgG1 against CWPS and against PC, but measured levels of IgG2 anti-
CWPS increased after pre-absorption with PC. Duplicated symbols, where present, indicate results from 
separate experiments.  
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When testing the effect of depletions on specific IgG1 levels, a comparable pattern was 
seen, except that pre-absorption with 2.5 μg/ml CWPS had minimal effect on IgG1 anti-
PC, whilst pre-absorption with 10 μg/ml appeared to increase measured levels of IgG1. 
Replication of this experiment was not attempted, but it had been performed in parallel 
with the analogous experiment for IgM anti-PC, and one replicate of the tested anti-
CWPS responses, using the same reagents for pre-absorption. 
Further complexity was seen when studying IgG2 responses to these antigens (Figure 
4-9). Levels of IgG2 anti-PC, and IgG2 anti-CWPS were both depleted by pre-absorption 
with their corresponding antigen, but measured levels of IgG2 against CWPS were raised 
by pre-absorption with both concentrations of PC.  
In summary, the evaluation of the assays for antibodies against PC and CWPS identified 
the following: 
1. The presence of prozones within serial dilution testing. 
2. Non-identical depletion patterns by the two antigens - when 2.5μg/ml CWPS and 
10μg/ml PC should contain approximately equimolar amounts of 
phosphorylcholine moieties. 
3. Discrepant results between different antibody subclasses tested for the same 
putative antigen. 
4. A substantial augmentation of some measured antibody titres after certain pre-
absorption conditions. 
It was thus concluded that PC is not likely to be the immuno-dominant epitope in all 
isotypes of the human response to CWPS, and so responses to both antigens should be 
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tested in subsequent experimental samples from patients. Nevertheless, sufficient 
evidence of cross-reactivity between the antibody specificities was obtained to preclude 
secure multiplexing of the two assays, and so subsequent testing of these two responses 
was performed separately. 
4.9 Testing of anti-tetanus toxoid antibodies by microsphere 
assay. 
The performance of microspheres coated with tetanus-toxoid was also tested by depletion 
assays. At the antigen concentration chosen for pre-absorption (2.5 μg/ml) measured IgG 
anti-tetanus toxoid in the pneumococcal standard serum 89-SF was reduced 
approximately 4 fold. In subsequent multiplex testing, pre-absorption with 2.5 μg/ml 
tetanus toxoid had minimal effects on measured levels of IgG against the 7 PnCP, and 
IgG anti-CWPS (data not shown), and vice-versa. It was concluded that anti-tetanus 
toxoid antibodies could be multiplexed with assays of anti-PnCP antibodies (in the 
presence of preabsorption with CWPS and PnCP-22f) or with an assay of anti-CWPS 
antibody.  
4.10  Discussion. 
This work, performed early in my MRC clinical training fellowship, sough to establish 
and validate the subsequent use of microsphere based assays for analysis of isotype 
specific antibodies to various PnCP, to CPS, PC, and to tetanus toxoid, and to perform 
them multiplex where possible.  
The various experiments performed demonstrated satisfactory conditions for antigen-
bead conjugation, and that antigenic epitopes within reagents appear to be maintained 
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after the chemical conjugation to Poly-L-lysine (where necessary), and subsequent 
conjugation to the microspheres themselves.   
Ensuring the presence of excess antigen during conjugation reactions (Figure 4-3), and 
optimal preabsorption conditions (with CPS and PnCP-22f) before performing assays 
(Figure 4-5) minimised the presence of predicted prozone phenomena, but did not 
completely prevent them. It was thus decided that during the subsequent testing of 
multiple experimental sera (chapter 5), serial dilutions should be performed for all 
samples instead of using single dilutions of test sera to be compared with a standard 
curve.  
In contrast, and despite theoretical concerns, extensive cross testing of reagents 
confirmed that there was remarkably little impact on anti-PnCP assay performance when 
performed in the presence of other bead specificities, thus such multiplexed assays were 
used for work described elsewhere in this thesis. Nevertheless, it was notable that during 
PnCP depletion testing, serotype specific IgM titres appeared to fall less than 
corresponding IgG titres (Figure 4-6, Figure 4-7, Figure 4-8). This is not due to the 
relative amounts of serotype specific IgM and IgG in the standard serum [203]. An 
explanation is offered by a recent publication by Baxendale et al [204] which studied 
several human IgM antibodies, produced by hybridomas derived from vaccinated 
volunteers. These antibodies had titratable anti-PnCP activity in a microsphere-based 
assay. In keeping with the findings reported in this thesis chapter, Baxendale et al 
demonstrated the limited sensitivity of their hybridoma-antibodies to depletion by excess 
PnCP, CWPS, or PC, but demonstrated additional poly-reactivity with other antigens 
including self antigens. Molecular analysis of the hybridomas demonstrated minimal 
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deviation from immunoglobulin V, D, and J germline sequences. Based on these findings 
they conclude these are likely to be natural antibody specificities produced by cells of the 
B-1 cell like lineage. They do not report the presence, or absence, of such polyreactive 
species within the IgM fraction of standard serum 89-SF, but if present, they could 
account for the findings shown here (in Figure 4-6, Figure 4-7, and Figure 4-8). 
Importantly, analogous work in isotype-switched, antibody responses to PnCPs do not 
seem derived from the same lineages [205;206]. 
As reported above, general opinion based on published literature from mouse studies 
[200-202] holds that PC is the immunodominant epitope in responses to CWPS. However 
experiments reported here using pooled human serum demonstrated complex and 
mutually-discrepant effects of pre-absorption with either reagent. The findings (Figure 
4-9) are not consistent with the simple concept that PC is the immunodominant epitope to 
human CWPS responses. The published literature includes a report of similar findings, 
with additional variability between individual subjects, when using ELISA based assays 
of human sera [207]. Determining the true specificity, relative quantity, and affinity, of 
these antibodies was beyond the needs of this work as regards the development of the 
assays, but it serves to highlight the complexity of interactions underlying microsphere 
based assays (and ELISAs) and their vulnerability to effects arising from cross-reactive 
antibodies. It was not formally tested whether such interactions are greater in the context 
of multiplexing assays of antibody against CWPS and PC, but it was concluded that for 
subsequent assays of patient sera, these antibodies should be measured separately. 
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4.11  Future work. 
The University of Birmingham Clinical Immunology service have expressed interest in 
further developing the PnCP antibody assays for clinical use, as at present the standard 
(semi-automated) pneumococcal antibody assay only measures bulk isotype-specific 
responses to a mixture of serotypes. The protocols developed during this work have been 
passed on to the clinical lab, but further work is likely to be needed before this assay can 
be offered for clinical use. Their parsimonious use of serum makes them suitable for 
studies where only small samples are available, for instance from infants. 
In the setting of a clinical laboratory the ability to use point dilutions of test samples 
would be of great value, and the need to confirm the accuracy and precision of absolute 
measurements of antibody is essential. This is likely to involve further work to minimise, 
or control for, prozone phenomena, and validation with QC sera (available from NIBSC) 
would be required. All the serotypes chosen for this work are amongst those in 
Pneumovax II - the 23 valent polysaccharide vaccine, and include some but not all those 
in the 7 valent conjugate pneumococcal vaccine Prevnar, and it may be desirable to widen 
the assay repertoire accordingly. It is reasonable to speculate that other pneumococcal 
antigens could be conjugated to microspheres in a similar fashion, but the testing required 
to exclude significant cross reactivity would increase exponentially.  
The recent paper by Baxendale et al [204] indicates that polyreactive IgM antibody 
produced after pneumococcal vaccination (and thus likely also to be produced after 
infection) can be detected by apparently serotype-specific microsphere based assays (and 
ELISAs) when configured to measure IgM antibody. Whilst it may yet be determined that 
the level of such „natural antibody‟ proves to be the best measurable human correlate of 
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protection against pneumococal infection, its potential presence in serum samples has 
implications for the correct interpretation of apparently serotype specific anti-PnCP IgM 
assay results. This is especially so in clinically important settings where the proportion of 
„natural antibody‟ may be increased, such as lymphoid malignancy [208], the response to 
microbial antigens [204;209], autoimmunity [210] or ageing [211]. Thus the ability to 
accurately determine amounts, in serum samples, of IgM that is truly specific for 
particular PnCP serotypes would appear to require further work to clarify this complex 
area. 
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5 AUTOANTIBODIES, UNLIKE ANTIBODIES TO ALL 
EXTRINSIC ANTIGEN GROUPS, FALL FOLLOWING B 
CELL DEPLETION WITH RITUXIMAB 
5.1 Introduction. 
Rituximab causes profound depletion of B cells, which express CD20, from blood and 
tissues [2]. It has been used successfully to treat a number of autoimmune diseases. 
Significant falls in disease-associated IgG and IgM autoantibody levels are often seen 
[3;6;12;212] although this does not always happen [22;23]. 
Autoantibodies against the neutrophil serine protease, proteinase-3 (PR3), are encoded by 
immunoglobulin V region genes that have acquired somatic mutations [24]. These 
findings are consistent with the autoantibodies being produced by plasma cells whose 
precursors have undergone affinity maturation through hypermutation of their 
immunoglobulin V-region genes and selection in GC [44], although immunoglobulin V-
region mutations can be acquired without GC [77;78]. Plasma cells derived from GC in 
the spleen and peripheral LN against protein-based antigens, reside in the bone marrow, 
have the capacity to be very long lived, and typically do not express CD20 [58;59]. 
Nevertheless, as immunoglobulin levels are remarkably constant in adults [155] and 
responses giving persistent antibody levels to new antigens can be induced throughout 
life there must be some turnover of long-lived plasma cells. It is possible that if the 
production of new plasma cells is blocked, for example by B cell depletion with 
Rituximab, this turnover would cease and existing plasma cells would persist indefinitely. 
Levels of affinity matured antibody against tetanus toxoid remain unchanged after B cell 
depletion by Rituximab [3] and falls in serum immunoglobulins are generally modest, 
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although falls in IgM have been seen after repeated cycles of treatment [192]. As levels 
of IgG autoantibodies fall following B cell depletion, we set out to test if this was 
attributable to them being produced by a population of intrinsically short-lived AFC.  
Certain types of antigen seem to induce only extrafollicular antibody responses and many 
of the antibody forming cells produced in these responses are short-lived [74;75]. These 
antigens include those based on pure polysaccharides and lipopolysaccharides that are not 
able to complete the CD4 T cell-dependent selection process required for plasma cells to 
differentiate from GC B cells [44]. In addition, B1 cells produce extrafollicular antibody 
responses, but probably do not form GC [46].  
B cell depletion by Rituximab allows the opportunity to investigate whether cells that 
maintain chronic antibody production after an extra-follicular response to antigen can be 
long-lived in the absence of B cell precursors. In this study these findings are directly 
compared to concurrent antibody production against T-dependent extrinsic antigens, and 
the autoantigen PR3. Such comparisons inform our understanding of why autoantibodies 
often fall after B cell depletion therapy. 
5.2 B cell depletion, clinical responses and autoantibody level 
changes associated with Rituximab. 
A criterion for treatment with Rituximab has been that patients should have active 
disease. This is shown by their pretreatment BVAS [17]. Following Rituximab 7 of the 
11 patients were in clinical remission within 1 month and all patients were in remission 
by 5 months (Figure 5-1, top left). As observed by others [3;213;214], the number of 
CD19
+
 lymphocytes in peripheral blood fell to undetectable levels within 2 weeks (all 
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patients) and remained depleted in 10 of 11 patients throughout the five-month 
observation period (Figure 5-1, top right). In one patient, a very low level of CD19
+
 cells 
was detected 5 months after Rituximab but not on retesting one month later.  
IgG anti-PR3 levels fell progressively in most patients, though in two patients little 
change in autoantibody titre was seen during the 4-5 month period studied. (Figure 5-1, 
bottom right). In two other patients titres became undetectable 2 weeks after treatment 
and remained so through 4-5 months. A further two patients‟ autoantibody titres became 
undetectable after 4-5 months. Clinical response characteristically antedated the fall in 
anti-PR3 levels. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5-1 shows changes in disease activity, B cell 
numbers, and serum IgG anti-PR3 titre, after 
treatment with Rituximab. 
Each triangle represents results from one patient. Top 
left - change in disease activity score (BVAS). Top 
right - change in peripheral B cell count during 
treatment. Bottom left - change in IgG anti-PR3 
antibody titre during treatment. Some dotted lines have 
been used in panel C to identify patients‟ sequential 
results without ambiguity. 
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5.3 Resistance of serum antibody titres against extrinsic 
antigens to depletion by Rituximab. 
The fall in anti-PR3 levels induced by Rituximab were not reflected by a parallel fall in 
antibody levels to different classes of antigen, including those that do not induce 
productive GC. Responses putatively induced from MZ B cells, B1 cells or both of these, 
were assessed by measuring antibody titres to PnCP 1, 3, 6b, 9v, 14, 19, and 23f, as well 
as PC and CWPS. PnCP 3 and CWPS evoke responses in the first year of life, perhaps 
from B1 cells. Other serotypes, including PnCP 1, 6, 14, and 23 produce responses later 
in infancy [102] and are candidate responses of MZ B cells; the antibody response to a 
purified PnCP serotype vaccine does not induce responses that are associated with 
affinity maturation [215]. Natural IgM antibody against A and B blood group antigens 
[103] were also measured. Finally, antibody against tetanus toxoid and EBV-CA – 
responses in which other studies have demonstrated affinity maturation [216-218] –  were 
used as exemplars of TD responses with plasma cells arising GC.  
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Figure 5-2 shows absolute 
levels of IgM and IgG, and 
relative titres of antibodies 
that are specific for either 
Proteinase 3 or one of a 
range of entrinsic antigens, 
in sera of patients about to 
receive treatment with 
Rituximab.  
Panel A shows relative titres 
of IgG anti-Proteinase 3, and 
IgG anti-EBV CA, and the 
absolute serum levels of total 
IgM and IgG. Panels B, C, 
and D respectively show the 
serum titres of IgM, IgG1 and 
IgG2 specific for various 
extrinsic antigens, relative to 
the titre in pneumococcal 
standard serum 89SF (dotted 
line).Each  represents a pre-
treatment serum antibody titre 
in a patient for whom the same 
antibody was also detectable 
in the subsequent post-
treatment sample. Each  
represents a pre-treatment 
serum antibody titre in a 
patient for whom the same 
antibody was not detectable in 
the subsequent post-treatment 
sample.  represent the 
lower limits of detection for 
each assay. In each panel, 
numbers just above the x axis 
report the number of patients 
in whom the relevant antibody 
could not be detected in serum 
prior to treatment.  
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Pre-treatment, relative antibody titres indicate that most patients had detectable IgM 
antibody for each antigenic specificity. Seven of eleven patients had IgG1 against tetanus 
toxoid and each patient had IgG2 against at least one PnCP other than PnCP 3. All had 
IgG2 against CWPS (Figure 5-2). In striking contrast, log10 % change in titres for each 
antibody demonstrated that anti-PR3 antibodies are the exception, falling to a median of 
22% of pre-treatment value in 4-5 months (Figure 5-3 ). IgM titres against all extrinsic 
antigens fell to medians around 70% of starting values (medians 83 to 40%). Comparable 
changes were seen in total serum IgM (median fall to 55% of original value). IgG titres 
against extrinsic antigens typically remained unchanged; only IgG2 antibodies against PC 
fell to a median of 70% of the starting value. Analogous results were obtained for total 
serum IgG (median fall to 70% of original value). IgM antibody titres to A and B blood 
group antigens typically remained unchanged.  
The percentage change in IgG anti-PR3 levels was significantly different to the changes 
in IgG2 titres against all PnCP (p<0.05 for each comparison) and in IgG2 against CWPS 
(p<0.05). Changes in levels of IgG anti-PR3 were also significantly different to those in 
IgG against EBV-CA and IgG1 against tetanus toxoid (both p<0.05), and significantly 
different to changes in IgM against CWPS, and changes in IgM isohemagglutinins (both 
p<0.05). The differences between the changes in IgG anti-PR3 and that in IgM against 
PC (p=0.08) were not significant. 
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Figure 5-3 shows that 
patients’ serum titres of 
IgG anti-PR3 typically fall 
substantially in 4-5 months 
after treatment with 
Rituximab, whereas serum 
levels of IgM and IgG1 and 
IgG2 specific for various 
extreinisc antigens are 
generally preserved. It also 
demonstrates that most 
patients’ total serum IgG 
and IgM levels are little 
changed after Rituximab. 
Panel A shows post treatment 
serum titres of IgG anti-
Proteinase 3 and IgG anti-
EBV CA and total serum IgM 
and total serum IgG, 
expressed as a percentage of 
the level in the corresponding 
pre-treatment sample. Panels 
B, C, and D respectively 
show post treatment serum 
titres of IgM and IgG1 and 
IgG2 specific for various 
extrinisic antibodies, also 
expressed as a percentage of 
the level in the corresponding 
pre-treatment sample. The 
dotted lines (at 100%) 
represent no change in titre 
during the intervening time. 
Each  represents a result 
from a patient in whom both 
samples contained detectable 
antibody. Numbers along 
each x axis report the small 
number of patients whose 
antibody titres became 
undetectable after treatment. 
(The initial antibody titre of
these patients and the lower 
limit of detection of the antibody are shown in Figure 5-2.)  represent median % change (where 3
paired values are available and all patients with antibody at presentation retained a detectable antibody 
titre).
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5.4 Discussion and future work. 
The falls in circulating anti-PR3 autoantibody levels seen in patients treated with 
Rituximab in this study are consistent with findings of other groups treating patients with 
ANCA-associated vasculitis [212;219;220] or rheumatoid arthritis [221] with this agent.  
The relative insensitivity to Rituximab of levels of antibody against some extrinsic 
antigens has also been reported previously [3;13;221]. The current work extends this by 
studying in greater detail antibodies to a wider range of antigens that have been found to 
have a different cellular basis for antibody production in experimental animals. The 
observed fall in autoantibody titres contrasts markedly with the relative preservation of 
antibody levels against extrinsic antigens of each of the classes studied.  
Although many AFC resulting from extrafollicular responses in lymph nodes (LN) and 
spleen are short lived, close examination indicates that this short lifespan is not intrinsic. 
Rather it relates to limited local stroma that supports long-term plasma cell survival. 
Those plasma cells that gain access to this stroma can survive for extended periods [60]. 
If, against this evidence, antibody from extrafollicular responses is produced exclusively 
by short-lived plasma cells, Rituximab therapy would be expected to cause a fall in titres 
of antibody against antigens, like PnCP, that exclusively provoke extrafollicular 
responses. In autoimmune disease, where antigen is virtually limitless, plasmablasts could 
contribute substantially to antibody production. Available evidence indicates that 
unsupported AFC die well within a week of their precursor B cells being triggered by 
antigen [60]. Thus even if maximal tissue depletion of B cells by Rituximab took up to 4 
weeks, it is likely that no AFC would exist outside supportive niches 5 weeks after 
Rituximab administration. If this resulted in the cessation of all anti-PR3 production, 
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levels of this autoantibody would be expected to halve in 20 days – the serum half life of 
IgG [222]. Complexation with circulating autoantigen would probably accelerate loss of 
anti-PR3 from the circulation, making the fall in titre even faster. All studies reporting the 
kinetics of change in IgG autoantibody levels following Rituximab [13;219;221] indicate 
a gradual fall in autoantibody titre that is not consistent with this scenario. Similarly, if 
production of antibody against extrinsic antigens also ceased, measured levels of antigen-
specific IgG would fall to around 6% of their starting values by 4-5 months after 
Rituximab. With a half-life of 5 days [222], IgM antibodies would go through at least 17 
half lives before the time when titres were remeasured. No such fall in IgM antibody 
titres was observed in patients during our study. These considerations indicate that, 
following Rituximab, there must be substantial ongoing production of all antibodies 
tested, and it is consistent with a hypothesis that chronic antibody production is 
predominantly by cells that can be long-lived in the absence of competition from newly-
formed plasma cells. 
We do not know if Rituximab treatment depleted all plasma cell precursors in patients. 
The loss of blood B cells is impressive, but tissue studies could not be performed, for 
ethical reasons. Rituximab therapy has been reported to deplete B cells from the appendix 
[223], and the spleen [224]. Vos et al have reported a reduction in CD22
+
 cells in 
rheumatoid synovium one month after treatment [225]. More recently we have reported 
that CD20
+
 cells were detectable in diseased lung tissue removed from a patient with WG 
who was relapsing at a time when peripheral B cells remained undetectable - 13 months 
after prior Rituximab therapy [226]. Recall responses to antigen are impaired (but not 
abolished) during the period of post-Rituximab B cell depletion, consistent with an effect 
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on non-circulating memory B cells [67]. Two other studies have reported residual B cells 
in lymphoid tissue after Rituximab, but both used suboptimal depletion regimes 
[214;227]. 
Studies of anti-CD20 antibody therapy in mice with B cells that express human CD20, 
show some non-circulating B cells are spared from depletion [40]. It is speculative 
whether this reflects B cell depletion by Rituximab in humans, for efficacy of antibody-
mediated effector mechanisms – complement, and cell damage by phagocytes and 
antibody-dependent NK cell cell-mediated cytotoxicity – differs in humans and mice. 
Serotype specific antibody responses to natural pneumococcal infection can include 
production of plasma cells that have acquired somatic mutations in immunoglobulin V-
region genes [205;228]. This is likely to result from pneumococcal cell protein being 
associated with capsular polysaccharide forming a natural conjugate antigen. This could 
have occurred in the PnCP antibody responses measured in our patients.  
After the bulk of the work contained in this chapter was published [229], Baxendale et al 
[204] have reported findings that indicate caution may be warranted in interpreting IgM 
anti-PnCP titres derived from luminex based assays. This issue is discussed in greater 
depth in section 4.10 above. Importantly, these concerns do not appear to relate to the 
measurement of IgG anti-PnCP titres. 
Notwithstanding these caveats, the preservation of antibody levels against all extrinsic 
antigens assessed makes it unlikely that selective anti-PR3 loss reflects a type of antibody 
response that is uniquely sensitive to Rituximab. 
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If neither variations in the expected half-lives of different antibodies, nor differences 
between particular antibody production pathways, can account for the differential 
sensitivity of autoantibody production to Rituximab, why do autoantibody titres fall after 
Rituximab? Such observations are most comfortably explained by treatment destroying 
niches in inflammatory tissues that selectively support the survival of autoantibody 
secreting cells. „Inflammatory‟ plasma cell niches may have biological value in the 
response to infection by linking the duration of antibody production to the duration of 
injury. 
Figure 5-4 shows a plasma cell present in the renal 
interstitium of a patient with ANCA-associated renal 
vasculitis.  
Photo courtesy of Dr Desley Neil, University of 
Birmingham.  European Journal of Immunology. 2008. 
Plasma cells are present at inflamed sites in ANCA-associated vasculitis [49] (see also 
Figure 5-4), rheumatoid arthritis [53;230], lupus [231] and animal models of lupus 
[232;233]. Plasma cells are also reported in human kidney allografts [234] and liver 
allografts [235] that are undergoing rejection.  
Furthermore, some reports indicate that a disproportionate number of plasma cells at 
these sites produce disease related autoantibodies [230;233]. Interestingly a recent 
publication reports that even where local lymphoid neogenesis occurs in inflamed tissue, 
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nearby plasma cells do not appear clonally related [53]. This implies that plasma cells 
migrate there from secondary lymphoid organs. Ectopic antibody production may not be 
confined to autoimmune inflammation, for AFC have been identified in inflammation 
associated with osteoarthritis, a disease that probably does not have an autoimmune 
aetiology [236]. 
Our hypothesis predicts that the plasma cells producing IgG anti-PR3 might have 
chemokine receptors and cell adhesion molecules that allow them to home to and adhere 
to stroma in inflammatory sites. Some appropriate chemokine ligands – CXCL9 and 
CXCL12 - have already been reported in other inflamed tissue [141;237]. 
The molecules present on autoantibody-producing plasma cells may differ from those that 
lead plasma cells in healthy subjects to find stroma in the bone marrow that sustains their 
survival. For example in mice there is evidence that AFC that express CXCR3 are 
attracted to chemokines produced in inflamed tissue [14]. Such differences, if confirmed, 
could have potential implications for the rational design of new therapeutic agents for use 
in autoimmune disease. 
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6 CUCKOO PLASMA CELLS IN INFLAMMATION 
6.1 Introduction. 
Chapter 5 reported the finding that serum levels of human autoantibodies fall after B cell 
depletion by Rituximab. This fall occurs despite preservation of levels of extrinsic 
antibodies representative of all known pathways of antibody production. The differential 
loss of autoantibody is consistent with the hypothesis that plasma cells can be sustained 
in additional niches intrinsically related to autoimmune inflammation. Upon resolution of 
inflammation, the related plasma cell population would be expected to wane, resulting in 
a selective fall of autoantibody levels. 
There is no satisfactory animal model for the autoimmune nature of ANCA-associated 
vasculitis [21]. We therefore sought to test this hypothesis in a wider context – whether 
additional plasma cells could be sustained by „newly-induced inflammatory niches‟, even 
if the immune response generating the plasma cells was unrelated to cause of the 
inflammation. Furthermore we sought to understand the mechanisms for retaining plasma 
cells in such a site, and the way these sites maintain plasma cell survival.  
To this end, we combined two animal models that have been well characterised in our 
research laboratory: 
1. The T-independent response to NP conjugated to the neutral polysaccharide Ficoll 
in QMxB6 mice. In these mice around 5% of the B cells carry a heavy chain 
transgene that renders them NP-specific. Massive numbers of red-pulp splenic 
plasmablasts are produced by 4 days after immunization with NP-Ficoll, but by 6 
days over 95% of these cells have undergone apoptosis. Nevertheless, most of the 
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small proportion of plasmablasts that survive and differentiate into plasmablasts 
survive for more than 2 weeks. It was noted that after immunizing with a variety 
of antigens the number of red pulp antibody secreting cells sustained longer term 
is relatively stable, and consistent between models. The findings have been 
interpreted as evidence for an inherent limit on long-lived plasma cell numbers 
due to a finite number of supportive niches [60]. By using mice with transgenic 
NP-specific B cells massively more NP-specific plasma cells are produced in 
response to NP-Ficoll than can find niches that can secure their long term 
survival. QM mice are transgenic for a heavy chain that, when combined with any 
lambda light chain, confers NP-specificity on resultant immunoglobulins [123]. 
Of the 5% of the B cells in QM x B6 F1 hybrid (QMxB6) mice are NP-specific a 
high proportion are located in the marginal zone. As mentioned above, after 
immunizing these mice with NP-Ficoll there is a massive extrafollicular antibody 
response and 4 days after immunization the red pulp is crammed with NP-specific 
plasmablasts [128].  It is postulated that a lack of niches to sustain the survival 
results in the demise of >95% of the NP-specific antibody forming cells (AFC) on 
the 5
th
 day after immunization. It is also hypothesized that the scattered islands of 
AFC that remain in the red-pulp after this time are sustained by special plasma 
cell-sustaining microenvironments [60]. 
2.  The response to attenuated Salmonella enterica serovar Typhimurium (S. 
Typhimurium). This infection induces a large number of AFC in the splenic red 
pulp and plasma cells can be seen in this site for weeks after immunization [57]. 
Intra-peritoneal infection of C57/B6 mice with 10
5
 live organisms induces a 
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complex immune response, associated with splenomegally. Induction of the 
impressive early and sustained extrafollicular response is T independent, though 
the isotype switched response is a T dependent process. No germinal centres are 
induced in this response until the 4th week when the infection has largely cleared 
[57]. The important point, for our combined model, is that many of the AFC in the 
red pulp and extrafollicular foci persist through the first three weeks of infection 
[57]. The great majority of the AFC in the 3rd week from infection are mature 
(non-dividing) plasma cells. It is postulated that the infection induces a major 
increase in the number of niches that can secure plasma cell survival.  
Figure 6-1 shows a schematic indication of the hypothesis that splenic inflammation results in 
increased numbers of sites that can sustain antibody forming cells beyond 6 days after immunization 
with NP-Ficoll. 
This Figure modified from Sze et al (2000) [60] shows that peak AFC numbers in mouse spleen relate to 
the number of antigen-specific precursor B cells, but that the proportion of AFC sustained after 6 days is 
similar whatever the peak number of AFC produced. The black dashed line shows the AFC numbers in QM 
mice following immunization with NP-Ficoll. We postulated that NP-specific AFC survival might be more 
like the red curve if QMxB6 mice were infected with S. Typhimurium at the time they were immunized 
with NP-Ficoll, due to the increase in AFC-sustaining niches induced by the infection. 
QMxB6 mice that have been infected with 105 live S. Typhimurium intra-peritoneally 
develop new AFC-sustaining niches in the red pulp. We hypothesised that if mice were 
immunized with 30 g NP-Ficoll at the time of infection a proportion of the AFC 
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occupying the infection-induced niches would be NP-specific and NP-specific antibody 
titres would be higher than in control immunized but non-infected mice (Figure 6-1). In 
this scenario an increased proportion of the NP-specific AFC produced would survive 
past the first week after immunization. This has been a collaborative laboratory project 
involving several people, and a range of techniques. The division of work amongst 
members of the research group is summarised in Table 6-1. 
 Dr Alastair 
Ferraro 
(PhD 
student) 
Ms Jenny 
Marshall 
(PhD 
student) 
Dr Elodie 
Mohr 
(Post-
doctoral 
researcher) 
Ms Saeeda 
Bobat  
(PhD 
student) 
Immunizations, harvesting 
spleens and blood 
    
Flow cytometric analyses of 
cell suspensions from spleens 
    
Quantification of serum 
antibody levels 
    
Immunohistochemistry     
Cell counting from sections     
Confocal microscopy     
RT-PCR analysis of  bulk 
tissues 
    
Microdissection and real-time 
RT-PCR of AFC-associated 
and control tissues 
    
Culturing and quantification 
of attenuated S. Typhimurium 
    
Table 6-1 shows the division of laboratory work reported in this chapter. 
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6.2 Splenomegally induced in QMxB6 mice infected with S. 
Typhimurium. 
As expected from published work, mice infected with S. Typhimurium developed 
splenomegally. This was generally seen by day 4 post immunization, was universal at day 
8, and was somewhat reduced at day 35 (Figure 6-2 ). Additional co-immunization with 
NP-Ficoll had little effect on the development of splenomegally and immunization with 
NP-Ficoll alone did not induce splenomegally. 
 
 
 
 
 
 
 
 
 
Figure 6-2 shows splenic weight increases following infection of QMxB6 mice with S. Typhimurium. 
Each symbol shows values from one mouse. The legend for the symbols is above the figure.  
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6.3 Infection with S. Typhimurium prolongs the serum IgM 
response to NP that follows immunization of QMxB6 mice 
with NP-Ficoll. 
As previously reported for QMxB6 mice immunized with NP-Ficoll there is a 45 fold rise 
in the median IgM anti-NP antibody titre by 4 days after immunization. Strikingly this 
titre has already started to fall by day 8 (Figure 6-3). At four days after immunization and 
co-infection titres were if anything higher than in mice receiving only NP-Ficoll. In 
contrast to the non-infected mice the IgM titres in immunized and infected mice were 
sustained at day 8, and still higher than in non-infected animals at day 35. Thus on the 
basis of the serum IgM anti-NP titres co-infection with S. Typhimurium significantly 
augments the durability of the AFC response to NP-Ficoll. The next section probes the 
cellular basis for this difference. Interestingly the group of mice infected with S. 
Typhimurium without NP-Ficoll showed significant rises in IgM anti-NP titres. 
 
Figure 6-3 shows a 
graph of changes in 
IgM anti-NP titre 
in QMxB6 mice 
after immunization 
with NP-Ficoll, 
infection with S. 
Typhimurium, or 
both, which shows 
prolonged elevation 
of IgM anti-NP 
titre after 
immunization in 
the context of co-
infection. 
Each symbol shows 
values from one 
mouse. The legend 
for the symbols is 
above the figure. 
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6.4 Splenic NP-specific antibody forming cell numbers are 
increased by concurrent S. Typhimurium infection. 
The effect of co-infection with S. Typhimurium on the serum antibody response of 
QMxB6 mice to NP-Ficoll is reflected in the numbers of antibody producing cells 
induced. The number of such cells was estimated both by flow cytometric analysis of 
splenic cell suspensions, and by counting of cells in histological sections of spleen.  
6.4.1 Splenic CD138+ cell counts estimated by flow cytometry. 
Flow-cytometry was used to identify the total number of CD138
+
 cells present, and the 
number that also bound NP-phycoerythrin (NP-PE). Representative gating strategies are 
shown in Figure 6-4. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6-4 shows representative flow cytometry dot plots showing the proportion of CD138
+
 cells 
staining for intracellular IgG3
 
and anti-NP in individual mice at day 8 after infection or 
immunization. 
Numbers on the dot plots show the percentage of cells in the corresponding gate. 
By day 4, total CD138
+
 cell numbers increased over 45-fold after immunization with NP 
Ficoll alone, and over 180-fold in those immunized and also infected with S. 
Typhimurium (Figure 6-5). An overwhelming proportion of these cells were specific for 
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NP, irrespective of co-infection with S. Typhimurium. Thus compared to naïve mice, NP-
specific CD138
+
 cell numbers were 100-fold higher in immunized mice, and more than 
400-fold higher in those immunized and co-infected.  
By day 8 median number of NP-specific CD138
+ 
cells in immunized mice then fell by 20 
fold consistent with published reports [60]. In contrast, in mice immunized and co-
infected with S. Typhimurium, the median number of NP-specific CD138
+
 cells fell 8 
fold. Thus, taking into account the higher day 4 AFC numbers in the mice coinfected with 
S. Typhimurium, at day 8, NP-specific CD138
+
 cell numbers in immunized and infected 
mice were over 10 times higher than in mice immunized with NP-Ficoll only. This 
differential is substantially greater than the difference in median splenic weights (5 fold) 
indicating a greater frequency of CD138
+
 cells in the infected mice. 
At day 35, NP-specific cell numbers still remained approximately 2.5-fold higher in 
immunized and co-infected mice than in their non-infected peers, but this was no greater 
than the difference in median weights at the time. 
Surprisingly the mice infected with S. Typhimurium but not immunized with NP-Ficoll 
mounted an NP-specific antibody response. Their total numbers of CD138
+
 cells and 
numbers of NP-specific CD138
+
 cells increased gradually until day 8. At this point the 
number of NP-specific AFC, as assessed by flow cytometry, was comparable to that in 
mice co-immunized with NP-Ficoll and this continued through to day 35. Not 
surprisingly the proportion of CD138
+
 cells specific for NP was higher in those mice that 
were immunized with NP-Ficoll (Figure 6-5). 
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Figure 6-5 shows flow 
cytometric quantification of 
changes in the total numbers 
of CD138
+ 
cells, and changes 
in the proportion and 
absolute numbers of CD138
+
 
cells that were NP-specific, in 
spleens of mice immunized, 
infected, or both. 
Within each panel, each 
triangle represents values from 
one mouse. The legend for the 
symbols is above the figures. 
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6.4.2 Co-infection with S. Typhimurium increases numbers of NP-
specific AFC in the splenic red pulp after immunization with NP-
Ficoll, but also generates extra-follicular foci of AFC. 
Splenic sections from non-immunized mice, and those immunized with NP-Ficoll, 
infected with S. Typhimurium, or both, were examined using immunohistochemical 
techniques (Figure 6-6 and Figure 6-7). Anti-IgD antibody was used to identify the B cell 
follicles. These were usually seen adjacent to a T zone that stained strongly with anti-
CD3 antibody (Figure 6-6B). Most NP-specific AFC were found in the red pulp, but in 
some sections, NP-specific AFC could be seen in extra-follicular foci. Extra-follicular 
foci are clusters of AFC located at the interface between the T zone and main red pulp 
area, and contiguous with both (see Figure 6-6F, and Figure 6-7).  
Before immunization, sparse numbers of cells containing cytoplasmic anti-NP antibody 
were present in the splenic red pulp. Four days after immunization with NP-Ficoll, 
massively increased numbers of NP-specific AFC were present throughout the red pulp. 
In mice immunized with NP-Ficoll and infected with S. Typhimurium the enlarged red 
pulp is filled with even more impressive expanses of NP-specific AFC.  
By day 8 after NP-Ficoll, far fewer NP-specific red pulp AFC are seen. This loss of cells 
was less marked in mice co-infected with S. Typhimurium. In the co-infected group but 
not the group receiving NP-Ficoll only, NP-specific AFC were also seen at day 8 in 
extra-follicular foci. By day 35 the differences in the number of NP-specific AFC 
between groups was not marked, except for the red pulp still being larger in the infected 
mice. Most NP-specific AFC at day 35 were in the red pulp. 
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Figure 6-6 shows histological 
changes associated with 
immunizing QMxB6 mice 
with NP-Ficoll with or 
without coinfection with S. 
Typhimurium 
The heading above each 
photomicrograph shows the 
mouse group in relation to 
immunization and/or infection 
and the staining used. NP-F / 
Sal = NP-Ficoll immunization 
with S. Typhimurium infection. 
Microscope magnification of 
the photomicrographs is x 50. 
Panel A, small background 
numbers of NP-specific AFC 
in the red pulp (R) and the 
concentration of NP-specific B 
cells in the marginal zone, 
which lies outside the IgD-
staining follicles (F). In a serial 
section (panel B) CD3 staining 
cells identify the T zone (T). 
Panels C and D show the 
massive numbers of blue-
staining AFC in the red pulp 4 
days after immunization with 
NP-Ficoll Blue staining within 
the follicles identifies NP-
specific germinal centres. The 
larger red pulp area seen in the 
co-infected mouse (panel D) 
compared to that in the non-
infected group (panel C) is 
representative of all mice in the 
co-infected group. Panels E 
and F show that by 8 days 
after NP-Ficoll, AFC in the red 
pulp are now confined to 
discrete areas. In addition there 
are AFC in extrafollicular foci 
(EF). By day 35 after NP-
Ficoll (panels G and H) NP-
specific AFC in both infected 
and non-infected groups are 
confined to discrete areas in 
the red pulp. 
Naïve mouse. CD3 IgD x50 
Day 8 NP-F / Sal. NP IgD. x50 
F 
Day 35 NP-F / Sal . NP IgD  x50 
H 
Day 35 NP-Ficoll NPIgD x50 
G 
Day 4 NP-Ficoll. NP IgD x50 
C 
Day 4 NP-F / Sal. NP IgD. x50 
D 
Day 8 NP-Ficoll. NP IgD x50 
E 
Naïve mouse. NP IgD x50 
A B 
R 
R 
T 
F 
EF 
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Figure 6-7 shows a representative photomicrograph of 
mouse spleen 8 days after infection with S. 
Typhimurium demonstrating prominent extra-
follicular foci containing NP-specific AFC. 
A large collection of NP-specific AFC is present in the 
extra-follicular focus (EF) adjacent to the T zone (T) 
(unstained). A few additional NP-specific AFC are seen 
in the red pulp (R). Original magnification x50. 
 
 
 
 
 
 
Relatively few NP-specific AFC were seen in mice sacrificed 4 days after infection with 
S. Typhimurium alone. At day 8, these mice had impressive extra-follicular foci filled 
with clearly NP-specific AFC and some red pulp NP-specific AFC (Figure 6-7). 
An estimate of NP-specific AFC numbers in the spleen of each mouse was also obtained 
by counting cells/unit area in histological sections using the Weibl point counting 
technique (Figure 6-8 top panel). Relative cell counts by this method broadly confirm the 
findings from flow cytometric studies.  
Where possible, the location of NP-specific AFC cells was also recorded - as being either 
in the red pulp or in extra-follicular foci. This was not possible in spleens from mice 
sacrificed at day 4 after immunization with NP-Ficoll, whether co-infected or not, due to 
confluent areas of NP-specific AFC. As previously described [60], red pulp NP-specific 
AFC dominated the response arising after immunization with NP-Ficoll, as shown by the 
ratio between numbers of NP-specific AFC in red pulp to those in extra-follicular foci at 
day 8 and 35 (Figure 6-8 bottom panel). Thus in these mice, changes in red pulp NP-
specific AFC numbers closely reflect changes in total numbers of NP-specific AFC 
(Figure 6-8 middle panel).   
   
EF 
RP 
T 
D8 Sal only. NP IgD x50. 
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In mice infected with S. Typhimurium, and irrespective of prior co-immuinzation wih 
NP-Ficoll, the NP-specific AFC response was not so overwhelmingly confined to the red 
pulp at day 8; the median ratio between the number of NP-specific AFC in the red pulp 
and the number in extra-follicular foci was less than 4. These extra-follicular foci, 
prominent in infected mice, also contained many AFC that were not specific for NP (see 
Figure 6-16). 
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Figure 6-8 shows total 
numbers of splenic NP-
specific AFC and their 
location following 
immunization with NP-Ficoll, 
with or without co-infection. 
Within each panel, each 
triangle represents the values 
from one mouse. Open 
triangles represent data from 
histological sections 
prospectively noted to have 
relatively indistinct staining. 
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6.5 AFC are still being produced at day 8 after infection as 
shown by the continued presence of plasmablasts. 
Increased numbers of plasma cells in the red pulp at day 8 after NP-Ficoll and co-
infection with S. Typhimurium could either be due to prolonged survival of AFC or their 
continued production, or a combination of both of these. To see if there were greater 
numbers of NP-specific plasmablasts in the co-infected mice compared to those receiving 
NP-Ficoll only histological sections were stained for anti-NP antibody and proliferation-
associated nuclear antigen - Ki67. By day 8 after immunization with either NP-Ficoll, or 
infection with S. Typhimurium, or both, few red pulp NP-specific AFC contained nuclear 
staining for Ki67 (Figure 6-9, and Figure 6-10). Thus the AFC in the red pulp in all 
groups of mice at this stage are plasma cells. On the other hand, both groups of infected 
mice had extrafollicular foci with ~30% of Ki67
+
 NP-specific AFC, while, as shown in 
the previous section, mice receiving NP-Ficoll had little or no evidence of extrafollicular 
foci. As expected at day 4 after NP-Ficoll, before the mass loss of NP-specific AFC from 
the red pulp, essentially all the NP-specific AFC that form sheets of cells in the red pulp 
were Ki-67
+
. 
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Figure 6-9 shows that eight 
days after immunization 
with NP-Ficoll almost all red 
pulp AFC have left cell 
cycle, while plasmablasts are 
still present in 
extrafollicular foci of mice 
infected with S. 
Typhimurium  
The mouse group, staining 
patterns and objective 
magnification are shown 
above each photomicrograph. 
Panels A-D show QMxB6 
spleen 8 days after NP-Ficoll. 
A) orients with CD3 and IgD 
staining while the same area 
of a serial section B) is co-
stained for NP binding and the 
proliferation-associated 
nuclear marker - Ki67. The 
red box encompasses red pulp 
with a focus of NP-specific 
AFC and the green box red 
pulp largely devoid of AFC as 
well as an area of T zone red 
pulp junction, which typically 
is associated with 
extrafollicular focus 
formation; no AFC are in this 
area. C) and D) show the 
boxed areas of B) in higher 
power).  
Panels E-H are analogous 
photomicrographs at day 8 
after immunization and co-
infection, but in this series the 
red box shows AFC-
containing red pulp and the 
green box extra-follicular 
focus. Approximately one 
third of AFC in the latter are 
Ki67+, indicating 
proliferation, while the red 
pulp AFC are Ki67-. In 
infected mice, extensive red-
pulp Ki67+ staining that is not 
associated with NP-specific 
AFC is likely to reflect extra-
medullary haemopoesis. 
Microscope magnification of 
the photomicrographs is either 
x50 or x200 as specified in the 
legend of each panel. 
   
  
A  B  
C  
  
Day 8. NP-Ficoll. CD3 IgD x50  
 
Day 8. NP-Ficoll. NP Ki67 x200  
 
Day 8. NP-Ficoll. NP Ki67 x200  
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Figure 6-10 shows the distribution of NP-specific AFC in the spleen 8 days after infection alone, 
where proliferation amongst these AFC is again confined to extra-follicular foci.  
The red box as in Fig 1-9 contains red pulp NP-specific AFC while the green box includes part of an 
extensive extrafollicular focus of NP-specific AFC. Red-pulp Ki67+ staining that is not associated with NP-
specific AFC is likely to reflect extra-medullary haemopoesis. Microscope magnification of the 
photographs is either x50 or x200 as specified in the legend of each panel. 
 
6.6 Increased numbers of non-proliferating splenic NP-specific 
plasma cells are sustained during S. Typhimurium infection.  
The lack of Ki-67 staining by red pulp AFC at 8 d after immunization shows that these 
cells had differentiated into plasma cells. Nevertheless, the presence of proliferating NP-
specific plasmablasts in extra-follicular foci is consistent with the possibility that these 
red pulp plasma cells are being rapidly renewed. To see if the new plasma cell niches 
were supporting longer term plasma cell survival we pulse labelled NP-specific AFC with 
 
 
  
  
A  
  
D  
  
C  
  
B  
Day 8. Sal only NP Ki67 x200 
Day 8. Sal only NP Ki67 x50 
Day 8. Sal only NP Ki67 x200 
Day 8. Sal only CD3 IgD x50 
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the thymidine analogue – 5-Bromo 2΄-deoxyuridine (BrdU) and assessed if the labelled 
cells persisted in the red pulp niches. BrdU was provided in mice‟ drinking water from 24 
hours to 120 hours after inoculations. During this time dividing cells, including 
plasmablasts, incorporate BrdU into cells‟ DNA but any division occurring after 120 
hours will result in subsequent loss of any previously incorporated BrdU. Thus BrdU
+
 
AFC present at later timepoints will be those plasma cells terminally differentiated before 
day 5. As plasma cells may live up to three days without specific supportive factors [45], 
only survival beyond that time could be attributable to supportive niches. Enhanced 
survival of plasma cells was therefore examined in mice at days 9, and at 25 days after 
immunization i.e. 4 and 21days after the BrdU pulse.  
Numbers of splenic CD138
+
 cells and NP-specific CD138
+
 cells as well as the proportion 
of NP-specific CD138
+
 cells that was BrdU
+
, were assessed by flow cytometry at 4 days 
(i.e. during the pulse), 9 day, and 25 days after the different inoculations. Representative 
flow cytometric dot plots are shown in Figure 6-11. 
The results of the second experiment are shown in Figure 6-12. This confirms previous 
findings that at day 4 and at day 9, total numbers of CD138
+
 cells (upper left panel), and 
also numbers of NP-specific CD138
+
 cells (upper right panel), are higher in immunized 
and co-infected mice than in their immunized but not infected peers. A median of 97% of 
NP-specific CD138
+
 cells had incorporated BrdU by 4 days after immunization with NP-
Ficoll, irrespective of co-infection with S. Typhimurium, thus confirming technical 
success of the BrdU methodology at identifying proliferating AFC. Amongst day 9 mice, 
median numbers of NP-specific CD138
+
 cells were 12-fold higher in immunized and co-
infected mice, as compared to mice receiving NP-Ficoll only. This impressive difference 
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was greater than the 7.7-fold differential in median weights, between the same two 
groups of mice. No difference in median numbers of NP-specific CD138
+
 cells was 
detectable between different groups of day 25 mice. 
Figure 6-11 shows that many of the NP-specific CD138
+
 cells present 9 days after immunization 
and/or infection retain BrdU taken up in the first 5 days of the response.  
Representative flow cytometry dot plots are from mice given BrdU between 24 and 120 hours after 
inoculation(s). In the 2nd column, and 3rd columns gated CD138+ cells in spleen suspensions are analysed 
for BrdU incorporated into DNA and NP binding. 
In infected but not immunized mice, a median 82% of NP-specific cells had incorporated 
BrdU at day 4, consistent with the more gradual increase in NP-specific AFC numbers 
seen in this group. However, the absolute number of BrdU
+
 NP-specific CD138
+
 cells 
present at day 9 after infection alone, was still more than median 3 fold above numbers 
seen in immunized, but uninfected mice. 
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The number of BrdU
-
 NP-specific CD138
+
 cells present after 9 days of infection, and 
irrespective of co-immunization, was substantially higher than the number present at day 
4. This is consistent with the ongoing plasmablast proliferation seen in extra-follicular 
foci of similar mice at day 8. It is likely to include both plasmablasts generated de-novo 
after day 5, or continued proliferation of plasmablasts that had previously incorporated 
BrdU between day 1 and the end of day 5. 
Close examination of the flow cytometry dot plots (Figure 6-11 and data not shown) 
reveals that amongst day 9 mice the median BrdU fluorescence in NP-specific CD138
+
 
cells in spleens of immunized mice was some 8 fold higher than in corresponding cells 
from mice both immunized and infected. Thus it may be that some plasmablasts in 
infected and immunized mice continued to divide up to 3 times more after BrdU feeding 
ceased at 120 hours. Nevertheless, as plasmablast divisions occur at 8 hourly intervals or 
less [238], even these AFC will have ceased dividing by day 6, consequently the resultant 
terminally differentiated plasma cells will have survived for at least 3 days in an animal 
studied at day 9. 
In conclusion, the results from the BrdU pulse chase extend the previously reported data, 
by providing evidence that extended survival of increased numbers of non-proliferating 
splenic NP-specific plasma cells can occur in the context of an unrelated source of 
inflammation. Histological examination of sections from these mice‟ spleens is yet to be 
performed, but will be likely to demonstrate that BrdU
+
 NP-specific AFC are 
predominantly in the red pulp. 
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Figure 6-12 shows that the increased number of NP-specific red pulp plasma cells present 9 days 
after immunization with NP-Ficoll and co-infection with S. Typhimurium is attributable, at least in 
part, to an increased number of plasma cells surviving for more than 3 days. 
The graphs show the number of NP-specific AFC that are labelled at 9 and 25 days after immunization with 
NP-Ficoll or infection or both by a BrdU pulse administered from days 2 to 5. The efficiency of the 
labelling was tested by assessing the proportion of plasmablasts labelled at 4 days; i.e. at the peak of the 
plasmablast response and before the onset of mass AFC apoptosis. Each symbol shows values for one 
mouse. Legend for the symbols is above the figure. The open triangles represent data from mice that were 
immunized and co-infected, but which did not demonstrate splenomegally, or other signs of infection with 
S. Typhimurium.  
6.7 Strategies to identify infection-related niches for antibody 
forming cells.  
Having obtained evidence to support the initial hypothesis, I sought to characterise the 
nature of the red-pulp niches that support survival of additional plasma cells during 
inflammation. Two broad approaches were used: 
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To identify cell populations, whose numbers are increased during inflammation, 
for which there is evidence to indicate they contribute to increased plasma cell 
survival. Such cell populations would be expected to co-localise with plasma cells 
(or their precursor plasmablasts). 
To identify changes in the splenic microenvironment consistent with a mechanism 
to increase plasma cell retention and survival. 
6.7.1 The potential role of phagocytes and dendritic cells in 
promoting prolonged survival of AFC in spleens of mice 
infected with S. Typhimurium.  
Acute inflammation is characteristically associated with an infiltrate of neutrophils and 
macrophages. In addition a range of phagocytes and dendritic cells have been shown to 
associate with AFC even in immune responses where there is no infection. There is 
evidence that cells with both neutrophil and macrophage features as well as dendritic 
cells contribute to plasma cell survival through release of factors including BAFF and 
APRIL and IL-6 [174;239-241]. Recently published work from our laboratory, using a 
different model, provides evidence that macrophages are associated with non-
proliferating AFC, and that they express substantial amounts of mRNA encoding for 
APRIL [130]. We thus considered the possible role of neutrophils, macrophages and 
dendritic cells in the maturation and survival of plasma cells in the models studied here.  
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6.7.1.1 Splenic numbers of CD11b+Gr1hiF4/80neg neutrophils and 
CD11b+Gr1intermediateF4/80intermediate macrophages increase after 
infection with S. Typhimurium. 
Flow cytometric studies show S. typhimurium infection results in a significant increase in 
the numbers of both splenic CD11b
+
Gr1
hi
F4/80
neg
 cells and 
CD11b
+
Gr1
intermediate(int)
F4/80
int
 cells. Gating strategies are shown in Figure 6-13. Results 
show that median numbers in both cell populations were more than 3 fold higher by day 
4, and at least 6 fold higher at day 8 after S. typhimurium infection (Figure 6-14). These 
increases occurred irrespective of co-immunization with NP-Ficoll, and were greater than 
the concurrent increases in splenic weight at the corresponding timepoints. By 35 days a 
more modest increase in number in each population compared with non-immunized non-
infected mice was still present. Immunization with NP-Ficoll, in the absence of infection 
was associated with a gradual fall in numbers of CD11b
+
Gr1
hi
F4/80
-
 cells, and 
CD11b
+
Gr1
int
F4/80
int
 cells at day 4 through to day 35. 
It will be seen that the Gr1+, F4/80+ cells separate into three subgroups on flow 
cytometry: Gr1
hi
F4/80
int
, Gr1
int
F4/80
int
 and Gr1
int
F4/80
hi
 cells (Figure 6-13). The numbers 
of all three of these subsets increased in a similar way in response to infection. The data 
for the Gr1
intermediate
F4/80
intermediate
 cells are shown in Figure 6-14B. The numbers of the 
cells in the other two subsets remained throughout approximately 10-fold lower, but 
changes in their number followed a similar pattern to that seen in 
Gr1
intermediate
F4/80
intermediate
 cells (data not shown). 
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Figure 6-13 shows representative flow 
cytometry dot plot demonstrating gates used to 
define populations by surface expression of 
Gr1, F4/80, and CD11b. 
Flow cytometric study of spleen removed 4 days 
after immunization with NP-Ficoll. Left – gating 
of CD11b+ cells that are Gr1+. Right – subgating 
according to intensity of staining with anti-Gr1 
and anti-F4/80 antibodies. Gr1hiF4/80- cells are 
likely to be neutrophils, whilst Gr1intF4/80int cells 
are likely to be macrophages. The phenotype of 
the other two, smaller, gated populations of cells 
is not clear. 
 
 
 
Figure 6-14 shows splenic numbers of CD11b
+
Gr1
hi
F4/80
neg
 cells, and CD11b
+
Gr1
int
F4/80
int
 cells rise 
after infection, but not immunization. 
Changes in numbers of CD11b+Gr1hiF4/80neg cells (left), and in numbers of CD11b+Gr1intF4/80int cells 
(right), as measured by flow cytometry of splenic cell suspensions. Each symbol shows values for one 
mouse. Legend for the symbols is above the figure. 
 
6.7.1.2 The relationship of red pulp AFC at day 8 with CD11b+Gr1+ cells and 
F4/80+ cells. 
Confocal microscopy was used to ascertain if NP-specific AFC were in proximity to Gr1
+
 
cells. The co-staining with Gr1 and F4/80 fails to show coincident staining (Figure 6-16 
top row). This suggests that only the Gr1
high
 cells and F4/80
high
 cells are detectable by this 
methodology and that the major Gr1
int
F4/80
int
 subset may not be detected. In addition the 
small Gr1
high
F4/80
int
 subset is not distinguishable from the Gr1
high
F4/80
-
 cells. 
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Day 8 NP-Ficoll x10. Day 8 Sal only. x10. Day 8 NP-F / Sal. x10. 
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A B C 
Nevertheless, F4/80
+
Gr1
-
 cells are widely distributed in the red pulp. Consequently, red 
pulp AFC are never far from F4/80
+
 cells. On the other hand there are large areas in the 
red pulp that contain F4/80
+
 cells but lack AFC. It follows many F4/80 expressing cells 
are unlikely to be providing a microenvironment that can support red pulp AFC survival. 
It remains possible that those F4/80
+
 cells that co-localize with AFC have a role in 
maintaining these AFC. Gr1
+
 cells are more focused in the red pulp, but similar 
arguments to those used for F4/80 apply to Gr1
+
 cell co-localization with red pulp AFC. 
Few Gr1
+
 cells were associated with extrafollicular foci, but some F4/80
+
 cells were in 
these foci. In keeping with data from flow cytometry, nearly all Gr1
+
 cells were CD11b
+
 
by confocal microscopy (Figure 6-15). 
 
 
 
 
 
Figure 6-15 shows that in spleens of mice that were previously immunized or infected or both, nearly 
all Gr1
+
 cells are CD11b
+ 
by confocal microscopy, 
In spleens of mice sacrificed 8 days after (A) immunization, (B) immunization and co-infection, or (C) 
infection alone, almost all Gr1+ cells (red) co-stain for CD11b (green) and so appear yellow. Original 
objective magnification x10 for all images. 
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L 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6-16 shows representative confocal microscopy images of spleens from mice sacrificed at day 8 
after immunization, infection, or both. These show that in each tissue (i) no cells are seen to be 
Gr1
+
F4/80
+
, (ii) most red pulp NP-specific AFC are IgM
+
, (iii) red pulp IgM
+
 AFC are not restricted 
to the proximity of Gr1
+
 cells and (iv) substantial areas of the red pulp contain F4/80
+
 cells  but no 
AFC.  
Panels A, D, G and J show the same splenic section from one representative mouse 8 days after NP-Ficoll 
alone. Panels B, E, H, and L show the same splenic section from one representative mouse 8 days after 
immunization and co-infection. Panels C, F, I and L show the same splenic section from one 
representative mouse 8 days after S. Typhimurium infection alone. Panels A-C show F4/80+ cells (green) 
and Gr1+ cells (red). In confocal microscopy, no Gr1+ cells co-stained for F4/80 (no yellow staining). Gr1+ 
cells were more common in the red pulp of infected mice. Panels D-F show IgM+ cells (blue) and NP-
specific cells (red). NP-specific IgM+ cells appear purple. In each experimental condition red pulp NP-
specific AFC were overwhelmingly IgM+. Extra-follicular foci in S. Typhimurium infected mice also 
included IgM+ AFC not specific for NP. Panels G-I show Gr1+ cells (red) and IgM+ cells (blue).  Neither 
red pulp IgM+ AFC, nor extra-follicular IgM+ AFC, were associated with Gr1+ cells at 8 days after 
immunization, infection or both. Panels J-L show F4/80+ cells (green) and IgM+ cells (red). F4/80+ cells 
are widely distributed within the red pulp and many areas containing F4/80 + cells do not contain IgM
+
 
AFC. All images were taken with x10 objective magnification.  
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6.7.1.3 Splenic numbers of CD11c+ dendritic cells, increase in mice 
infected with S. Typhimurium, but not those only immunized with 
NP-Ficoll. 
Previously published reports have described a CD11c
hi
 cell population of dendritic 
phenotype that are associated AFC and may assist plasmablast maturation to plasma cells 
[128]. We therefore considered the possibility that infection related increases in CD11c
hi
 
cells (or a subset thereof) might be causally associated with the increased numbers of 
AFC in infected mice on day 8 after NP-Ficoll. 
Flow cytometric analyses were therefore performed on splenic cell suspensions from 
mice sacrificed after immunization or infection or both, in order to define a phenotype of 
one or more candidate cell populations. Previous work in our laboratory has divided 
CD11c
+
 cells into CD11c
int
 and CD11c
hi
 subsets of CD8α- cells, and CD11c+CD8α+ cells. 
These subsets are shown in Figure 6-17, which also shows that there is heterogeneity 
within each of these subsets based on the varying expression of F4/80 and CD4. 
 
It will be seen from Figure 6-17 that infection results in major changes to the proportions 
of CD4
+
 and F4/80
+
 cells in the CD11c
+
 subsets. In particular the proportions of 
F4/80
-
CD4
+
 cells falls, while F4/80
+
CD4
-
 cell proportions increase. These changes 
expressed as numbers of cells per spleen are quantified in Figure 6-18. This shows that in 
the infected mice all 3 subsets defined by CD4 and F4/80 expression increase in number 
during infection, but this is most marked in the F4/80
+
 CD4
- 
subset. By contrast in mice 
immunized with NP-Ficoll, but not infected, only the F4/80
-
 subset increased and then 
only among the CD11c
hi
CD8
-
 and the CD11c
+
CD8
+
 subsets.  
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Figure 6-17 shows representative flow cytometry dot plots demonstrating gates used to define splenic 
cell populations according to staining with antibodies to CD11c, CD8α, CD4, and F4/80 in mice 
sacrificed after immunization, infection, or both. 
Dot plots shown are from mice 8 days after immunization with NP-Ficoll (upper panels), and 8 days after 
immunization with NP-Ficoll and infection with S. Typhimurium (lower panels). For each row, the left dot 
plot shows the gating for 3 subsets of CD11c+ cells, according to the intensity of staining with antibodies to 
CD11c and antibodies to CD8α. The remaining dot plots demonstrate subsets of these primary populations, 
according to intensity of staining for CD4 and F4/80.  
The increase in the CD11c
+CD8α+F4/80+CD4- subpopulation (maximal at day 8; a 
median 4.5 fold increase above baseline) was no greater than the concurrent changes in 
spleen weight in these mice. However the increase in median number of 
CD11c
hiCD8α-F4/80+CD4- cells was greater, at 5-6 fold by day 8 after S. Typhimurium 
infection. The median number of cells within the CD11c
lo
F4/80
+
CD4
-
 subset, increased 
more than 10 fold by day 8 after infection. 
The CD11c
lo
F4/80
+
CD4
+
 subset was also, more modestly, increased, in association with 
S. Typhimurium infection, but unaffected by immunization with NP-Ficoll. Some of this 
may have been attributable to cell populations spilling across the defined gating 
boundaries (Figure 6-17). 
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6.7.1.4 The relationship at day 8 between splenic AFC and CD11c+F4/80+ 
cells. 
Flow cytometric studies indicate that some CD11c
+
F4/80
+
 cell populations were 
selectively increased in infected mice. Within the remaining time available for this thesis 
it was not possible to develop the technology to co-stain for CD11c and CD8 and CD4 
and F4/80 and either NP or IgM in confocal microscopy. Confocal microscopy was 
therefore used to ascertain if AFC present at day 8 were associated with CD11c
+
F4/80
+
 
cells. 
As noted previously (Figure 6-16 panel J), and seen in the top left image of Figure 6-19, 
F4/80 cells (green) are seen scattered throughout the red pulp after immunization with 
NP-Ficoll. This is also the case for the expanded red pulp of infected mice (Figure 6-16 
panel L, top right image of Figure 6-19). By contrast, F4/80 cells are not seen in the B 
cell follicle, which contains small IgM
+
 B cells (white), in either group. Similarly, the T 
zone, which is devoid of either IgM
+
 B cells or large IgM
+
 AFC at day 8 after either 
inoculation, has few F4/80
+
 cells either. However, at the edge of the T zone in infected 
mice there are clusters of AFC that are likely to be in extra-follicular foci, and these are 
amongst F4/80
+
 cells. 
Interestingly, when visualising binding to CD11c, as well as binding to F4/80 and IgM 
(Figure 6-19 lower panels), it is clear that CD11c
+
 cells (red) encroach much further 
towards, and probably into, the T zone than F4/80
+
 cells do. Furthermore at the sites of 
extra-follicular foci, but not elsewhere along the margin of the T zone, these CD11c
+
 
cells are F4/80
+
 (and so appear yellow) (compare bottom right panel of Figure 6-19 and 
Figure 6-20).  
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Figure 6-18 shows a summary of changes in splenic cell numbers within defined subsets of CD11c
+
 
cells, following infection or immunization or both, in which F4/80
+
CD4
-
 subsets of CD11c
intCD8α-
cells, CD11c
hiCD8α- cells, and CD11c+CD8α+ cells are increased after infection but not immunization. 
Each symbol represents values from one mouse. The legend for the symbols is below the figure. 
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As seen in the lower panels of Figure 6-19, the CD11c
+
F4/80
+
 cells of greatest interest 
are distributed widely throughout the splenic red pulp in both conditions. Some, but not 
all, CD11c
+
F4/80
+
 cells are in contact with red pulp IgM
+
 AFC, though not all AFC are 
adjacent to CD11c
+
F4/80
+
 cells. 
Flow cytometric studies (Figure 6-15) had also demonstrated further heterogeneity within 
CD11c
+
F4/80
+
 cells. It follows that the confocal microscopy images presented here 
cannot exclude the possibility that those CD11c
+
F4/80
+
 cells found near to red pulp 
plasma cells comprise a subpopulation that is able to contribute to the survival of some 
AFC. Nevertheless, as some day 8 red pulp AFC are not near any CD11c
+
F4/80
+
 cells, it 
is tempting to conclude that the survival of some red pulp plasma cells is independent of 
the any of CD11c
+
F4/80
+
 cells populations identified in flow cytometry as increased in 
infection. However there is an important caveat to this, which is analogous to the 
difficulties in identifying F4/80
int
 staining on CD11b
+
 cells (discussed in 6.7.1.2 above). 
Amongst the subsets of CD11c
+
 cells defined by flow cytometry, CD11c
intCD8α- 
contains the most cells, especially in infected mice (Figure 6-17). The majority of 
CD11c
intCD8α- cells are F4/80int. Thus CD11cintCD8α-F4/80+ cells comprise over half of 
all splenic CD11c
+
 cells, as estimated by flow cytometry.  
This is not apparent in confocal microscopy where there seem to be far fewer 
CD11c
+
F4/80
+ 
cells than CD11c
+
F4/80
-
 cells (Figure 6-19). This could be due to 
insufficient expression of either F4/80, or CD11c, or both on cells that are CD11c
+
F4/80
+
 
by flow cytometry. Irrespective of the technical cause, the likely failure to identify all 
CD11c
+
F4/80
+
 correctly in confocal microscopy leaves the possibility that infection-
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related increases in numbers of CD11c
+
F4/80
+
 cells do contribute to enhanced survival of 
red pulp plasma cells in infected mice. 
 
Figure 6-19 shows 
representative 
confocal micro-
scopy images of 
spleens of mice 8 
days after immun-
ization with or 
without co-
infection, and 
stained for IgM 
and F4/80 with or 
without staining 
for CD11c. These 
show that i) F4/80 
cells are confined 
to the red pulp 
and extra-
follicular foci and 
ii) some 
CD11c
+
F4/80
+ 
cells are identif-
iable in the red 
pulp of both 
groups of mice, 
but that in each 
group, not all red 
pulp AFC (large 
IgM
+
 cells) are 
close to identified 
CD11
+
F4/80
+ 
cells.  
The inoculations 
received by the mice are listed above each column. Images in one column are of the same splenic area. The 
colour coding for the antigens (and NP-binding cells) visualized in each image are shown in the top left 
corner of the image. All images taken at 10x original objective magnification. Blue box in lower right panel 
indicates area magnified in Figure 6-20. 
IgM F4/80 IgM F4/80
IgM
CD11c F4/80
CD11c + F4/80
IgM
CD11c F4/80
CD11c + F4/80
Day 8: NP Ficoll only Day 8: NP Ficoll + Sal
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Figure 6-20 shows 
magnified images 
of an extra-
follicular focus of 
AFC 8 days after 
NP-Ficoll with co-
infection. Areas 
flanking the T 
zone and margin 
contain 
CD11c
+
F4/80
- 
cells, while the 
extra-follicular 
focus contains 
CD11c
+
F4/80
+
 cells 
and CD11c
-
F4/80
+
 
cells. 
Both images are of the same splenic area, which is also seen within the blue box in lower right panel of 
Figure 6-19. The colour coding for the antigens (and NP-binding cells) visualized in each image are shown 
in the top left corner of the image. All images taken at 63x original objective magnification. 
6.7.2 An expansion in supportive niches near splenic trabeculae may 
accommodate some of the additional AFC sustained during 
infection. 
Previous publications have reported that red pulp AFC aggregate around collagen fibres 
or trabeculae [45;133]. We thus considered the possibility that these structures support 
the additional plasma cells sustained in the red pulp of infected mice. Eight days after 
immunization with NP-Ficoll, some but not all red pulp NP-specific AFC are found near 
trabeculae that bind antibodies raised against human collagen III, and which appear to 
traverse the red pulp (Figure 6-21A). The specificity within mice of this cross reactive 
polyclonal antibody is not known, though splenic red pulp trabeculae also bind antibodies 
to laminins [121]. The same structures are identified by antibodies to ER-TR7 antigen 
[242] (see Appendix 5).   
Day 8: NP Ficoll and Salmonella
IgM
CD11c F4/80
CD11c + F4/80
CD11c F4/80
CD11c + F4/80
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Interestingly, 8 days after immunization and co-infection with S. Typhimurium, increased 
numbers of NP-specific AFC were seen clustered around these trabeculae though 
additional NP-specific AFCs were also seen scattered elsewhere in the red pulp.  
This association raises the possibility that the trabecular structures might themselves 
contribute to plasma cell survival either by direct interaction with plasma cells or by 
providing a niche where plasma cell-sustaining cells gather. Plasma cells express surface 
receptors that bind to extra-cellular proteins including fibronectin and some collagens 
[243;244]. Furthermore, signals transduced by one of these - VLA-4 - can enhance 
plasma cell survival, at least in vitro [160].  
The association between the trabeculae and NP-specific AFCs was more closely 
examined in eight serial sections from the spleen of a mouse 8 days after infection and 
immunization. All sections were stained for NP binding, and with the antibody against 
human collagen III. Two separate trabeculae, that both had associated AFC aggregates, 
were followed through the multiple sections. Whilst this confirmed the close proximity of 
NP-specific AFCs to the trabeculae, at least some of the AFC in these clusters were not 
visibly in direct contact with the anti-collagen III stained fibres themselves (Figure 6-22).  
Thus it appears that some red pulp NP-specific AFCs generated in the response to 
immunization reside in niches that are close to splenic trabeculae, but these niches are not 
defined by the trabeculae themselves. Further studies are required to characterize all the 
components of these peritrabecular zones. There may be other microenvironments in the 
red pulp that sustain plasma cell survival for a minority of red pulp plasma cells do not 
associate with fibrous trabeculae.  
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Figure 6-21 shows photomicrographs demonstrating that eight days after immunization with NP-
Ficoll, some NP-specific AFCs are found clustered near splenic trabeculae that bind antibody raised 
against human collagen III, and that immunization and co-infection increases the number of such 
cells, but that infection per se does not. 
Photomicrographs of splenic sections immunohistochemically stained with anti-human collagen III (blue) 
and with NP (brown), from representative mice sacrificed 8 days after (A) immunization with NP-Ficoll, 
(B) infection alone and (C and D) immunization with co-infection (two separate mice). After immunization 
some NP-specific AFCs are associated with trabeculae. The number of trabecula-associated cells is 
increased in co-infected mice. Infection alone is not associated with clusters of NP-specific AFCs around 
the trabeculae. Red box in panel C denotes approximate area shown in 8 serial sections in Figure 6-22. 
Images taken at x5 original objective magnification.  
 
 Day 8. NP-Ficoll only. NP. Collagen III. x5 
Day 8. NP-F / Sal. NP. Collagen III. x5 
Day 8. Sal only. NP. Collagen III. x5 
 
Day 8. NP-F / Sal. NP. Collagen III. x5 
 
A B 
D C 
-  / Sal. P e  I   .   .   I  
 I . i ll ly.  ll  I I  
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A E 
B F 
C G 
D H 
All images: day 8. NP-F / Salmonella.  NP Collagen IIII x200 Figure 6-22 
shows 
photomicro-
graphs of eight 
serial sections 
through the 
spleen of a 
mouse 8 days 
post immuniz-
ation with NP-
Ficoll and co-
infection, 
showing that 
some NP-
specific AFC 
clustered 
around 
trabeculae are 
not in direct 
contact with 
the anti-
collagen III 
stained fibres. 
Serial sections 
(A-H) were 
taken from the 
same mouse 
shown in 
Figure 6-21 
(right image), 
and immuno-
histochemically 
stained with 
anti-human 
collagen III 
(blue) and with 
NP (brown). 
Red circles 
highlight the 
same cluster of 
AFC in two 
serial sections, 
close to, but not 
in contact with 
a bundle 
binding anti-
collagen III 
antibody. 
Dotted red 
circles indicate the comparable areas in sections on either side, demonstrating the outer limits of the cluster. 
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6.7.3 Clusters of BP3+ cells become prominent in the splenic red pulp 
of S. Typhimurium-infected mice, but are not consistently 
associated with plasma cells. 
BP3
+
 nurse like cells are present within the bone marrow, but also the inflamed 
rheumatoid joint [161]. Furthermore, rheumatoid BP3
+
 cells are reported to produce IL-6 
in vitro [161]. We thus considered the possibility that such BP3
+
 cells could contribute to 
splenic plasma cell survival within the model studied here.  
In non-immunized mice, a diffuse reticular staining pattern is seen with anti-BP3 
antibody in the T zone, and inner B cell follicle. In addition isolated cells in the red pulp 
are also stained (Figure 6-23). These cells are not consistently associated with the small 
numbers of NP-specific AFC found in the red pulp of control mice. 
Sections from mice 8 days after immunization with NP-Ficoll with or without co-
infection with S. Typhimurium, were stained in parallel. In mice immunized with NP-
Ficoll alone, the staining pattern was similar to that in naïve mice. In contrast, 8 days 
after immunization and co-infection with S. Typhimurium, the reticular staining for BP3 
was less clear. Multiple clusters of cells staining for BP3 were seen in the red pulp. Some 
NP-specific AFC were seen on the outer rim of these BP3
+
 clusters, but many plasma 
cells were distant from BP3
+
 cells and some clusters of BP3
+
 cells had no associated AFC 
(Figure 6-23). In mice infected with S. Typhimurium only, it was striking that the 
extrafollicular foci were located within the reticular network of BP3 positivity associated 
with the white pulp.  
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Figure 6-23 shows representative photomicrographs of splenic sections from non-immunized mice, 
and from mice 8 days after immunization with or without co-infection. Both are stained for BP3 
antigen and NP binding. These show that infection increases the red pulp area stained with anti-BP3, 
but that these areas are not directly associated with NP-specific AFC.  
In each row the right image (x200 microscope magnification) shows in detail the area enclosed in the red 
box in the left image (x50 microscope magnification). In naïve mice (panels A and B), and mice 8 days 
after immunization with NP-Ficoll (panels C and D) reticular expression of BP3 (blue) is seen in the T 
zone, and inner part of the B cell follicle. Isolated cells in the red pulp are also BP3+, but NP-specific AFC 
(dark brown) are not consistently near the BP3+ cells. In mice 8 days after immunization with co-infection 
(panels E and F) increased clusters of cells within the red pulp stain BP3+, but few NP-specific AFC are 
amongst them.   
 
 
A B 
Naïve mouse. NP BP3 x50 Naïve mouse NP BP3 x200 
A B 
Day 8, NP-Ficoll. NP BP3 x50 Day 8, NP-Ficoll.NP BP3 x200 
E F 
Day 8, NP-Ficoll. NP BP3 x50 Day 8, NP-Ficoll. NP BP3 x200 
C D 
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6.7.4 CD169+ cells are confined to the splenic marginal zone and not 
associated with AFC.  
In a different experimental model used in our laboratory AFC appear associated with 
CD169
+
 cells [130]. We thus considered the possibility that CD169
+
 cells co-localise with 
splenic AFC in this model, and contribute to their survival. 
Confocal microscopy was used to study the location of CD169
+
 cells in non-immunized 
mice, and those 8 days after either immunization with NP-Ficoll, or after infection with S. 
Typhimurium and immunization with NP-Ficoll (Figure 6-24). In contrast to the other 
model, CD169
+
 cells were confined to the marginal zone in the spleens of QMxB6 mice, 
irrespective of infection with S. Typhimurium. They were not associated with red pulp 
IgM
+
 AFC. 
 
 
 
 
 
Figure 6-24 shows images from con-focal microscopy demonstrating that CD169
+
 cells are confined 
to the splenic marginal zone, irrespective of immunization with NP-Ficoll, or co-infection with S. 
Typhimurium. 
Representative splenic sections from (A) a non-immunized mouse, (B) a mouse 8 days after immunization 
with NP-Ficoll, and (C) a mouse 8 days after immunization and co-infection. CD169+ cells appear green. 
These are confined to the splenic marginal zone, amongst small IgM+ B cells (grey). Larger IgM+ cells, 
AFC, are predominantly confined to the red pulp. All images were taken with x10 objective magnification. 
 
Naïve mouse. x10 Day 8, NP-Ficoll. x10 Day 8, NP-F / Sal. x10 
CD169+ 
IgM+ 
CD169+ 
IgM+ 
CD169+ 
IgM+ 
A B C 
141 
 
6.8 Investigating the splenic expression of mRNA for known 
AFC chemotaxis, differentiation and survival factors. 
There are likely to be two main components contributing to the long term survival of 
AFC:  
(i) The presence of niches that provide factors that support long term survival. 
(ii) Factors that induce AFC to home to these niches.  
Splenic changes in either component could impact upon observed numbers of mature 
plasma cells in the splenic red pulp. Possible changes in both of these components 
associated with immunization and or infection are considered in this section.  
The migration of AFC appears to occur in two phases: first the migration of activated B 
blasts from the T zone to extrafollicular foci, where the AFC grow as plasmablasts. The 
second phase is where mature plasma cells locate in niches in the splenic red pulp that 
secure their long term survival. In addition some of the AFC leave the spleen and find 
survival niches in the bone marrow. This movement from spleen to bone marrow and the 
bone marrow niches are not considered in this study.  
The migration from the outer T zone to extrafollicular foci is coordinated by expression 
of chemokines and their receptors [133;134] and coincides with the differentiation of 
CD138
-
Blimp-1
- 
B blasts to CD138
+
Blimp-1
+
 plasmablasts [238;245]. The chemokine 
CXCL12 is chemotactic for plasmablasts which constitutively express the appropriate 
receptor CXCR4 [133;134]. This ligand-receptor pair contributes to homing of plasma 
cells to the bone marrow [133].  Expression of CXCR4 is maintained on most bone 
marrow plasma cells. These plasma cells do not respond to CXCL12 by migration [134], 
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although the interaction between this chemokine and its receptor may stabilize the 
localization of AFC in the marrow. There are conflicting reports of in vitro work as to 
whether CXCL12 supports plasma cell survival [149;162].  
Available evidence indicates that a proportion of plasmablasts migrate towards CXCL9 
or CXCL10 or CXCL11 [134]. All three chemokines are induced in cells of the 
monocyte-macrophage lineage (amongst other cell types) by stimulation with γ-IFN 
[138;139]. Furthermore, CXCL10 and CXCL11 are induced following direct 
lipopolysaccharide (LPS)-mediated activation of macrophages [147;148] and γ-IFN also 
acts synergistically on this response [147]. The receptor for all three of these chemokines 
is CXCR3, which itself can be upregulated by γ-interferon, at least in vitro [14]. There is 
no published evidence for, or against, the possibility that ligands for CXCR3 promote 
survival of any CXCR3-expressing plasma cells in vitro or in vivo. 
Certain cytokines are known to favour AFC differentiation and survival. These have been 
most extensively studied in vitro, and in the context of bone marrow plasma cells in vivo. 
IL-6 by itself can enhance plasma cell survival in vitro, though its efficacy is very much 
greater when acting synergistically with other plasma cell supporting factors [162]. Its in 
vivo role is less clear; long term antibody responses are reported to be unaffected in IL6
-/-
 
mice [162], though in the short term (up to 10 days after secondary immunization) the 
antibody response appears reduced. This may be due to an impact of IL-6 upon cell 
proliferation [246], and may be of relevance in the model studied here. Cassese et al also 
reports a modest in vitro effect of TNF-α on plasma cell survival [162].  
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IL-21 is one of a group of cytokines whose receptors share a common γ chain [247]. It is 
reported to act in concert with B cell receptor ligation to promote the production of 
Blimp-1 and thereby the terminal differentiation of B cells into plasma cells [184]. 
O‟Connor et al have reported a non-redundant role for BCMA-mediated signalling in 
achieving bone marrow plasma cell survival [165]. Published data on adult mice indicates 
this is mediated via APRIL, one of the ligands for BCMA, but not by BCMA‟s other 
ligand BAFF [179].  
The role of these various factors in splenic plasma cell survival is less clear. In contrast to 
their findings in bone marrow, Belnoue et al state (but do not provide data to show) that 
48 hours after in-vivo transfer of antigen-specfic AFCs, the splenic recovery of these 
AFC was no different in BAFF
-/-
 or APRIL
-/-
 recipient mice compared to wild type 
recipient controls [179]. Furthermore bone marrow stromal cells sustain in-vitro plasma 
cell antibody production more effectively than splenic stromal cells, despite higher IL-6 
production by the splenic cells [149].  
The role of any of these factors in enhanced plasma cell survival in the context of splenic 
inflammation is not reported. Furthermore, such cytokines and chemokines may be 
produced by more than one cell type. When this is the case there would be sporadic rather 
than universal association of AFC with each of the different cell types that produced 
AFC-survival factors; a situation that makes interpretation of histological associations 
difficult.  
Immunohistochemical staining of cytokine-producing cells in tissue sections generally 
has proved unreliable. Consequently two alternative approaches were used. In each, 
levels of cytokine mRNA were quantified using real time reverse transcriptase 
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polymerase chain reaction assays (RT2-PCR). First levels of mRNA transcripts that 
encode for various cytokines, or chemokines, and their receptors, were measured in 
spleen cell suspensions from the different groups of mice. Although this will identify if 
leucocyte-produced cytokine message has increased it does not localize the cytokine 
production and would fail to detect cytokines produced by stromal cells that were not 
contained in the cell suspensions studied. Consequently mRNA levels were also assessed 
in microdissected areas taken from tissue sections. 
In keeping with conventional methodology, changes in levels of mRNA species of 
interest were normalized by reporting changes relative to levels of reference gene mRNA 
in the same samples. Cellular levels of mRNA for reference genes (β2-microglobulin and 
β-actin) are usually assumed to be unaffected by experimental conditions. However, total 
splenic cell numbers increase substantially following infection with S. Typhimurium, and 
all cells will express the reference gene mRNA. As only a subset of the cells is likely to 
be producing a plasma cell survival factor any observed increases in normalised levels of 
mRNA for the survival factor of interest will underestimate the upregulation of 
expression in the cell subset producing the mRNA for the factor.  
Assays were also performed on the same tissues to estimate levels of mRNA encoding for 
BCMA, which in the spleen is solely expressed on differentiated AFC. This confirms that 
increases in BCMA mRNA levels following immunization, or infection, or both, broadly 
reproduce corresponding increases seen in total CD138
+
 cell numbers as estimated by 
flow cytometry (Figure 6-25). For this reason BCMA mRNA levels have been used as a 
comparator with levels of different cytokines reported in Figure 6-26, Figure 6-30, and 
Figure 6-31. 
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Figure 6-25 shows changes induced by immunization, infection or both in the absolute numbers of 
splenic CD138
+
 cells reflect concurrent changes in relative levels of BCMA mRNA in splenic 
leucocyte suspensions. 
Each symbol shows values for one mouse. Absolute numbers of CD138+ cells were estimated by flow 
cytometry, and are replotted from Figure 6-5A. Levels of BCMA mRNA were measured by RT2-PCR, and 
are reported relative to levels of β2-microglobulin reference gene mRNA in the same sample. 
6.8.1 In spleen cell suspensions infection induces mRNA for CXCR3-
binding chemokines while the NP-Ficoll response in non-
infected mice upregulates message for CXCR4-binding 
chemokine. 
Changes in levels of mRNA for CXCL9, CXCL10, CXCL11 and CXCL12, were 
assessed by RT2-PCR, in spleen cell suspensions from mice immunized with NP-Ficoll, 
infected with S. Typhimurium, or both. Consistent with published reports, levels of 
CXCL9, CXCL10 and CXCL11 increase substantially following infection, and 
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irrespective of co-immunization, but changes in these chemokines are modest after 
immunization alone. By contrast, increases in CXCL12 were greater in immunized but 
non-infected mice (Figure 6-26). Thus compared with naïve mice, peak median levels of 
CXCL9 mRNA were 11 fold above baseline, CXCL10 were 20 times baseline and 26 
fold for CXCL11. By comparison immunization without infection resulted in changes 
that were never more than 4-fold above baseline for any of these chemokines. Unlike -
IFN levels which were highest at day 35 after infection the levels of these chemokines, in 
parallel with the numbers of plasma cells declined between d8 and d35. Conversely the 
chemokine upregulation occurred earlier than that of -IFN, key cytokine produced in the 
T-helper type 1 (TH-1) protective response against S. Typhimurium infection. These data 
raise the possibility that increased splenic expression of CXCL9, CXCL10 or CXCL11 
during S. Typhimurium could alter the migration patterns of emergent NP-specific 
plasmablasts, if such AFC express CXCR3.
6.8.2 CXCR4 protein is expressed on the surface of AFC from all 
groups of mice although some late switched plasma cells, 
again from all groups of mice, express CXCR3.  
We sought evidence of increased CXCR3 expression within the spleen of infected mice 
as: i) spleens of infected mice have increased splenic expression of CXCL9, and 
CXCL10 and CXCL11 (section 6.8.1 above); ii) some AFC migrate towards these 
chemokines [134] and iii) γ-IFN can increase expression of CXCR3 on AFC [14] In the 
first instance RT2-PCR of splenic cell suspensions was used to assess levels of mRNA for 
CXCR3 as well as CXCR4, which is expressed on most AFC [133].
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Figure 6-26 shows 
that in splenic cell 
suspensions, levels 
of mRNA for γ-
IFN, and CXCL9, 
CXCL10, and 
CXCL11, but not  
CXCL12, increase 
more after 
infection than 
after 
immunization. 
Each symbol 
represents values 
from one mouse. 
Levels of mRNA 
were measured by 
RT2-PCR and are 
all reported relative 
to reference gene 
(β2-microglobulin) 
mRNA levels in 
the same sample. 
Where less than 
three symbols are 
shown per group, 
no mRNA was 
detected in samples 
from unreported 
mice. Changes in 
BCMA mRNA 
levels, which 
broadly reproduce 
changes in CD138+ 
cell numbers 
estimated by flow 
cytometry, are 
shown for 
comparison. 
 
 
 
D
ay
 0
D
ay
 4
D
ay
 8
D
ay
 3
5
D
ay
 4
D
ay
 8
D
ay
 3
5
D
ay
 4
D
ay
 8
D
ay
 3
5
NP-Ficoll Sal NP-F / Sal
101
102
103
CXCL12 
101
102
104
103
CXCL10 
101
102
104
103
CXCL9 
CXCL11 
≤100
101
102
103
BCMA 
103
104
101
102
BCMA 
101
2
104
103
104
103
γ-Interferon 
 L
e
v
e
l 
o
f 
m
R
N
A
 s
p
e
c
ie
s
 o
f 
in
te
re
s
t,
 r
e
la
ti
v
e
 t
o
 l
e
v
e
l 
o
f 
re
fe
re
n
c
e
 g
e
n
e
 m
R
N
A
 
148 
 
The results of these experiments are shown in Figure 6-27. Levels of CXCR3 mRNA in 
spleen cell suspensions were little changed after either infection, or immunization, or 
both. Surprisingly, levels of CXCR4 mRNA were found to be lower than baseline for at 
least 8 days after all types of inoculation. This decrease was most marked in infected 
mice.  
These findings contrast with the changes in BCMA mRNA following inoculation, which 
are represented on the same figure – and which are a reasonable surrogate for total 
CD138
+
 cell numbers in these mice. It can be concluded from this that much of the 
CXCR3 and CXCR4 expressed within the leucocyte suspension is not present in AFC. At 
least in CD4 T cells, surface turnover of CXC4 can be substantial and intracellular stores 
exist, thus dissociation of mRNA levels from surface expression of the corresponding 
protein is likely [153;248].  
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Figure 6-27 shows that in spleen cell suspensions, relative levels of CXCR4 mRNA are below baseline 
levels for at least 8 days after immunization, or infection or both, whilst CXCR3 mRNA levels change 
little in the same mice, over the same time.  
Figure also shows contemporary changes in BCMA mRNA that reflect changes in splenic CD138+ cell 
numbers. Each symbol represents values from one mouse. Levels of mRNA were measured by RT2-PCR 
and are reported relative to levels of β2-microglobulin reference gene mRNA in the same sample.  
 
Given these difficulties with the assessment of CXCR3 and CXCR4 expression on AFC 
by mRNA, in the repeat experiment the surface expression of these molecules on NP-
specific AFC was assessed by flow cytometry. Technical issues precluded co-staining for 
CD138 expression with either chemokine receptor, so intracellular NP
high
 staining was 
used to identify NP-specific AFC. As most NP-specific AFC generated after infection 
alone are NP
int
 (Figure 6-4), AFC chemokine expression could not be studied in these 
 
 L
e
v
e
l 
o
f 
m
R
N
A
 s
p
e
c
ie
s
 o
f 
in
te
re
s
t,
 r
e
la
ti
v
e
 t
o
 l
e
v
e
l 
o
f 
re
fe
re
n
c
e
 g
e
n
e
 m
R
N
A
 
 
D
ay
 0
D
ay
 4
D
ay
 8
D
ay
 3
5
D
ay
 4
D
ay
 8
D
ay
 3
5
D
ay
 4
D
ay
 8
D
ay
 3
5
102
103
101
102
103
104
CXCR4
CXCR3
NP-Ficoll Sal NP-F / Sal
BCMA 
103
104
101
102
150 
 
mice. Representative flow cytometry dot plots for mice that were immunized, and those 
that were immunized and co-infected, are shown in figure Figure 6-28. 
Figure 6-28 shows that although NP-specific AFC express CXCR4 they are only a small proportion 
of the CXCR4-expressing cells in the spleens of responding mice and few AFC express CXCR3 and 
these are mainly a subset of non-switched AFC in co-infected and immunized mice.  
The 2 left columns show representative dot plots CXCR4 expression related to cytoplasmic+surface NP 
binding. The centre columns show gated cells showing cytoplasmic + surface NP-binding and the right two 
columns IgM and CXCR3 expression in the gated NP-specific AFC.showing the proportion of NP-specific 
AFC that are CXCR4+, and the proportions of IgM NP-specific AFC and isotype switched NP-specific 
AFC that are CXCR3+, at 4 and 9 days after immunization, with or without co-infection. Numbers on the 
dot plots show the percentage of cells in the corresponding gate. 
In all mice studied at day 4 - irrespective of inoculation received - more than 95% of NP-
specific AFC had detectable CXCR4 expression (Figure 6-29, top left panel). CXCR4 
expresion was also detectable on more than 85% of NP-specific AFC in each of the day 9 
mice. Amongst the few mice studied it appeared that the the proportion of NP-specific 
AFC expressing CXCR4 was slighly lower in uninfected mice than their infected peers. 
Importantly only a small proportion of the cells expressing CXCR4 are NP-specific AFC. 
Surface expression of CXCR3 was examined separately on IgM
+
 NP-specific AFC and 
isotype-switched NP-specific AFC. At both timepoints studied, most NP-specific AFC 
were IgM
+
 (Figure 6-29, top right panel). Irrespective of timepoint studied or inoculation 
receieved, fewer than 10% of IgM
+
 NP-specific AFC were CXCR3
+
 (Figure 6-29, bottom 
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left panel). At 4 days after either inoculation, a median of 5% of isotype switched NP-
specific AFC are CXCR3
+
. (Figure 6-29, bottom right panel). Strikingly, however, the 
proportion of splenic isotype-switched NP-specific AFC that are CXCR3
+
 in all day 9 
mice is signifcantly higher than that in all day 4 mice (p<0.01, Mann Whitney test). It 
was not possible to discern any additional effect of infection on the proprotion of isotype 
switched NP-specific AFC were CXCR3
+
 at day 9. 
It is tempting to conclude that the rise in the proportion of isotype switched NP-specific 
AFC that express CXCR3 reflects either i) preferential retention of CXCR3
+ 
AFC in the 
spleen or ii) a survival advantage for such AFC relative to other AFC retained within the 
spleen. Two other observations from these data do not concur with this: 
i) at day 4, the proportion of IgM
+
 NP-specific AFC that are CXCR3
+ 
is not less 
than the proportion amongst the switched NP-specific AFC – and no equivalent 
enrichment for CXCR3
 
expressing IgM NP-specific AFC is seen between day 4 
and day 9. 
ii) the proportion of isotype switched NP-specific AFC that are CXCR3
+ 
 
increases between 4 and 9 days after immunization alone – but the proportion of 
all splenic NP-specific AFC that is isotype switched does not (Figure 6-29, top 
right panel).  
These results still need to be repeated, but an alternative explanation is possible. The 
median proportion of day 9 NP-specific CD138
+
 cells that were BrdU
-
 was 25% in 
immunized mice, and 57% in immunized and co-infected mice (see Figure 6-12). Thus 
many AFC present at day 9 developed after day 5. Any alteration, between day 4 and day 
9, in the proportion of newly emergent AFC that are CXCR3
+
 could influence the 
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proportion of prevalent AFC that are CXCR3
+
 at day 9. This scenario seems most 
plausible in the context of evolving S. Typhimuruim infection though it remains 
unproven, and could be the subject of future work. 
Figure 6-29 shows the proportion ofNP-specific AFC that express CXCR4
+ 
or CXCR3
+
. 
Each symbol shows values for one mouse. The legend for the symbols is above the figure. The open 
triangle represents one mouse that was inoculated with NP-Ficoll and S. Typhimurium, but did not develop 
splenomegally or any other signs of infection. 
B blasts usually migrate from the white pulp as they differentiate into plasmblasts; i.e. the 
migration occurs in proliferating cells. Thus the plasma cells that at day 9 retain BrdU 
taken up before day 6 are likely to have migrated from the white pulp several days before. 
The continued expression of CXCR4 in day 9 plasma cells may refect retention in red 
pulp niches rater than migration to these niches. The high splenic levels of CXCL9 or 
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CXCL10 or CXCL11 seem unlikely to be having influence more than a small proportion 
of AFC from infected day 9 mice. 
6.8.3 Levels of mRNA for IL-6 and IL-21, but not mRNA for TNF-α or 
BAFF or APRIL, are selectively increased in spleens of mice 
infected with S. Typhimurium. 
RT2-PCR assays were performed to assess changes induced by infection and/or 
immunization in mRNA encoding the putative AFC survival and maturation factors in 
spleen cell suspensions. The factors assessed were IL-6, IL-21, TNF-α, BAFF and 
APRIL.  
Levels of IL-6 and IL-21 mRNA are increased more after infection than after 
immunization (Figure 6-30). In contrast levels of mRNA for TNF-α, BAFF and APRIL 
changed remarkably little following any inoculation (Figure 6-31). 
Amongst both groups of infected mice changes in IL-6 mRNA levels tracked changes in 
levels of BCMA mRNA and hence, by inference, the numbers of AFC. The highest 
measured levels of IL-6 mRNA (median 16-fold above baseline) were found at day 4 
after infection and co-immunization, whilst levels in infected but not-immunized mice 
peaked at median 7-fold above baseline, at day 8. In both groups of infected mice, levels 
of IL-6 mRNA were still elevated at day 35. By contrast, in immunized but not infected 
mice, no correlation between levels of IL-6 mRNA and BCMA mRNA was seen, and 
median levels remained within 2-fold of baseline throughout.  
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Figure 6-30 shows that in splenic cell suspensions, levels of IL-6 and IL-21 mRNA are more 
substantially increased after infection, than after immunization.  
Each symbol represents values from one mouse. Levels of mRNA were measured by RT2-PCR and are 
reported relative to reference gene (β2-microglobulin) mRNA levels in the same sample. Where less than 
three symbols are shown per group, no mRNA was detected in the samples from unreported mice. Changes 
in BCMA mRNA levels, which broadly reproduce changes in CD138+ cell numbers estimated by flow 
cytometry, are shown for comparison. 
Irrespective of co-immunization, in infected mice peak levels of IL-21 mRNA were seen 
at day 8, and the medians were more than 10-fold above baseline. Levels in both these 
groups declined only marginally by day 35. The only impact of co-immunization of IL-21 
mRNA levels was seen at day 4; levels had already begun to climb in this group, whereas 
they were virtually unchanged in mice that were infected but not immunized. Whereas 
infection, and to a lesser extent additional co-immunization, has a substantial effect on 
 Open diamonds – naïve mice. Coloured diamonds – day 4 mice. 
Circles – day 8 mice. Triangles – day 35 mice. 
 L
e
v
e
l 
o
f 
m
R
N
A
 s
p
e
c
ie
s
 o
f 
in
te
re
s
t,
 r
e
la
ti
v
e
 t
o
 l
e
v
e
l 
o
f 
re
fe
re
n
c
e
 g
e
n
e
 m
R
N
A
 
 
D
ay
 0
D
ay
 4
D
ay
 8
D
ay
 3
5
D
ay
 4
D
ay
 8
D
ay
 3
5
D
ay
 4
D
ay
 8
D
ay
 3
5
IL-6
100
101
102
BCMA 
103
104
101
102
NP-Ficoll Sal NP-F / Sal
101
102
103
IL-621
155 
 
IL-21 mRNA levels, immunization alone only resulted in median 3-fold rise in levels 
seen at day 8. 
Figure 6-31 shows that in splenic cell suspensions, levels of mRNA encoding for TNF-α, BAFF and 
APRIL are little changed after infection, immunization or both, and that none of these mRNA species 
increase more after infection than after immunization.  
Each symbol represents values from one mouse. Levels of mRNA were measured by RT2-PCR and are 
reported relative to reference gene (β2-microglobulin) mRNA levels in the same sample. Changes in 
BCMA mRNA levels, which broadly reproduce changes in CD138+ cell numbers estimated by flow 
cytometry, are shown for comparison. 
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Surprisingly, and in contrast to levels of IL-6 and IL-21 mRNA in spleen cell 
suspensions, levels of mRNA encoding TNF-α, or BAFF, or APRIL changed relatively 
little after immunization, or infection, or both. Changes in the levels of all 3 mRNA 
species varied no more than 4-fold different from baseline at any timepoint. 
Thus amongst the mRNA species studied here in spleen cell suspensions, only IL-6 and 
IL-21 mRNA shows increases in levels in bulk splenic cell suspensions that are plausibly 
associated with the increased numbers of splenic AFC present in S. Typhimurium 
infected mice.  
6.9 Estimation of regional variations in mRNA levels within the 
spleen by RT2-PCR of laser microdissected sections. 
To look for regional variations in the levels of AFC-supporting chemokines and 
cytokines that can influence AFC-survival in vivo, levels of mRNA encoding these were 
assessed in different compartments of the spleen. In order to obtain reliable data multiple 
dissected areas, each representative of the compartment of interest, are needed. Multiple 
sections of a tissue are cut and placed on a single, membrane coated slide, which is 
subsequently stained with cresyl violet to assist the identification of compartments within 
the tissue. However additional localisation techniques are needed to identify splenic 
compartments with confidence, and AFCs themselves cannot be identified by cresyl 
violet staining alone. Two additional sections were thus cut before the sections to be used 
for microdissection, and two additional sections cut after. These four were stained by 
immunohistochemical techniques. Within each flanking pair, one was stained for NP-
specific AFC and for IgD
+ 
cells, whilst the other was stained for Ki67
+
, a nuclear marker 
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of proliferation, and for IgD
+
 cells. By cross reference between composite 
photomicrographs of the immunohistochemically stained slides and the cresyl-violet 
stained sections we identified AFC-rich and AFC-sparse areas of red pulp, and 
plasmablast-rich extrafollicular foci for microdissection. In addition areas of B cell 
follicles with continuous IgD
+
 small recirculating B cells (Ki67
- 
areas) and central T 
zones were dissected. Further details of this technique are provided in the methods 
chapter (section 3.3.13.3). Previous work had shown that the majority of red pulp AFC at 
day 4 and day 8 after immunization or infection or both, were NP-specific IgM
+
 AFC, 
(Figure 6-5, Figure 6-16, and Figure 6-29).  
Localisation of splenic compartments by this process, and the laser microdissection itself 
are highly time-consuming and so only selected tissues that were expected to be 
informative were to be used. These were spleens from mice sacrificed at day 4 and day 8 
after immunization, day 8 spleens from infected mice, and day 8 spleens from infected 
and co-immunized mice. In the event, tissue from the 3 mice sacrificed at day 8 after 
infection and co-immunization had become unavailable. Three mouse spleens were 
available for each of the other conditions of interest.  Extra-follicular foci of AFC, of 
sufficient size to microdissect accurately, could only be identified in infected mice. 
Additionally, the presence of confluent red pulp plasma cells in day 4 mice precluded the 
identification of AFC-sparse red pulp areas in these mice. The tissues examined, and the 
splenic compartments that were successfully identified and microdissected are 
summarised in Table 6-2. 
Levels of Blimp-1 mRNA, and BCMA mRNA were measured in the dissected tissues, to 
test the technical success in discriminating AFC-rich red pulp areas, and AFC-sparse red 
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pulp areas, and in identifying AFC-rich extra-follicular foci. The results, which are shown 
in Figure 6-32, confirm the association between the levels of each of these mRNA 
species, and also the association of each with the relative frequency of NP-specific AFCs 
in corresponding immunohistochemically stained sections. Blimp-1 mRNA levels are 
thus used as a comparator with levels of different cytokines reported in Figure 6-33 and 
Figure 6-34 and Figure 6-35 in the next section). 
Splenic Compartment Corresponding 
legend on 
Figure 6-32 
through to 
Figure 6-35 
Day 4 
after 
NP-Ficoll 
Day 8 
after 
NP-Ficoll 
Day 8 after  
S. Typhimurium 
infection. 
AFC rich red pulp  Red pulp NP
+
    
AFC sparse red pulp Red pulp NP
-
    
Extra-follicular foci EF Foci    
Primary B cell follicles IgD
+
    
Central T zone T zone    
Table 6-2 shows the range of mouse spleen compartments identified and microdissected, according to 
the experimental conditions and timepoints chosen.   
Three mice were available for each condition and splenic tissue was obtained from each.  
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Figure 6-32 shows relative amounts of Blimp-1 mRNA, and BCMA mRNA in different splenic 
regions, at day 4 and day 8 after NP-Ficoll immunization, and at day 8 of S. Typhimurium infection. 
These both closely reflect the distribution of AFCs in the corresponding tissue sections as identified 
by immunohistochemistry.  
Each symbol represents values from one mouse. Levels of Blimp-1 mRNA and BCMA mRNA were 
measured by RT2-PCR, and are each reported relative to levels of β2-microglobulin reference gene mRNA 
in the same sample. The legend for the symbols is shown above the figure. Where less than three symbols 
are shown per group, no mRNA was detected in the samples from unreported mice. Red pulp NP+ = NP-
specific AFC-rich areas of red pulp. Red pulp NP- = NP-specific AFC-sparse areas of red pulp. EF foci = 
Extra-follicular foci. T zone = central T zone. IgD+ = primary B cell follicles.  
6.9.1 Evidence for different chemokines present in the splenic red 
pulp of infected mice compared to those responding to NP-
Ficoll only 
Levels of mRNA encoding for the chemokines CXCL9, CXCL10, CXCL11, and 
CXCL12, and for γ-IFN were studied in the different microdissected splenic 
compartments. The results were consistent with those from spleen cell suspension RT2-
PCR assays. As seen in Figure 6-33, levels of the inflammation related chemokines 
CXCL9, CXCL10 and CXCL11, and also levels of  γ-IFN mRNA, are higher in day 8 
infected mice, than in day 8 immunized peers. Red pulp levels of these same mRNA 
species are also generally higher 8 days than 4 days after immunization. By contrast 
Blimp mRNA
R
ed
 p
ul
p 
N
P
+
R
ed
 p
ul
p 
N
P
-
E
F 
Fo
ci
T 
zo
ne
Ig
D
+
1
10
100
D4 NP-Ficoll
D8 NP-Ficoll
D8 Salmonella
R
e
la
ti
v
e
 a
m
o
u
n
t 
o
f 
B
li
m
p
-1
 m
R
N
A
BCMA mRNA
R
ed
 p
ul
p 
N
P
+
R
ed
 p
ul
p 
N
P
-
E
F 
Fo
ci
T 
zo
ne
Ig
D
+
0.1
1
10
100
1000
D4 NP-Ficoll
D8 NP-Ficoll
D8 Salmonella
R
e
la
ti
v
e
 a
m
o
u
n
t 
o
f 
B
C
M
A
 m
R
N
A
CXCR3 mRNA
R
ed
 p
ul
p 
N
P
+
R
ed
 p
ul
p 
N
P
-
E
F 
Fo
ci
T 
zo
ne
Ig
D
+
10
100
1000
D4 NP-Ficoll
D8 NP-Ficoll
D8 Salmonella
R
e
la
ti
v
e
 a
m
o
u
n
t 
o
f 
C
X
C
R
3
 m
R
N
A
CXCR3 mRNA
R
ed
 p
ul
p 
N
P
+
R
ed
 p
ul
p 
N
P
-
E
F 
Fo
ci
T 
zo
ne
Ig
D
+
10
100
1000
D4 NP-Ficoll
D8 NP-Ficoll
D8 Salmonella
R
e
la
ti
v
e
 a
m
o
u
n
t 
o
f 
C
X
C
R
3
 m
R
N
A
CXCR3 mRNA
R
ed
 p
ul
p 
N
P
+
R
ed
 p
ul
p 
N
P
-
E
F 
Fo
ci
T 
zo
ne
Ig
D
+
10
100
1000
D4 NP-Ficoll
D8 NP-Ficoll
D8 Salmonella
R
e
la
ti
v
e
 a
m
o
u
n
t 
o
f 
C
X
C
R
3
 m
R
N
A
160 
 
CXCL12 mRNA levels are similar at day 4 and day 8 after NP-Ficoll, and these levels are 
higher than those at day 8 after infection alone.  
The microdissection methodology provides location specific information at different 
timepoints, so additional, and much more detailed, analysis is possible. At day 4 after 
NP-Ficoll, CXCL12 mRNA levels were highest in the red pulp (Figure 6-33 bottom right 
panel). This gradient, if reflected in CXCL12 protein expression, would favour migration 
of CXCR4
+
 AFC towards the red pulp. Histological evidence (Figure 6-6) and 
compartmental levels of Blimp-1 mRNA (Figure 6-33, top left panel) indicate that much 
migration of AFC has already occurred by this time. There is no co-existing gradient in 
levels of mRNA for CXCL9 or CXCL10 or CXCL11. It is therefore unlikely that the few 
CXCR3
+ 
NP-specific AFC use these chemokines to migrate to the red pulp (Figure 6-33, 
middle panels and bottom left panel). As the proportion of cells expressing CXCR3 and 
the proportion expressing CXCR4 totals more than 100% (Figure 6-29), it is likely that 
some of these CXCR3
+
 AFC also express CXCR4. 
Eight days after NP-Ficoll, the CXCL12 gradient persists. However, there is no 
difference in CXCL12 levels between red pulp areas still rich in Blimp-1 mRNA, and red 
pulp areas with lower levels of Blimp-1 mRNA. Differential CXCL12 expression cannot 
therefore account for the selective survival to day 8 of AFC in some red pulp areas but 
not others.  
In the same day 8 immunized mice a gradient in CXCL10 mRNA levels is present that, if 
present at the protein level, would favour migration to the red pulp of late emerging 
CXCR3
+ 
AFC. There is no detectable difference in CXCL10 mRNA between AFC-rich 
and AFC-spare red pulp areas, but there are differences between these areas in levels of 
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mRNA for γ-IFN (Figure 6-33, top right panel) and CXCL11 (Figure 6-33, bottom left 
panel). The significance of these findings, if any, is not clear. 
Eight days after infection, there is no CXCL12 gradient to favour migration of new AFC 
to the red pulp, but CXCL12 mRNA levels in these mice are marginally higher in the 
extra-follicular foci than the T zone. Since at day 9 after infection, the majority of NP-
specific AFC are BrdU
- 
(Figure 6-12), it is likely that most of the AFC present at day 8 
after infection are formed after day 5. The continued formation of AFC, in the absence of 
a CXCL12 gradient to guide migration to the red pulp, may account for the substantial 
accumulation of NP-specific AFC seen in the extra-follicular foci of these mice. Similar 
factors likely account for the same observation at day 8 after infection with co-
immunization.  
162
Figure 6-33 shows that mNA for CXCL9, CXCL10 and CXCL11 and IFN-  are selectively induced 
by infection rather than immunization, but do not relate specifically to sites where AFC are located. 
CXCL12 by contrast is increased in immunized rather than infected mice, but again this is not 
clearly associated to AFC-containing areas.  
Corresponding levels of mRNA for Blimp-1, which is only expressed in AFCs are shown for comparison. 
Each symbol represents values from one mouse. The legend for the symbols is shown above the figure. 
Levels of mRNA were measured by RT2-PCR; mRNA species of interest are reported relative to levels of 
β2-microglobulin reference gene mRNA in the same sample. Where less than three symbols are shown per 
group, no mRNA was detected in the samples from unreported mice. Red pulp NP+ = NP-specific AFC-rich 
areas of red pulp. Red pulp NP- = NP-specific AFC-sparse areas of red pulp. EF foci = Extra-follicular foci. 
T zone = central T zone. IgD+ = primary B cell follicles.
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In these day 8 infected mice there is no evidence of a gradient in CXCL9 or CXCL10 or 
CXCL11 that could favour migration of newly formed CXCR3
+
 AFC from the T zone to 
extra-follicular foci. CXCL11 is higher in the red pulp of these mice than in their extra-
follicular foci so one might consider that any extra-follicular CXCR3
+
 AFC could use this 
to migrate to the red pulp, but levels are also higher in the T zone and no accumulation of 
AFC is seen there.  
Nevertheless, the red pulp of day 8 infected mice does contain NP-specific AFC, and it is 
likely – but as yet unproven – that these include relatively long lived AFC. Circumstantial 
evidence in support of this is that i) NP-specific AFC are already present in the red pulp 4 
days post infection (Figure 6-8) but that ii) most NP-specific CD138
+
 cells present at 4 
days after infection are newly formed (BrdU
+
) (Figure 6-12) and – as discussed above – 
iii) it is not clear how migration to the red pulp can occur at later timepoints.  
Spleens of day 4 infected mice were not examined by RT2-PCR analysis of 
microdissected areas. It seems possible that early in infection a CXCL12 gradient still 
exists in these mice to favour migration to the red pulp. A similar argument holds for 
AFC migration to the red pulp by day 4 after immunization with co-infection – especially 
as for these mice it has been shown that almost all their NP-specific AFC are CXCR4
+
, 
and relatively few are CXCR3
+
 (Figure 6-29).  
None of the inflammatory chemokines, nor γ-IFN, nor CXCL12, exhibit differential 
mRNA expression between AFC-rich and AFC-sparse areas of red pulp in infected mice 
so it is unlikely that these factors contribute to extended survival of AFC in selected areas 
of these mice‟ spleens. 
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6.9.2 Levels of BAFF mRNA, but not APRIL or TNF-α mRNA, correlate 
with AFC frequency in splenic red-pulp areas, eight days after 
immunization or infection. 
Levels of mRNA encoding for TNF-α, BAFF and APRIL (all AFC-supporting factors in 
the TNF-α superfamily) were also measured in the microdissected compartments of the 
selected mouse spleens (Figure 6-34). For each of these three cytokines, comparison of 
overall levels of mRNA in microdissected tissues revealed only modest differences 
between groups of mice subjected to different inoculations. As with the data on 
chemokine mRNA, levels of BAFF, APRIL and TNF-α mRNA were comparable in 
microdissected tissues to those in spleen cell suspensions (Figure 6-31).  
Within spleens of mice BAFF mRNA levels were appreciably higher 8 days after NP-
Ficoll or S. Typhimurium in AFC-rich red pulp areas than in AFC-sparse red pulp areas 
(Figure 6-34, top right panel). Median levels of BAFF mRNA were also selectively raised 
in AFC-rich extra-follicular foci of infected mice. Thus, 8 days after either infection or 
immunization, levels of mRNA encoding for BAFF are raised in areas where AFC were 
located and the presence of AFC is confirmed by the high levels of Blimp-1 mRNA in 
these areas (Figure 6-34, top left panel). There was no clear association between levels of 
TNF-α mRNA, or APRIL mRNA and AFC containing areas. The high levels of BAFF in 
the white pulp may well reflect the known roles of this cytokine in homeostasis of resting 
and activated B cells [86].  
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Figure 6-34 shows higher levels of BAFF mRNA, but not mRNA for TNF-α, or APRIL, are present in 
NP-specific AFC containing splenic regions of mice sacrificed 8 days after immunization or infection. 
Corresponding levels of mRNA for Blimp-1, which is only expressed in AFCs, are shown for comparison. 
Each symbol represents values from one mouse. The legend for the symbols is shown above the figure. 
Levels of mRNA were measured by RT2-PCR, and mRNA species of interest are reported relative to levels 
of β2-microglobulin reference gene mRNA in the same sample. Where less than three symbols are shown 
per group, no mRNA was detected in the samples from unreported mice. Red pulp NP+ = NP-specific 
AFC-rich areas of red pulp. Red pulp NP- = NP-specific AFC-sparse areas of red pulp. EF foci = Extra-
follicular foci. T zone = central T zone. IgD+ = primary B cell follicles.
6.9.3 IL6 and IL21 mRNA are selectively up regulated in infected 
mice. 
The studies of spleen cell suspensions showed selective upregulation of IL-6 and IL-21 in 
infected mice. Microdissection confirms this association with S. Typhimurium infection 
but fails to identify any differences between AFC-containing and other compartments for 
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IL-6. It does show higher IL-21 levels in both the T and B cell areas of the white pulp 
compared to the red pulp (Figure 6-35).
Figure 6-35 shows that mRNA for IL-6 and 
IL-21are rarely detectable in different splenic 
regions of uninfected mice and that in 
different splenic regions of mice infected 8 
days previously levels of these mRNA species 
do not correlate with corresponding numbers 
of prevalent NP-specific AFC present.  
Corresponding levels of mRNA for Blimp-1, 
which is only expressed in AFC, are shown for 
comparison. Each symbol represents values 
from one mouse. The legend for the symbols is 
shown above the figure. Levels of mRNA were 
measured by RT2-PCR, and mRNA species of 
interest are reported relative to levels of β2-
microglobulin reference gene mRNA in the 
same sample. Where less than three symbols are 
shown per group, no mRNA was detected in the 
samples from unreported mice. Red pulp NP+ =
NP-specific AFC-rich areas of red pulp. Red 
pulp NP- = NP-specific AFC-sparse areas of red 
pulp. EF foci = Extra-follicular foci. T zone = 
central T zone. IgD+ = primary B cell follicles.
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6.10  Discussion and future work. 
Detailed results are reported here of an experiment designed to test the hypothesis that 
„inflammatory niches‟ can secure extended survival of additional plasma cells, even those 
unrelated to the cause of the inflammation. Available results from a repeat experiment 
have also been included. A preliminary experiment – not reported here – had measured 
serum levels of IgM anti-NP and numbers of splenic AFC at days 4, 10 and 35 after 
immunization with or without co-infection. All three experiments have consistent results 
and support the original hypothesis that more NP-specific AFC survive in QM x B6 mice 
immunized with NP-Ficoll if AFC sustaining niches are induced by co-infection with S. 
Typhimurium. 
Splenic red pulp niches supporting NP-specific AFC 8 days after immunization with co-
infection appear close to, but not necessarily in contact with, red pulp fibrous trabeculae 
(Figure 6-21 and Figure 6-22). Similar co-localization of AFC and splenic trabeculae was 
seen in immunized but not infected mice (Figure 6-21), as has been reported previously 
[45;133]. Further studies are needed to test whether most trabecula-associated plasma 
cells are actually long lived. The repeat experiment that included BrdU administration to 
immunised mice was designed to do this. Histological examination of spleens of mice 
sacrificed at day 9 or later should confirm that most trabecula-associated plasma cells are 
BrdU
+
.  
Our RT2-PCR assays of microdissected splenic compartments also identify high levels of 
BAFF mRNA level as a feature of red pulp areas that contain plasma cells at day 8 after 
infection and immunization. It was unfortunate that doubly inoculated mice were not 
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available for microdissection and subsequent RT2-PCR in the first experiment. This will 
need to be performed on spleens of mice in the repeat experiment, but there is no reason 
to expect a different result in this group.  
The implied requirement for BAFF in achieving plasma cell survival is consistent with 
the reports that BCMA is essential for plasma cell survival (albeit in a study of bone 
marrow plasma cells) [165]. This contrasts with published work on plasma cell survival 
in the bone marrow [179], in the medullary cords of the lymph node [130], and the tonsil 
[249]. All of these associate the local production of APRIL with plasma cell survival. We 
have not been able to find a report of the roles of BAFF and APRIL in sustaining AFC 
survival at inflamed sites. 
Locally elevated BAFF levels, and proximity to trabeculae, are features common to AFC-
niches in both immunized, and infected, mice. It therefore appears that the infection-
related increase in red pulp niches reflects increased capacity at „conventional‟ trabecula-
associated niches. If so, why does infection render them capable of supporting more 
AFC? The data do not indictate that increased levels of BAFF contribute to the increased 
numbers of NP-specific AFC at 8 d after immunization in the infected mice. In contrast, 
though levels of neither IL-6 nor IL-21 vary substantially between AFC-rich and AFC-
sparse areas (Figure 6-35), levels of IL-6 mRNA and levels of IL-21 mRNA are higher in 
infected mice, than in their immunized but uninfected peers (Figure 6-30). Of these two 
cytokines, IL-6 levels seems the more likely to have a role in AFC survival in vivo, as i) 
IL-6 supports AFC survival in vitro [162], ii) levels of IL-6, but not levels of IL-21, have 
already risen by day 5 post infection (Figure 6-30), when apoptosis of most unsupported 
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splenic AFC occurs, and iii) in infected mice levels of IL-6 mRNA, but not IL-21 mRNA, 
are typically highest in the red pulp (Figure 6-35). 
O‟Connor et al report that IL-6 and BAFF have additive effects on plasma cell survival, 
at least in vitro [165]. In the context of our study, it is therefore tempting to speculate that 
additional red pulp IL-6 enables plasma cell to survive at lower levels of BAFF and/or 
APRIL. If this effect is superimposed upon levels of BAFF that decline with distance 
from a trabeculae-related source, the net result would be an enlarged peri-trabecular area 
capable of supporting plasma cell survival. This, in turn, would increase the number of 
NP-specific AFC supported in the red pulp of infected mice (Figure 6-36).  
 
 
 
 
 
 
 
 
Figure 6-36 is a schematic diagram illustrating how the effective size of a BAFF-dependent AFC 
niche might be increased by a diffuse increase in levels of red pulp IL-6, without a change in 
localiazed levels of BAFF. 
The minimum support sufficient to sustain AFC survival remains constant throughout the red pulp, and is 
indicated by the dashed black line. BAFF levels vary within the splenic red pulp, and provide dose-
dependent support to AFC (green line). The effective support to AFC provided in uninfected mice by a 
combination of uniformly low levels of IL-6, and locally variable levels of BAFF is represented by the thin 
red line. This results in a narrow region where total support is sufficient for AFC survival (thin red double 
ended arrow). In infected mice BAFF levels do not change, but the uniformly higher levels of red pulp IL-6 
increase the total support provided at any location (thick red line) results in an increased size of red pulp 
niche (thick double ended red arrow). 
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It is remarkable that even infected, and not immunized, QMxB6 mice have more long-
lived NP-specific plasma cells at day 9 than their conventionally immunized QMxB6 
peers (Figure 6-12). This may reflect LPS mediated „bystander‟ activation of available B 
cells [250;251], alternatively, it may be due to cross reactivity between antigens from S. 
Typhimurium and surface immunoglobulin on NP-specific B cells. 
Hargreaves et al have previously demonstrated that most migration of AFC to the red 
pulp is CXCR4 dependent [133]. The present study supports this in identifying, in mice 
that received NP-Ficoll, a CXCL12 gradient favouring migration of CXCR4
+
 AFC to the 
red pulp. It is striking that in infected mice there is no such gradient, and many AFC 
accumulate in extra-follicular foci. Only a minority of these are still proliferating (Ki67
+
), 
and BAFF levels at this site are comparable to AFC-supporting areas of the red pulp. It 
therefore seems possible that, in S. Typhimurium-infected mice, extra-follicular foci 
comprise an additional niche to sustain long term plasma cell survival. Again, 
histological examination of BrdU fed mice can examine this possibility.  
In addition to the marked accumulation of AFC in extra-follicular foci, infected but non-
immunized mice have some NP-specific red-pulp AFC. No evidence was found for 
significant CXCR3
+
 mediated migration of AFC within the spleen. A recent report has 
described a new chemokine receptor, CXCR7, which binds CXCL11 and CXCL12 [252]. 
This report indicates widespread expression of CXCR7 mRNA in a range of tissues 
(including the spleen). However it appears that expression of the corresponding protein, 
at least in adult mice and humans, is confined to transformed cells. A detailed 
examination of the presence or absence of CXCR7 in various immune cells is yet to be 
reported, but could be of great interest – e.g. in CXCR4-independent AFC migration 
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within the spleen. Others have previously demonstrated expression of CXCR6 on human 
plasma cells [253], and expression of CXCL16, the ligand for CXCR6 in the spleen, the 
bone marrow and the inflamed rheumatoid joint [253;254]. The possibility that CXCR6 
mediates splenic plasma-cell migration has not explored here. 
Splenic CD11b
+
F4/80
+ 
macrophages, and some splenic CD11c
+
F4/80
+
 dendritic cells, 
could not be satisfactorily identified by presently available confocal microscopy 
techniques. This is particularly frustrating as these cell types are increased in the spleen 
after S. Typhimurium infection, and could produce either BAFF or IL-6 or both 
[170;241;255]. It may yet be possible to identify other antigenic markers for these cells 
that enable their identification using confocal microscopy. It is possible that more than 
one cell type is capable of providing all sufficient support for AFC - perhaps by 
producing the necessary BAFF, with or without IL-6. If so then the histological 
approaches just discussed – and those reported elsewhere in this chapter – will fail to 
identify the association between AFC and any of the relevant cell types. 
Flow-assisted cytometric cell sorting (FACS) of splenic cell types, and subsequent RT2-
PCR analysis of homogeneous post-sort populations could at least address the relative 
contribution of these various cell types to overall splenic production of various putative 
AFC-survival factors, including BAFF and IL-6. This approach has already been applied 
in our laboratory in other models.  
Previous publications have reported that, in addition to the AFC-supportive molecules 
studied here, other factors can enhance plasma cell survival, at least in vitro. IL-5 can 
promote plasma cell survival in vitro although there appears to be functional redundancy 
in its action [162], and so we did not explore any role for IL-5 in the present model. The 
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plasma cell surface receptors VLA-4, and CD44 may contribute to the cells‟ survival, 
though the published findings are not consistent [160;162].  
At least one ligand for VLA-4 – fibronectin – is  widely expressed in the spleen [256], 
and so it alone cannot be a determinant of a plasma cell niche. In contrast histologically 
detectable expression of hyaluronic acid (a ligand for CD44) in the splenic red pulp is 
restricted to vascular structures [257]. As production of hyaluronic acid is widely 
upregulated in inflammation [258;259] infection-related increases in splenic expression 
of hyaluronic acid might provide additional support to plasma cells. This merits 
investigation but was not undertaken here. 
A large part of information in this report regarding niches, and infection-related changes 
in the spleen, was derived from RT2-PCR based assays of mRNA levels. This is 
necessary given the difficulties in interpreting histological staining for cytokines, and 
chemokines. Nevertheless, inferences about protein levels from levels of corresponding 
mRNA as measured by RT2-PCR requires caution - and even more so in the context of a 
substantial, and changing, cellular infiltrate. Levels of mRNA are expressed relative to 
levels of reference gene mRNA. As discussed in section 6.8 above, increased production 
of reference gene mRNA due to infection related increases in cell numbers will tend to 
result in underestimation of absolute levels of mRNA species of interest. This, in turn, 
many results in more modest infection-related changes in mRNA levels being 
overlooked. The use of microdissection did enable us to test if mRNA detected in spleen 
cell suspensions was localized within certain compartments in the spleen. 
Furthermore, the sequential relationship between cellular mRNA expression, cellular 
protein synthesis, cellular secretion of protein, and extra-cellular (or cell surface) 
173 
 
persistence of protein is not invariable. The example of variable cell surface expression of 
CXCR4 has already been cited [153;248], but there are other examples pertinent to this 
work. CXCL12 can bind to CXCR4
-
 cells via cell-surface heparin sulphate, and can bind 
to other negatively-charged glycosaminoglycans in the extra-cellular matrix [260]. In 
both circumstances the CXCL12 retains functional activity.  Neutrophils can store BAFF, 
and possibly APRIL, in cytoplasmic granules, with secretion of granule contents after 
stimulation [255;261]. Secreted APRIL can also bind to extra-cellular proteoglycans and 
may thus accumulate there [177]. All these phenomena would result in levels of 
functional protein that are not reflected in contemporary local mRNA production. This 
could, for example, result in a failure to detect a true association between APRIL and 
supportive niches. 
Although interesting, and contrasting, observations were made in the various groups of 
mice, the experiments reported here cannot confirm a causal, and non-redundant, 
relationship between BAFF and niche-related support for AFC. It is common to test such 
observations by the use of mice genetically deficient for the critical factor, or its ligand, 
or the addition of blocking substances (e.g. anti-BAFF antibodies, or BAFF-receptor Ig).  
However, BAFF has multiple roles within the B cell lineage and elsewhere so 
interpretation of the results obtained would be virtually impossible in the present model 
that involves active infection. 
The present study indicates that AFC survival in spleens of uninfected mice is also 
through a similar BAFF-dependent pathway. This has previously been investigated 
experimentally. Consistent with our findings, Ingold et al have reported that post-
immunisation BAFF-selective blockade reduces the number of splenic NP-specific AFCs 
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present [177]. Others have reported strain-dependent effects when using such approaches 
[262]. 
The more complex infection/immunization model reported here has many potentially 
interesting, and informative, permutations. One could administer antibiotics to previously 
infected and co-immunized mice – a crude analogy to the therapeutic role of Rituximab 
in autoimmune disease. The resultant, accelerated, resolution of inflammation would be 
expected to cause a loss of established splenic NP-specific plasma cells.  
Alternatively one might consider immunization with a T-dependent antigen (preferably 
with prior priming) instead of NP-Ficoll. This scenario may test more fully any role for 
CXCR3 in splenic AFC migration or survival as in published reports that used recall 
responses to antigen, the proportion of AFC that are CXCR3
+
 is higher than seen in our 
present work [14;134].  
It would also be interesting, and useful, to confirm the original hypothesis – namely that 
plasma cells unrelated to a cause of inflammation can be sustained in inflammatory sites 
– in mice suffering an alternative form of inflammation that does not involve an infection 
(or autoimmunity). The study of a non-lymphoid organ may also simply the interpretation 
of the findings. One such model is that of ischaemia reperfusion injury in the kidney 
[263].  
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7 GENERAL DISCUSION AND IMPLICATIONS FOR 
FUTURE RESEARCH 
The studies presented here arose from the surprising clinical observations that in patients 
with various autoimmune diseases, including Wegener‟s granulomatosis, serum titres of 
disease-associated IgG autoantibodies fall after therapeutic B cell depletion with 
Rituximab, while total serum IgG levels show little change.  
First we considered whether such sensitivity to Rituximab was a) a feature of a certain 
pathway of antibody production, or b) a feature of antibody producing cells arising from a 
particular B cell subset, or c) a feature of autoantibies that are produced exclusively by 
short lived plasma cells. Initially we developed the technology to measure antibodies of 
several different specificities in parallel (Chapter 4), This technology, and other 
established techniques, were then deployed to measure levels of antibodies against 
different classes of antigen from in sera from patients with active disease, and paired 
samples from the same patients after treatment with Rituximab (Chapter 5). The findings 
were most consistent with the following hypothesis: 
1. Plasma cells, including those producing autoantibody, accumulate in sites of 
inflammation. 
2. Inflamed sites provide supportive niches that enhance the survival of such plasma 
cells. 
3. Treatment of autoimmune disease by Rituximab, results in resolution of the 
disease related inflammation. 
4. As the inflammation resolves, the unsupported plasma cells die. 
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5. Subsequently the serum autoantibody titres, previously maintained by those 
plasma cells, then fall. 
Further work sought to test, in an experimental model, the underlying hypothesis that 
long lived plasma cells can be supported in inflamed tissues. Results obtained following 
intra-peritoneal inoculation of QM x B6 mice, in which some 5% of their B cells are NP-
specific, with either NP-Ficoll, or live attenuated S. Typhimurium or both. S.
Typhimurium infection creates new niches that support plasma cells in the spleen. The 
finding that increase numbers of NP-specific plasma cells survived in those mice that 
were infected with S. Typhimurium as well as immunized with NP-Ficoll is consistent 
with the hypothesis set out above.
Based on the published literature one may conclude that emergent AFC are likely to 
migrate to inflamed sites through interactions between CXCR3 and its ligands CXCL9, 
CXCL10 and CXCL11 [264]. These publications include reports that:
Indicate CXCL9 and CXCL11 are present in at least some inflamed tissues, 
including the rheumatoid joint [141;265], and CXCL9 is upregulated in inflamed 
lymph nodes [266]. These nodes become enriched for CXCR3+ monocytes [266].
Additionally, CXCL10 is induced in experimental models of renal injury [267].
Show CXCR3+ plasmablasts can migrate to these ligands [134]. 
Plasma cells are found at non-lymphoid sites of inflammation in mouse models 
[232], and in many inflamed human tissues [49;53;230;231;234-236] (see also 
Figure 5-4 in this thesis).
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Provide evidence that indicates that some plasma cells in rheumatoid joints are 
indeed CXCR3+ [141].
The proportion of new AFC that express CXCR3 may be increased in certain 
circumstances. Thus: 
In vitro studies have found that -IFN increases surface expression of CXCR3 
during in the process of memory B cell differentiation into AFC [14], at least in 
the subpopulation switched to IgG1.
Others have found, in patients with SLE,  an unusual circulating population of 
CD19hi cells that is enriched for autoreactive specificities [268]. These CD19hi
cells, which appear to be memory B cells [268], typically express higher levels of 
CXCR3 than CD19lo/normal cells from the same subject and exhibit chemotaxis to 
CXCL9 [269].
Why then do findings presented in Chapter 6 not support this model of CXCR3 mediated 
AFC migration? There are several possibilities. These include:
1. The time constraints and resources of the mice studies mean that findings 
should be considered as provisional until they have been repeated. 
2. The timepoints chosen for study may not reveal the impact of infection 
and related inflammation on AFC expression of CXCR3. 
3. S. Typhimurium may prevent increases in AFC expression of CXCR3 as a 
virulence strategy.  
4. CXCR3 expression on AFC might only be modulated by T-dependent 
responses, or perhaps only in responses derived from memory B cells. The 
178 
 
mouse studies reported in Chapter 6 involved T-independent responses to 
NP-Ficoll. 
By contrast we did find evidence that most intra-splenic AFC migration in our model is 
mediated by CXCR4. This is consistent with some published literature [133]. 
Upregulated expression of CXCL12 has also been reported at several inflamed sites 
including the rheumatoid synovium [270], and in more than one model of renal 
inflammation [271;272]. Interestingly, in NZB/W mice – animals whose kidneys are 
recognised to be a major site of AFC accumulation [232] – treatment with anti-CXCL12 
mAb results in a fall in serum anti-DNA IgG, but not total levels of serum IgG [272].  
Other work presented in Chapter 6, which still needs to be replicated, raises the 
possibility that during S. Typhimurium infection the increased splenic capacity for 
supporting plasma cells – above and beyond that attributable to splenomegally alone – is 
attributable to a combination of a) inflammation related increases in local IL-6 production 
and b) local production of BAFF. 
Could a similar mechanism apply in human autoimmune disease? Published work 
indicates that levels of IL-6 are higher in the inflamed rheumatoid synovium than in the 
serum [273] consistent with local production. Others have found direct [274] and indirect 
[275] evidence of local IL-6 production in renal lupus nephritis. To our knowledge, only 
indirect evidence has so far been published regarding locally increased IL-6 production in 
kidneys affected by ANCA-vasculitis [275], but this seems a plausible possibility given 
the available evidence, and the biology of IL-6 production (2.8.1.1). Appendices 3 and 4 
report our findings that serum levels of IL-6 are greatly elevated in patients with active 
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vasculitis, and that these systemic levels fall after remission induction with Rituximab 
based treatment. 
The published literature also includes several reports of local BAFF production at sites of 
clinical inflammation [276-278]. Given that BAFF can be produced by neutrophils and 
macrophages [170;255], and that both cell types can be activated by ANCA antibodies 
present in WG [21], it is possible that BAFF is present at sites of vasculitic damage in 
patients with WG. 
As with IL-6, serum levels of BAFF are elevated in most patients with WG, compared to 
healthy controls [279]. Serum BAFF levels are also elevated in most patients with SLE or 
RA [277;280].  Serum levels of BAFF correlate with disease activity score (and serum 
auto-antibody titres) in patients with conventionally treated SLE [281]. However, 
available evidence indicates that therapeutic B cell depletion in patients with SLE [282] 
and in patients with Rheumatoid Arthritis [221] is associated with a rise in serum BAFF 
levels, whilst autoantibody levels fall in such patients [11;23]. The rise in serum BAFF 
may be due to the operation of homeostatic mechanisms, but superficially does contradict 
the hypothesis offered here. However, there is no published information on levels of 
BAFF at inflamed sites (or their anatomical correlates during clinical remission), and 
only local levels are likely to be of relevance regarding local AFC survival. 
The emergent hypothesis from this work – that antibody producing plasma cells, 
including autoantibody producing plasma cells, are supported and sustained at sites of 
disease related inflammation – remains an attractive candidate explanation for the 
selective falls in most serum autoantibody titres after Rituximab. However it appears that 
not all autoantibody titres fall in this way – even within a common patient cohort. For 
180 
 
example amongst 16 patients with SLE treated with Rituximab, reported in detail by 
Cambridge et al [23], serum titres of anti-nucleosome antibodies (n=11) and anti-dsDNA 
antibodies (n=14) fell significantly whilst serum levels of antibodies against histone 
(n=10), SSA (n=9), and ribonucleoproteins (n=7) did not.  
In SLE some autoantibodies are circulating in significant quantities several years before 
symptoms develop [283]. The corresponding autoantibody-producing AFC are therefore 
presumably present before significant disease related inflammation develops. One might 
expect that the autoantibody-producing AFCs that emerge during this prodromal phase 
would mostly accumulate in „conventional‟ niches within the bone marrow. Our model 
would predict that such autoantibody production from these AFC would not be sensitive 
to Rituximab. 
 
 
 
 
 
 
 
 
 
Figure 7-1 shows the gradual development of autoantibodies prior to the emergence of symptoms of 
SLE. Taken from Arbukle et al 2003 [283]. 
In patients that subsequently develop SLE, auto-antibodies become detectable at variable intervals before 
clinical symptoms. Some, such as anti-Ro antibodies, are present long before disease, and their titres appear 
relatively preserved after Rituximab [23]. Others, such as anti-DNA antibodies, often emerge soon before 
symptoms, and more often fall after Rituximab therapy. ANA – Anti nuclear antibody. APL – Anti 
phospholipid antibody. dsDNA – double stranded DNA. nRNP – nuclear ribonucleoprotein.  
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The available evidence supports this to a certain extent. As shown in Figure 7-1, anti-
dsDNA antibodies emerge relatively late in pre-clinical SLE [283], and as previously 
noted, seem relatively sensitive to Rituximab treatment [23]. Conversely anti-Ro (SSA) 
antibodies emerge earlier [283], and are reported to be less Rituximab sensitive [23]. As 
such comparisons would be better made within one patient cohort, the value of this 
evidence is limited at present. No published reports describe the timescale of ANCA 
emergence prior to clinical ANCA-associated vasculitis.  
It may be that important differences between the animal model used in this work and the 
human diseases of interest limit the capacity to translate mechanisms from one to the 
other. Nevertheless, the technologies successfully applied to the „cuckoo project‟ 
(Chapter 6) ought to be adaptable to the studies of human pathological tissue. Such work, 
an obvious extension of the research reported here, would test whether local production 
of one or more factors that support AFC survival contributes to the survival of CXCR3
+
 
AFC, or CXCR4
+
 AFC, at sites of pathological inflammation. Alternatively, as discussed 
at the end of Chapter 6, different animal models could be used that bear closer analogy to 
the clinical scenarios of interest.  
Finally, whilst Rituximab is clearly finding a role as a valuable new therapeutic option in 
the treatment of autoimmune disease, it is likely that further biological therapies will 
continue to emerge. For example, a therapeutic agent that antagonises BAFF is already 
being developed [284]. As several life threatening autoimmune diseases, such as 
Wegener‟s granulomatosis, have less than ideal conventional therapies, it is likely that 
difficult clinical scenarios will continue to arise in patients are treated with new agents 
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that are at early stages of clinical development [21]. Some of these new treatments in 
time may find their own „niches‟ in the therapeutic arsenal.   
The experience with Rituximab over the last 5-8 years sets a precedent for further 
treatment development. It provides the hope that „experiments of medicine‟ that deploy 
specific therapeutic agents in a clinical setting will provide unexpected insights into 
human immunology. 
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8 APPENDIX 1: PROFORMA FOR BIRMINGHAM 
VASCULITIS ACTIVITY SCORE (BVAS) 
 
Figure 8-1 is reproduced from Luqmani et al, 1994, [17] and shows the standard proforma used to 
assess disease activity in ANCA associated vasculitis. 
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9 APPENDIX 2: RT2-PCR PRIMER AND PROBE SEQUENCES
mRNA species Origin Forward primer sequence Reverse primer sequence Probe sequence
IL6 MacLennan group TCGGAGGCTTAATTACACATGTTC AAGTGCATCATCGTTGTTCATACA CAGAATTGCCATTGCACAACTCTTTTCTCAT
BAFF MacLennan group GAAGTGTGCCATGTGAGTTATGAGA TCACCCAAGGCAAAAAGCA TCCTTTGCCAACACGCACCGC
APRIL MacLennan group CGAGTCTGGGACACTGGAATTT AGATACCACCTGACCCATTGTGA CTGCTCTATAGTCAGGTCCTGTTTCATGATGTGAC
Blimp-1SC MacLennan group CAAGAATGCCAACAGGAAGTATTTT CCATCAATGAAGTGGTGGAACTC TCTCTGGAATAGATCCGCCA-MGB
-IFN MacLennan group TCTTCTTGGATATCTGGAGGAACTG GAGATAATCTGGCTCTGCAGGATT TTCATGTCACCATCCTT-MGB
IL-21 MacLennan group ACACCCAAAGAATTCCTAGAAAGACTAA TGCATTCGTGAGCGTCTATAGTG AGCATCTCTCCTAGAACACATAGGACCCGAAGAT
CXCL12 MacLennan group CAAGCATCTGAAAATCCTCAACAC CACTTTAATTTCGGGTCAATGCA TGCACGGCTGAAGAACAACAACAGACAA
BCMA MacLennan group TCCAACCCTCCTGCAACCT CGTGTACGTCCCTTTCACTGAA TCAGCCTTACTGTGATCCAAGCGTGACC
CXCL9 Applied Biosystems Unknown Unknown Unknown 
CXCL10 Applied Biosystems Unknown Unknown Unknown
CXCL11 Applied Biosystems Unknown Unknown Unknown
TNF-α Applied Biosystems Unknown Unknown Unknown
CXCR3 Applied Biosystems Unknown Unknown Unknown
CXCR4 Applied Biosystems Unknown Unknown Unknown
β2-microglobulin MacLennan group CATACGCCTGCAGAGTTAAGCA ATCACATGTCTCGATCCCAGTAGA CAGTATGGCCGAGCCCAAGACCG
Table 9-1 lists the source of RNA primers and probes used in RT2-PCR assays, and the probes’ RNA sequences where known.
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10 APPENDIX 3: SERUM LEVELS OF CYTOKINES IN 
PATIENTS WITH ACTIVE ANCA-ASSOCIATED 
VASCULITIS, COMPARED TO LEVELS IN HEALTHY 
CONTROLS 
 Naïve patients Relapsed patients 
Cytokine 
 
Median serum 
level as 
multiple of 
controls‟ 
median serum 
level 
Significant 
difference 
with 
controls 
 
Median serum 
level as 
multiple of 
controls‟ 
median serum 
level 
Significant 
difference 
with 
controls 
 
Significant 
difference 
between 
naïve and 
relapsed 
patients 
IL-1β 2.2 x  1.6 x   
IL-1Rα 2.8 x  2.6 x   
IL-2 5.9 x  2.7 x   
IL-4 2.1 x  1.1 x   
IL-5 10.2 x  3.9 x   
IL-6 5.7 x  3.0 x   
IL-7 3.2 x  2.0 x   
IL-8 3.2 x  1.5 x   
IL-9 4.9 x  4.4 x   
IL-10 8.5 x  4.7 x   
IL-12 4.8 x  3.1 x   
IL-13 3.8 x  3.2 x   
IL-17 8.5 x  6.7 x   
Eotaxin 1.6 x  2.3 x   
G-CSF 1.2 x  1.2 x   
GM-CSF 2.7 x  1.5 x   
γ-IFN 1.5 x  1.1 x   
IP-10 1.9 x  1.2 x   
MCP-1 4.1 x  3.4 x   
MIP-1α 1.9 x  1.3 x   
MIP-1β 2.7 x  2.1 x   
PDGF 1.1 x  1.6 x   
TNF-α 1.4 x  1.1 x   
VEGF 7.9 x  5.7 x   
Table 10-1 summarizes the serum levels of various cytokines in treatment-naïve patients with ANCA-
vasculitis, and in patients with relapsed ANCA-vasculitis relative to levels in healthy controls’ serum.  
Subsequent pages show dot plots with results for individual patients and controls. 
Levels of each cytokine (listed in far left column) in patients with untreated ANCA associated vasculitis 
(n=19; left columns), and those with relapsed ANCA-associated vasculitis (n=13; right columns) are 
reported relative to the median level amongst healthy controls (n=8). Statistical significance (Mann 
Whitney test) for each comparison is reported is as follows: p<0.05 (), p<0.01 (), or p<0.001 (). 
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Scatter plots representing results for each patient or control subjects (where appropriate) 
regarding parameters of disease activity, serum autoantibody titres, and levels of each 
cytokine, are presented below. Dotted lines, where present, indicate the limits of the 
assay‟s range. Statistical significance (Mann Whitney test) for each comparison is 
reported as follows:  p<0.05 (    ), p<0.01 (        ), or p<0.001 (            ). 
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11 APPENDIX 4: CHANGES IN SERUM LEVELS OF 
CYTOKINES IN PATIENTS WITH ANCA- ASSOCIATED 
VASCULITIS AFTER TREATMENT WITH 
CYCLOPHOSPHAMIDE OR RITUXIMAB  
Cytokine 
 
Changes in 5 months after 
Cyclophosphamide based therapy 
Changes in 5 months after 
Rituximab based therapy 
 Median % fall (or 
rise) 
Significance 
of change 
(p<0.05) 
Median % 
fall (or 
rise) 
Significance 
(p<0.05) 
IL-1β 8%  28%  
IL-1Rα 35%  4%  
IL-2 87-93%  86%  
IL-4 18%  33%  
IL-5 70-72%  83%  
IL-6 70%  67%  
IL-7 64%  48%  
IL-8 33%  48%  
IL-9 69%  40%  
IL-10 57%  35%  
IL-12 52%  46%  
IL-13 71%  69%  
IL-17 35%  45% rise  
Eotaxin 77% rise  42% rise  
G-CSF 11%  31%   
GM-CSF 44%  43%  
γ-IFN 28%  25%  
IP-10 50%  113% rise  
MCP-1 10%  9% rise  
MIP-1α 34%  28%  
MIP-1β 9%  32% rise  
PDGF 36%  4%  
TNF-α 12%  57%  
VEGF 66%  29%  
Table 11-1 summarizes the changes in serum levels of various cytokines in the 5 months following 
treatment of ANCA-associated vasculitis with either cyclophosphamide or Rituximab based regimes.  
Subsequent pages show dot plots with results for individual patients and controls. 
The table reports the median percentage change in various cytokines (far-left column) in the 5 months 
following treatment with either a cyclophosphamide based regime (left columns; n=7) or a Rituximab based 
regime (right columns; n=6). Percentage changes were calculated for each cytokine in each patient and the 
median percentage in each treatment group is reported here. Statistical significance (Wilcoxon signed rank 
test) for each comparison is reported is p<0.05 (). No tests reached significance of p<0.01. 
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Scatter plots representing the changes within each patient, in levels of parameters 
indicating disease activity, in serum levels of autoantibody, and in serum levels of each 
cytokine, are presented on the subsequent pages. In each plot two dots, linked by a solid 
line, represent the results from one patient. Horizontal dotted lines, where present indicate 
the limits of the assay‟s range. Where appropriate, levels in control patients (n=8) are 
included for comparison. Statistical significance (Wilcoxon signed rank test) for each 
comparison is reported as follows: p<0.05 (    ). 
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12 APPENDIX 5: IMMUNOHISTOCHEMICAL STAINING 
WITH ANTIBODIES AGAINST ER-TR7 AND AGAINST 
HUMAN COLLAGEN III 
Additional immunohistochemical studies indicated that antibodies against human 
Collagen III and antibodies against ER-TR7 [242] identify similar structures in the 
spleens of naïve QMxB6 mice, and those inoculated with NP-Ficoll, or S. Typhimurium 
or both. Examples are shown in Figure 12-1. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 12-1 shows that in the spleens of QMxB6 mice, analogous trabecular structures are identified 
by antibodies against human Collagen III, and antibodies against ER-TR7 [242].  
The mouse group, staining patterns and original magnification are shown above each photomicrograph. 
Panels A and B are photomicrographs of proximate spleen sections from one representative naïve mouse, 
whilst Panels C & D are photomicrographs of proximate spleen sections from a representative mouse 8 
days after S. Typhimurium infection. All sections were stained for antibodies to NP (brown). Panels A & C 
are also stained with antibodies against human Collagen III (blue), whilst panels B & D are stained with 
antibodies against ER-TR7 (brown). Analogous structures, including red pulp trabeculae, are identified by 
the antibody against human Collagen III and the antibody against ER-TR7.  
 
Day 8. Sal only. NP Collagen III x50 Day 8. Sal only. NP ER-TR7 x50
Naïve Mouse. NP ER-TR7 x50Naïve Mouse. NP Collagen III x50
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